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Hypoqlycaemia in type 1 diabetes: risk factors, symptoms and recovery
Hypoglycaemia is the commonest side-effect of insulin treatment for diabetes mellitus.
Appreciation of the risk factors for hypoglycaemia and early recognition of its symptoms can
help the affected individual with prompt self-treatment of hypoglycaemia, preventing
progression to severe hypoglycaemia. The proposed MD project will consist of three major
studies to investigate the risks for, symptoms of, and rate of recovery from, hypoglycaemia.
Study one
This study will examine the alleged association between severe hypoglycaemia and serum
angiotensin converting enzyme (ACE) levels. While many patients rarely experience severe
hypoglycaemia, a small subgroup experiences recurrent episodes. These are very disruptive
to daily life and may be dangerous, for example if they occur when the individual is driving.
It is therefore of clinical importance to identify risk factors for severe hypoglycaemia.
Scandinavian studies have reported an association between elevated serum ACE activity and
an increased risk of severe hypoglycaemia in type 1 diabetes. A hypothetical explanation for
these findings is that lower ACE activity confers increased ability for cerebral function to be
maintained despite metabolic substrate deprivation. It is possible that in diabetes, this could
manifest as greater impairment of mental ability during hypoglycaemia in people with high
ACE activity. This would explain their increased risk of severe hypoglycaemia for a given
level of blood glucose as they would be more incapacitated, and therefore less able to self-
treat. However these studies have methodological limitations and these findings have not yet
been reproduced outside Scandinavia.
In this study, it is proposed to examine the relationship between serum ACE levels and the
incidence of severe hypoglycaemia. Blood will be sampled for serum ACE activity and the
self-estimated frequency of severe hypoglycaemia will be recorded in 300 people with type 1
diabetes attending diabetes clinics at the Royal Infirmary of Edinburgh.
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Study two
This study will examine the variability of hypoglycaemia symptom reporting. It is known
that the symptoms of hypoglycaemia are idiosyncratic and age-specific. However, no studies
have assessed the extent of any intra-individual variability in symptom reporting.
A cohort of 350 people with type 1 and type 2 diabetes, with different disease durations and
varying treatment modalities, will be recruited and the symptoms associated with each
hypoglycaemic episode will be recorded prospectively over a 12 month period. The reported
symptom clusters will be analysed to assess the consistency of symptom reporting for each
individual. Regression analysis will be used to assess whether an individual's consistency
coefficient is related to any other factors such as disease duration or treatment modality. The
ability to predict which individuals will report a consistent group of symptoms and which
individuals will experience an erratic pattern of symptoms would assist patient education and
allow clinicians to inform patients about how to anticipate and recognise hypoglycaemia.
Study three
This study will examine the time taken for full cognitive recovery from hypoglycaemia and
the possible effect of the clinical syndrome of impaired awareness of hypoglycaemia on this
process. The effects of acute insulin-induced hypoglycaemia on cognitive function have been
investigated extensively but the recovery period after hypoglycaemia has not been rigorously
assessed. Previous studies examining recovery have had multiple limitations.
The objective of this third study is to measure the recovery time for various domains of
cognitive function in a large group of patients with type 1 diabetes who have either normal
(n=20) or impaired (n=l 6) awareness of hypoglycaemia. A hyperinsulinaemic glucose clamp
technique will be used to induce controlled hypoglycaemia and a battery of cognitive tests
will be applied at baseline, at the beginning and end of a one hour period of hypoglycaemia,
then at ten minute intervals during a 90 minute recovery period. Each subject will act as their
own control by undergoing a euglycaemic clamp on a separate occasion. Test scores will be
compared using general linear modelling with awareness of hypoglycaemia as a between-
subjects factor. The findings of this study will have important clinical implications and help
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Chapter 1: Clinical and Physiological Effects of
Hypoglycaemia in Humans
1.1 Introduction
The consequences of iatrogenic hypoglycaemia were recognised shortly after the discovery of
insulin in 1922 (1) with a list of hypoglycaemic symptoms being published that same year
(2). However, it was many years before interest developed in hypoglycaemia as a formal
research area. It is now well established that hypoglycaemia is the commonest side-effect of
insulin treatment (3) and that people with diabetes fear hypoglycaemia as much the vascular
complications of advanced diabetes, such as renal failure or blindness (4), and that it
therefore represents the principal barrier to good glycaemic control (5). Although the
symptoms of hypoglycaemia had been described in the 1920's, it is only in the last 20 years
that researchers have addressed clinically pertinent issues such as determining which
symptoms are most commonly and most reliably associated with hypoglycaemia. Similarly,
it was only in the 199CFs that researchers formally grouped hypoglycaemic symptoms into
categories using physiological and statistical techniques (6-9).
An understanding of hypoglycaemia requires an appreciation of the difficulties involved in
defining this clinical entity as well as a knowledge of normal glucose metabolism, the various
physiological defence mechanisms that have evolved to defend us from hypoglycaemia and
the symptoms generated by low blood glucose levels, all of which will be reviewed. In some
individuals, the symptomatic warnings of hypoglycaemia wane. These people with impaired
awareness of hypoglycaemia are therefore at increased risk of hypoglycaemia and merit
special consideration. Finally, in order to put the physiology into context, the epidemiology
of hypoglycaemia in type 1 diabetes and the risk factors that contribute to hypoglycaemia will
be considered. The ways in which hypoglycaemia can affect cognitive function will be
discussed in chapter two.
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1.2 Definitions
There is no universal consensus on the definition of hypoglycaemia (10). A set of purely
biochemical criteria overlook the fact that blood glucose thresholds for the onset of
symptoms and counterregulatory hormonal changes may vary according to factors such as
recent antecedent hypoglycaemia (11-15) or the prevailing level of glycaemic control (16.17).
Nonetheless, pragmatic biochemical cut-offs are often employed when offering advice to
patients in order to ensure safety. For example, while this would not be regarded as a
definition of hypoglycaemia. Diabetes UK recommends that people with diabetes "make four
the floor" and avoid blood glucose levels below 4 mmol/1 (18).
Whipple's triad, developed in the context of pancreatic surgery for insulinoma patients,
requires the presence of biochemical evidence of hypoglycaemia. symptoms of
hypoglycaemia and resolution of symptoms with rescue carbohydrate (19). In practice,
individuals with diabetes frequently treat hypoglycaemia on the basis of symptoms without
biochemical confirmation and it is therefore often accepted that two out of Whipple's three
criteria are sufficient to confirm the presence of hypoglycaemia. However, in one
prospective study, biochemical hypoglycaemia only accompanied apparently hypoglycaemic
symptoms on 29% of occasions (20) so there are clearly inaccuracies inherent in any
definition of hypoglycaemia that does not require biochemical corroboration.
For the purposes of clinical practice, perhaps the most useful definition is the one that was
used in the Diabetes Control and Complications Trial (DCCT) (3) to distinguish between
mild and severe hypoglycaemia. The former is self-treated while the latter requires external
assistance. Severe hypoglycaemia is easier to quantify than mild hypoglycaemia, partly
because the former is more likely to be memorable. In people with type 1 diabetes, recall of
severe hypoglycaemia is relatively robust over a period of one year, while recall of mild
hypoglycaemia is unreliable after an interval of one week (4,21).
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1.3 Glucose metabolism and glucose sensing
In humans, glucose homeostasis is tightly regulated in order to protect the body from the
vascular complications of chronic hyperglycaemia and the brain from the neuroglycopenic
effects of hypoglycaemia. An understanding of normal glucose metabolism is necessary to
appreciate the defence mechanisms that have evolved to protect against hypoglycaemia.
1.3.1 Normal glucose metabolism
The two principal hormones controlling glucose homeostasis are insulin and glucagon.
Insulin is an anabolic hormone which reduces hepatic glucose output by increasing
glycogenesis, proteogenesis and lipogenesis and decreasing gluconeogenesis and
glycogenolysis. Glucagon opposes the hepatic effects of insulin. However, whereas
glucagon has no significant extra-hepatic actions, insulin is also active peripherally. It
increases the uptake of glucose by both adipose tissue and muscle and increases glycolysis
and glycogenesis in muscle.
During the fasted state, the concentration of insulin decreases and glucagon increases,
resulting in increased hepatic glucose output, availability of alternative fuels such as amino
acids and lipids and decreased peripheral glucose utilisation. During short fasts, glycogen
provides 60-80% of the glucose used, with the brain consuming up to 80% of this as it is
unable to use alternative fuels to any significant extent. During more prolonged fasts,
glycogen stores are depleted and glucose is primarily provided by gluconeogenesis. The
reduced plasma concentrations of insulin and increased glucagon during the fasted state have
a greater catabolic effect on fat than on muscle, favouring the relative preservation of muscle
while ensuring adequate cerebral glucose supplies (22). Conversely, in the fed state, insulin
secretion increases while glucagon secretion decreases. This favours an anabolic state with
an increase in protein synthesis, inhibition of lipolysis, increased hepatic glycogenesis and
decreased glycogenolysis and gluconeogenesis.
The brain is the most vulnerable organ to hypoglycaemia because it has a restricted capacity
to synthesise or store glucose and relies on a constant supply of glucose for its energy supply.
Transport of glucose across the blood-brain barrier acts as the rate-limiting step in this
process. The brain does have the capacity to metabolise fuels such as amino acids, lactate.
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lipids and ketones in certain situations. For example, during prolonged starvation, the brain
metabolises ketones to provide up to 60% of the energy it requires (23).
Hypoglycaemic clamp studies in healthy volunteers have also demonstrated reductions in
symptoms and counterregulation during hypoglycaemia with the infusion of intralipid and
heparin, although these measures were unable to prevent changes in measures of cognitive
function such as reaction time (24). More recently however, a clamp study in 11 adults with
intensively treated type 1 diabetes demonstrated that the ingestion of medium chain fatty
acids prevented hypoglycaemia-associated impairment on tests of immediate and delayed
verbal memory, and verbal memory recognition. Flowever, it did not protect all cognitive
functions, with performance on the digit span backwards test deteriorating despite fatty acid
ingestion (25). Studies in rats undertaken by the same authors to investigate the mechanism
by which fatty acids are protective demonstrate that beta-hydroxybutyrate supports synaptic
transmission in vitro (25).
Although alternative metabolic fuels may be utilised under experimental conditions, under
physiological conditions the supply of these alternative substrates is insufficient to make their
use viable and the brain's two main sources of energy are ATP and creatine phosphate. It is
possible to detect changes in cerebral function once blood glucose levels fall to 3 mmol/1,
although neither ATP nor creatine phosphate are depleted at these blood glucose
concentrations. It is possible that some of these changes in cerebral function are linked to
reductions in the production of phospholipids required for cell membrane synthesis and
neurotransmitters such as acetylcholine and gaba-amino butyric acid.
1.3.2 Glucose sensing
The capacity to detect changes in blood glucose levels is widely distributed throughout the
body and proteins called glucose transporters (GLUT) mediate the movement of glucose into
cells down a concentration gradient by facilitated diffusion. The pancreatic beta cell is the
classical glucose sensing cell, as it enables modulation of the secretion of insulin in the fed
and fasted states as discussed above. However, glucose-sensing neurones have also been
demonstrated in the intestine (26), the hepatic portal vein (27,28), the carotid body (29) and
in multiple areas within the brain such as the septum (30), amygdala (31), striatum (32),
motor cortex (33), hindbrain (34) and hypothalamus (35).
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Glucose-sensing neurones in the hindbrain and hypothalamus are closely linked to glucose
sensing during hypoglycaemia (36) and in 1953. the 'glucostatic hypothesis" was proposed,
which suggested that hypothalamic 'glucoreceptors' could translate changes in ambient
glucose into neural signals (37). Glucose sensing neurones can be divided into those that
demonstrate an increase in activity in response to glucose (glucose-excited [GE] neurones)
and those that show decreased activity (glucose-inhibited [Gl] neurones) (38.39).
It is now known that Katp channels and glucokinase play a central role in the mechanisms
governing GE cells (36.40-43) and that these mechanisms appear similar to those involved in
glucose sensing in the pancreatic beta cell (Figure 1.1). Glucose is transported into the GE
cell by GLUT2 or GLUT3 and is subsequently phosphorylated by glucokinase, which acts a
gatekeeper by regulating the production of ATP. In turn, A TP closes Katp channels, resulting
in depolarisation and subsequent influx of calcium ions through voltage dependent calcium
channels (VDCC), stimulating neurotransmitter release. Lactate, produced by astrocytes,
enters the neurone by monocarboxylate transporter-2 (MCT2) and is also metabolised to
ATP, which contributes to neurotransmitter release as above.
Single cell RT-PCR studies have demonstrated that glucose-sensing neurones express mRNA
for the Kir 6.2 and SUR-1 subunits of the sulphonylurea receptor (44). Injection of
glibenclamide (a Katp blocker) into the ventromedial hypothalamus (VMH) has been shown
to suppress the hormonal counterregulatory responses to systemic hypoglycaemia (45).
Conversely, in vivo perfusion of the VMEI with diazoxide (a Katp opener) augments the
counterregulatory responses to hypoglycaemia (46).
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Figure 1.1
Hypothetical glucose sensing mechanism of GE neurones. Glucose enters the GE cell via
GLUT2 or GLUT3 transporters and is phosphorylated by glucokinase. ATP closes Katp
channels, resulting in influx of calcium ions through voltage dependent calcium channels
(VDCC), stimulating neurotransmitter release. Lactate, produced by astrocytes, enters the
neurone by monocarboxylate transporter-2 (MCT2) and is metabolised to ATP. Adapted
from McCrimmon, 2009 (42).
G1 neurones behave much more like pancreatic alpha-cells (36.42) and it is thought that
AMP-activated protein kinase (AMPK) plays a role in their glucose-sensing mechanisms
(42,47). A fall in glucose increases the AMP:ATP ratio. This in turn activates AMPK and
stimulates the formation of nitric oxide, which may act as a neurotransmitter. AMPK may
also act on chloride channels, leading to membrane depolarisation (figure 1.2).
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Figure 1.2
Hypothetical glucose sensing mechanism of Gl neurones. A fall in glucose increases the
AMP:ATP ratio which activates AMPK and stimulates the formation of nitric oxide (NO),
which may act as a neurotransmitter. AMPK may also act on chloride channels, leading to
membrane depolarisation. Adapted from McCrimmon, 2009 (42).
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Many of these Gl neurones are glutaminergic and recent rodent studies show that absence of
the VMM-specific glutamate transporter VGLuT2 is associated with an attenuated
counterregulatory response to insulin-induced hypoglycaemia (48). Our knowledge of how
Gl neurones function is more limited than our understanding of GE neurones (36,40).
However, it appears likely that both types of neurone are regulated by levels of intracellular
ATP rather than glucose levels because their responses to alternative fuels such as lactate are
similar to their responses to glucose (49-51).
Most of what we know about cerebral glucose sensing has been learnt from animal studies
and it is clear that the studies that will subsequently be described could not be replicated in
humans. The glucose-sensing neurones of the hypothalamus are located around the VMH,
paraventricular nucleus (PVN) and dorsomedial hypothalamus (DMH) and in vivo studies in
rat models have suggested that the VMH plays a central in the detection of hypoglycaemia.
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In the VMH. 14-19% of neurones are GE and 3-14% are GI neurones (41.52).
Pharmacological ablation of the VMH with ibotenic acid reduces counter-regulatory hormone
release by approximately 75% during hypoglycaemia (53). The release of counter-regulatory
hormones is markedly reduced during systemic hypoglycaemia by the infusion of glucose
locally into the VMH (54). Conversely, local hypoglycaemia can be induced in the VMH by
perfusion of 2-deoxyglucose, which is a non-metabolisable form of glucose. This excites a
systemic counter-regulatory response, even in the face of systemic normoglycaemia (55).
Brain glucose-sensing neurones are located in areas involved in controlling energy
homeostasis and regulating autonomic and neuroendocrine function, thereby enabling them to
respond appropriately to the detected blood glucose levels (36,42). A further significant
feature of this cerebral glucose-sensing system is that glucose-sensing neurones are generally
located in areas where the blood-brain barrier is permeable or absent, which allows them to
better sense the ambient glucose levels. This is an important feature of the glucose-sensing
system because extracellular brain glucose levels are approximately two thirds of the glucose
levels found in blood and it takes 15-30 minutes for CSF glucose to equilibrate with blood
glucose (56). In fact, animal studies suggest that basal glucose levels in the brain are even
lower at around 1.4 mmol/1 in the hypothalamus (57), 1.0 mmol/1 in the hippocampus (58)
and 0.5 mmol/1 in the striatum (58). Thus, cerebral glucose levels are often only 10-30% of
the levels seen in peripheral blood (36), which is well below the levels at which glucokinase
usually acts. Although the concept of the GE neurone acting as a cerebral equivalent of the
beta cell is attractive, it is inconsistencies such as this that mean that this hypotheses is not
universally accepted
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1.4 Counterrequlation during hypoqlycaemia
To protect cerebral function, several physiological mechanisms have evolved to counteract
the effects of hypoglycaemia (22,59-61). When blood glucose falls in a non-diabetic adult,
the secretion of counterregulatory hormones and the onset of cognitive, physiological and
symptomatic changes occur at reproducible blood glucose thresholds (60.62) within a defined
hierarchy (61) (Figure 1.3).
Figure 1.3






















































Glucagon, catecholamines and GH are secreted once blood glucose levels drop to 3.5-3.7
mmol/1 while Cortisol is only produced once blood glucose drops to 3mmol/l or less (61).
Cognitive dysfunction develops at lower blood glucose levels than those required to initiate
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the counterregulatory response, with changes such as impairment in reaction time occurring
at blood glucose levels between 2.8-3.0mmol/l (64.65).
1.4.1 Methodological considerations
Early studies examining the hormonal responses to hypoglycaemia employed bolus injections
of insulin or insulin infusions. These studies were hampered by the difficulties of conducting
measurements of counterregulation when the timing of the hypoglycaemic episode and the
depth of the glucose nadir were hard to control. It is now known that counterregulation can
be affected by factors such as antecedent hypoglycaemia (12-15), the depth of the glucose
nadir (66) and the duration of hypoglycaemia, with acute adaptation being observed during
longer periods of hypoglycaemia (67,68). Studies examining whether counterregulation is
affected by the rate at which blood glucose falls have produced mixed results. Most studies
suggest that counterregulation is unaffected (69,70). However, in one study the adrenaline
response to hypoglycaemia was blunted when blood glucose was rapidly lowered in the
postprandial state (71).
The amount of insulin used to induce hypoglycaemia can also affect the counterregulatory
response under certain circumstances. In nine healthy lean men who underwent two separate
glucose clamps, high doses of insulin (3056 ± 236 versus 486 ± 33 pmol/1) resulted in
significantly greater increases in catecholamine and Cortisol secretion, hepatic glucose output,
lipolysis, heart rate and systolic blood pressure, despite equivalent blood glucose nadirs (2.8
mmol/1) (72). However, when the same group repeated a similar experiment in seven lean
subjects with poorly controlled type 1 diabetes (HbAlc 10.9%), plasma levels of epinephrine,
norepinephrine, Cortisol and growth hormone increased similarly during low (742 ±212
pmol/1) and high (3360 ±710 pmol/1) dose insulin infusions (73). However, the plasma
concentration of insulin has now been standardised by the widespread use of the glucose
clamp technique (74) where insulin is infused at a constant rate while blood glucose levels
are altered by varying the rate of an infusion of glucose. Subjects are usually studied in the
semi-recumbent position as standing can augment the autonomic symptoms associated with
hypoglycaemia (75).
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The type of blood sample used for glucose measurement also affects interpretation of results
(10). In studies of the effects of hypoglycaemia on cognitive function, the blood glucose
levels that are theoretically of most interest are cerebral arterial blood glucose levels but
sampling is difficult, potentially dangerous and clearly impractical. By convention,
arterialised venous blood glucose samples are used as a surrogate measurement. These are
obtained by insertion of a retrograde cannula in a dorsal hand vein with warming of the hand
using techniques such as a warm-air box. Measurement of arterialised venous blood is less
invasive than sampling arterial blood and, given that the difference in whole blood glucose
concentration between venous arterialised blood and arterial blood is only around 0.1 mmol/1
(76), it is felt that the former provides a reasonable approximation of the arterial blood
glucose level.
Furthermore, some studies have measured plasma glucose while others use whole blood
glucose. Awareness of the method used is important when comparing results from different
studies as analysis of plasma yields glucose results that are 10-20% higher than on an
equivalent whole blood sample. When extrapolating results of hypoglycaemic clamp studies
it is also important to remember that the plasma glucose concentration in arterialised venous
blood is approximately 15% higher than the glucose concentration in a capillary sample (76).
Finally, factors such as recent (antecedent) hypoglycaemia can also modify the
counterregulatory response. An episode of hypoglycaemia in the preceding 24-48 hours can
blunt the symptomatic and counterregulatory responses to hypoglycaemia (11-15). Studies
are therefore usually postponed if there has been an episode of hypoglycaemia within the
preceding 24-48 hours. Moderators of hypoglycaemia outwith the setting of experimental
hypoglycaemia are discussed in more detail below.
1.4.2 Counterrequlatory hormones
Despite methodological limitations, early studies were able to infer the presence of a
counterregulatory hormonal defence system. In non-diabetic individuals, the intravenous
injection of O.l U/kg insulin provokes a fall in blood glucose within a few minutes with a
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glucose nadir being achieved after 20-30 minutes (77). Blood glucose levels rise
approximately 30 minutes after injection of insulin, even though blood insulin levels are still
at 10 times their baseline value at this stage. By implication, other hormones must be
involved in the process of counterregulation and the reversal of hypoglycaemia cannot simply
be attributed to a fall in insulin levels. Although in healthy adults the first defence against
falling blood glucose levels is suppression of endogenous insulin secretion, this defence
mechanism is not available to individuals with diabetes who are reliant on either exogenous
insulin or insulin secretagogues to control their blood glucose levels, as there is no feedback
between ambient blood glucose levels and insulin secretion. However, other hormones have
a role to play in counterregulation.
Subsequent studies were able to elucidate the role of the various counterregulatory hormones
and demonstrate that glucagon is the most important hormone during acute hypoglycaemia.
with the catecholamines providing a second-line defence (59). Growth hormone (GH) and
Cortisol become important counterregulatory hormones during prolonged hypoglycaemia but
do not play a major role in the counterregulatory response to acute hypoglycaemia (59).
This hierarchy has been established by the sequential blockade of individual
counterregulatory hormones. Somatostatin infusions block both glucagon and GH release
and individual effects can be studied by replacing each hormone separately.
Counterregulation is delayed in the case of isolated glucagon deficiency and combined
glucagon and GH deficiency but not in the case of isolated GH deficiency, confirming the
precedence of glucagon as an acute counterregulatory hormone (59). Phentolamine and
propranolol can be infused to achieve complete adrenoceptor blockade. An isolated
adrenoceptor deficiency does not impair the acute counterregulatory response whereas the
combination of glucagon and adrenergic blockade or glucagon deficiency alone does impair
the counterregulatory response (59). All four counter-regulatory hormones increase
gluconeogenesis. Both glucagon and the catecholamines increase glycogenolysis, while the
catecholamines, Cortisol and growth hormone also decrease peripheral glucose utilisation
(22). Although counterregulatory hormones exert the bulk of their effect on glucose
metabolism, they also affect fatty acid utilisation. Increased epinephrine levels stimulate
release of fatty acids via lipolysis, which can be used as an alternative fuel to glucose.
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However, counterregulatory deficiencies are associated with increasing duration of type 1
diabetes. Table 1.1 summarises the proportion of individuals with type 1 diabetes
demonstrating deficient responses in the various counterregulatory hormones over time.
Each counterregulatory hormone will then be discussed in turn.
Table 1.1
Percentage of individuals with type l diabetes with deficiencies in counterregulatory
hormones with increasing duration of diabetes. Adapted from Mokan et al. 1994 (78).
Duration of Glucagon Adrenaline Cortisol Growth
diabetes (years) (%) (%) (%) hormone (%)
<1 27 9 0 0
1-5 75 25 0 0
5-10 100 44 11 11
>10 92 66 25 25
The secretory response of glucagon to hypoglycaemia can be lost within 5 years of diagnosis
of type 1 diabetes (78-80). The glucagon response to other stimuli, such as a protein load,
remains largely intact (81), suggesting that the defective glucagon response to hypoglycaemia
is stimulus-specific and may result from defective alpha cell signalling rather than
irreversible structural damage. In a study of 14 non-diabetic individuals, hypoglycaemia was
induced on two separate occasions with an insulin infusion being administered from 0 to 120
minutes. Between -60 and +60 minutes, subjects also received an infusion of either
somatostatin or saline placebo, with the aim of suppressing endogenous intraislet insulin
secretion in the somatostatin arm and thereby reducing the decrement in intraislet insulin
during the second hour of hypoglycaemia. During the somatostatin session, the lack of a
decrement in intraislet insulin secretion was associated with 30% lower plasma glucagon
levels in response to hypoglycaemia, suggesting that the fall in intraislet (as opposed to
systemic or exogenous) insulin is necessary for the release of glucagon in response to
hypoglycaemia (82). This finding is consistent with the observation that defects in glucagon
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secretion develop in parallel to the loss of endogenous insulin secretion (83.84) and it
therefore seems plausible that the loss of reciprocal signalling between alpha and beta cells
with advancing diabetes underlies the loss of the glucagon secretory response (82.85-88).
The catecholamine response compensates for the defects in glucagon secretion for several
years but it too declines with time (89). The lipolytic effects of epinephrine can outweigh the
anabolic effects of insulin on insulin-resistant adipose tissue, resulting in a rise in plasma free
fatty acids in response to hypoglycaemia in type 2 diabetes (90-92) but not in type 1 diabetes
(93). After 10 years duration of type 1 diabetes, the glucagon response to hypoglycaemia is
almost universally lost while around two thirds of individuals will have lost their epinephrine
response (94). If individuals with type 1 diabetes who have lost both epinephrine and
glucagon responses are exposed to intensive insulin treatment, they are at 25-fold greater risk
of severe hypoglycaemic events than those who retain an intact epinephrine response (95,96).
The release of counterregulatory hormones contributes to the physiological changes evident
during hypoglycaemia. Direct recordings from sympathetic nerves demonstrate that injection
of insulin provokes an increase in the amplitude and frequency of muscle sympathetic
activity within 8 minutes, with the peak in sympathetic activity coinciding with the glucose
nadir (97). An increase is also seen in skin sympathetic activity which coincides with the
onset of sweating (98). It has been demonstrated that sweating occurs within 10 minutes of
blood glucose falling to 2.5 mmol/1 or below (99). The haemodynamic changes during
hypoglycaemia are also largely mediated via epinephrine secretion and activation of the
sympathetic nervous system. The increased cardiac output and vasodilatation associated with
hypoglycaemia, combined with epinephrine-mediated beta-adrenoceptor stimulation, are
responsible for the tremor seen during hypoglycaemia (100).
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1.4.3 Moderators of counterrequlation
1.4.3.1 Antecedent hypoqlycaemia
Several factors may affect the process of counterregulation including antecedent
hypoglycaemia. Early suggestions that antecedent hypoglycaemia affected counterregulation
came from small studies in non-diabetic adults. In a clamp study in 1992 of 9 non-diabetic
adults, blood glucose was maintained at 3 mmol/1 for 2 hours. Subjects underwent a second
clamp with a blood glucose nadir of 2.8 mmol/1 18 hours later, at which time symptoms and
counterregulatory responses were reduced (101).
These findings have been confirmed in subsequent clamp studies of diabetic volunteers. In
these studies, subjects underwent two stepped glucose clamps where thresholds for
symptoms, counterregulatory responses and cognitive function were compared between the
two sessions. Participant numbers ranged from 8 (13) to 38 (14) and the interval between the
first and second test clamps has ranged from one hour (13) to 2 days (12,15). In one study,
subjects underwent twice weekly glucose clamps to a nadir of 2.8 mmol/1 for one month prior
to a stepped clamp 48h later. Regardless of differences in methodology, these studies have
consistently demonstrated a reduction in counterregulatory responses (12-15), symptoms
(12,14) and cognitive impairment (11.12) during the second period of hypoglycaemia,
confirming that antecedent hypoglycaemia affects responses to subsequent hypoglycaemia.
1.4.3.2 Hypoqlycaemia Associated Autonomic Failure
In type 1 diabetes, individuals who experience frequent hypoglycaemia may develop a
condition that has been termed Hypoglycaemia Associated Autonomic Failure (HAAF)
(102,103). The underlying premise is that recurrent hypoglycaemia leads to failure of the
centrally mediated counterregulatory response to hypoglycaemia, resulting in impaired
awareness of hypoglycaemia. Impaired hypoglycaemia awareness has been associated
primarily with type 1 diabetes but people with insulin-deficient type 2 diabetes are also at risk
of developing HAAF (83). HAAF is discussed in more detail in the section on impaired
awareness of hypoglycaemia (section 1.6.3).
25
Figure 1.4
Diagram illustrating the concept of Hypoglycaemia Associated Autonomic Failure, based on
Cryer. 1992 (102).
1.4.3.3 Gender
Interestingly, the effects of antecedent hypoglycaemia differ between men and women. This
was studied in a group of healthy volunteers consisting of 8 men and 7 women who
underwent 4 separate 2-day protocols in random order (104). On day l of each protocol,
subjects underwent a glucose clamp for 2h in the morning and again in the afternoon. The
hypoglycaemic nadir differed depending on which of the four experimental protocols was
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employed that day. with glucose nadirs of 5.1 (euglycaemia), 3.9. 3.3 and 2.9 mmol/1. Day 2
on all four protocols involved a 2 hour hypoglycaemic clamp with a glucose nadir of 2.9
mmol/1. Following the day 1 euglycaemia protocol (5.1 mmol/1), day 2 counterregulatory
responses were greater in men compared to women. However, following the day 1
hypoglycaemic protocols (3.9, 3.3 and 2.9 mmol/1). counterregulatory responses were blunted
in men on day 2 while women appeared to be resistant to the blunting effects of antecedent
hypoglycaemia on their counterregulatory responses. In the female group, the diminished
counterregulatory response on day 2 was only evident following the lowest glucose nadir of
2.9 mmol/1 on day 1 (104).
This study demonstrates gender-related differences in the counterregulatory responses to
antecedent hypoglycaemia. However, it also demonstrates a more general effect of gender on
counterregulation because females were shown to have a lower counterregulatory response
compared to men following antecedent euglycaemia (104). However, the first indications of
sexual dimorphism in hypoglycaemic counterregulation date from the 1970's, when it was
observed that blood glucose levels during moderate fasting fell to lower levels in women than
in men (105).
It is now well established that in both non-diabetic and type 1 diabetic subjects, women have
attenuated counterregulatory responses to hypoglycaemia compared to men (106-108), with
observed reductions in glucagon and epinephrine and decreased endogenous glucose
production in response to hypoglycaemia (106,107,109,110). In healthy individuals who
underwent a single-step hypoglycaemic clamp, females had adrenaline responses that were
44% lower and noradrenaline responses that were 17% lower than those of their male
counterparts, with greater prolongation of endogenous glucose output in women (106).
Glucose counterregulation does not appear to alter between the follicular and luteal phases of
the menstrual cycle (111). Some researchers have suggested that the diminished
counterregulatory response in women is accounted for by a gender difference in the glucose
thresholds required for hormone release (110) while other studies report no gender difference
in glycaemic thresholds (112). Subsequent glucose clamp studies have demonstrated that the
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thresholds for release of glucagon, epinephrine, Cortisol and growth hormone occur between
glucose levels of 3.9 and 4.4 mmol/1 in both men and women and that it is actually
differences in central nervous system efferent output, measured by microneurography, which
underlie the observed sexual dimorphism in hypoglycaemic counterregulation (113).
It has been difficult for researchers to reconcile the fact that women have a lesser
counterregulatory response with the fact that the prevalence of hypoglycaemia appears to be
no higher in women with diabetes than in men (3), as it is to be expected that
counterregulatory deficiencies will lead to a vicious cycle of further hypoglycaemia (102).
However, it may be that women receive some protection from the fact that they are more
resistant to the down-regulation of counterregulation that is observed following antecedent
hypoglycaemia in men (104).
1.4.3.4 Exercise
One further observation regarding the sexual dimorphism of the counterregulatory response is
that female counterregulatory responses are less affected by exercise than in men (ll 4).
However, in both males and females, moderate intensity exercise prior to hypoglycaemia has
been shown to blunt the counterregulatory response to hypoglycaemia in both healthy
individuals (115,116) and subjects with type 1 diabetes (117).
In non-diabetic subjects, counterregulatory responses to hypoglycaemia were blunted by 2
exercise sessions the preceding day for 90 minutes at 50%VO2max (115) or for 60 minutes at
70%VCfimax (116). In a study in type 1 diabetes, 27 individuals underwent a hypoglycaemic
clamp one day after either no exercise or after two 90-minute exercise sessions 3 hours apart
at either low (30%VO2max) or moderate intensity (50%VO2max)- These repeated episodes of
both low and moderate intensity exercise were found to reduce muscle sympathetic nerve
activity and attenuate the responses of epinephrine and pancreatic polypeptide (117).
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One study found no effect of antecedent exercise (60 minutes at 60%VO2„iax) on
hypoglycaemic counterregulation 90 minutes later (118) but methodological inconsistencies
such as differences in the intensity, frequency and duration of exercise along with differences
in the timing between exercise and hypoglycaemia hamper direct comparisons between this
latter study and previously discussed studies in non-diabetic individuals. Interestingly,
hypoglycaemia can itself affect the physiological responses to exercise. Ninety minutes of
exercise with a work level of 50% V02max has been shown to reduce the neuroendocrine and
metabolic responses to exercise by around 50% (119).
1.4.3.5 Alcohol
Although alcohol can theoretically contribute to hypoglycaemia by causing a direct fall in
blood glucose, this is probably only relevant in a state of glycogen depletion such as
malnourishment or following prolonged exercise. In one glucose clamp study, 7 subjects
with type l diabetes and 8 healthy volunteers consumed either ethanol or placebo prior to
undergoing clamped hypoglycaemia. Counterregulatory hormone secretion following
ethanol did not differ from counterregulatory changes following placebo (120).
However, another research group found that the ingestion of alcohol 1 hour before clamped
hypoglycaemia does impair glucose counterregulation in individuals with type 1 diabetes,
possibly by suppressing lipolysis (121). It is therefore possible that the effects of alcohol on
blood glucose will only be relevant at certain times such as during the night, when lipolysis
increases to promote gluconeogenesis (122). Although one study found a reduction in the
glucagon response to hypoglycaemia, this has not been replicated in other studies (120).
A number of studies show that ingestion of alcohol attenuates the growth hormone response
to hypoglycaemia (120,123,124). Unpublished data described by Kerr and colleagues
suggests blunting of the epinephrine response to clamped hypoglycaemia following ingestion
of alcohol 12 hours earlier (125). The effects of alcohol on blood glucose can persist for
many hours with delayed hypoglycaemia following evening alcohol demonstrated in both
laboratory studies (126) and field studies employing continuous glucose monitoring (127).
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These findings are all consistent with the observation that glucagon is important or
counterregulation the setting of acute hypoglycaemia while growth hormone is more relevant
in prolonged hypoglycaemia (59).
1.4.3.6 Age
Early studies assessing the effects of age on counterregulation yielded conflicting results,
partly because data interpretation was confounded by the presence of co-morbidities in
elderly participants. However, subsequent studies point to the presence of age-related
alterations in counterregulation. One study used an intravenous infusion of insulin to
compare the counterregulatory responses to hypoglycaemia in non-diabetic elderly and young
adults and suggested that with advancing age, the secretion of glucagon, growth hormone and
Cortisol are diminished, the rise in plasma epinephrine is slowed, the rate of insulin clearance
is reduced and blood glucose recovery is modestly attenuated (128). A reduced rate of
clearance of insulin has also been noted in several other studies (129-131). These
counterregulatory changes do not appear to be affected by preceding physical training,
suggesting that they are not simply a consequence of a more sedentary lifestyle associated
with ageing (128).
The glycaemic thresholds for the secretion of glucagon and epinephrine in response to
hypoglycaemia also occur at a lower blood glucose level than in younger subjects. In young
non-diabetic adults, these hormones are released at a blood glucose level of 3.3mmol/l,
compared to approximately 2.8mmol/l in older adults (132).
With increasing age, the depth of the blood glucose nadir appears to influence the magnitude
of the counterregulatory response. In clamp studies comparing elderly and young non-
diabetic subjects, the magnitude of the glucagon and epinephrine responses was lower in the
elderly group during mild hypoglycaemia (blood glucose 3.3 mmol/1) but identical in the two
groups at a lower blood glucose of 2.8 mmol/1, indicating that in the elderly,
counterregulatory responses are preserved during more profound hypoglycaemia (66).
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Other similar studies in non-diabetic elderly subjects have not demonstrated any significant
age-related impairment of the counterregulatory hormonal responses to hypoglycaemia
(133.134). Furthermore, although the symptomatic and counterregulatory responses to
hypoglycaemia may be modified by advancing age, it is not known at what age these changes
become apparent nor whether these effects are influenced by gender or the menopause in
women.
1.4.3.7 Type of diabetes
An additional difficulty lies in the fact that most of the work on glucose counterregulation has
been conducted in type 1 diabetes or young healthy non-diabetic individuals. Most elderly
patients with diabetes will have type 2 diabetes so it is relevant to ask whether type 2 diabetes
per se has effects on the counterregulatory process.
Early studies of the counterregulatory responses to hypoglycaemia in type 2 diabetes were
limited by methodological factors such as differences in blood glucose nadir between the
diabetic and control groups, poorly matched or absent control groups and the inconsistent
methods used to induce hypoglycaemia with techniques such as intravenous or subcutaneous
bolus injections of insulin (135).
However, three later studies that examined counterregulatory responses to hypoglycaemia in
people with type 2 diabetes, receiving treatment either with diet alone or with oral
medication, are methodologically more robust. These studies demonstrated that the secretion
of counterregulatory hormones occurs at higher blood glucose levels in individuals with type
2 diabetes than in non-diabetic subjects (136,137) and in people with type 1 diabetes (138)
which may confer greater protection against hypoglycaemia on individuals with type 2
diabetes than those with type 1 diabetes. However, when HbAlc is lowered with intensive
therapy in type 1 diabetes, the thresholds for the counterregulatory responses are shifted to a
lower glycaemic level (89,139) and the same phenomenon appears to occur in type 2 diabetes
(136,138).
31
Similarly, some of the counterregulatory deficiencies seen in long-standing type 1 diabetes
are also evident in insulin-deficient patients with type 2 diabetes. The counterregulatory
responses to hypoglycaemia were examined in 15 non-diabetic controls and in 13 people with
type 2 diabetes, six of whom were treated with insulin, and who were demonstrated to be
insulin-deficient with low plasma C-peptide, while the remaining seven were being treated
with oral anti-diabetic agents (83). The glucagon response to hypoglycaemia was preserved
in the patients on oral agents and in the non-diabetic controls, but was virtually absent in the
insulin-deficient patients, demonstrating an association of acquired counterregulatory
abnormalities and insulin deficiency in type 2 diabetes. Deficient counterregulation was also
observed in a group of patients with type 2 diabetes with moderate beta cell failure, in whom
the reduction in endogenous insulin secretion that normally occurs during hypoglycaemia
was delayed and reduced, and responses of glucagon and growth hormone were impaired
(86).
1.4.3.8 Obesity
One potential confounding factor in studies of individuals with type 2 diabetes is obesity, as
this can also affect counterregulation in its own right. Morbidly obese non-diabetic subjects
underwent hypoglycaemic clamps (glucose nadir 3.4 mmol/l) before and after bariatric
surgery (average weight loss 40kg over 12 months). This study suggested excess activation
of the glucagon, epinephrine, norepinephrine and pancreatic polypeptide responses prior to
surgery with normalisation of these responses after surgery. Growth hormone results showed
an opposite pattern with an increased response after weight loss (140).
1.4.3.9 Sleep
Finally, the sleeping state has a direct effect on counterregulation. Studies in children with
type 1 diabetes conducted in their own homes demonstrated an attenuated epinephrine
response to spontaneous nocturnal hypoglycaemia (141). This finding has been replicated in
adolescents both with and without type 1 diabetes when counterregulation was compared
during daytime and night-time glucose clamps with a glucose nadir or 2.8 mmol/l (142). In
adults with type 1 diabetes, similar findings have been observed although non-diabetic adults
appear to have preserved counterregulation during sleep (143).
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1.5 Symptoms of hypoqlycaemia
The study of hypoglycaemic symptoms is clinically relevant because prompt recognition of
hypoglycaemic symptoms is required to allow the instigation of early corrective treatment
(144.145). The symptoms of hypoglycaemia were first described in 1922 (2) and these are
listed in table 1.2. Although more recent studies have categorised and refined these
symptoms, contemporary symptom lists do not differ substantially from this original one.
Symptoms are generated at arterialised blood glucose concentrations around 2.8-3.2 mmol/1
and field studies in which young adults with insulin-treated diabetes have reported symptoms
during episodes of hypoglycaemia have allowed the most common symptoms to be identified
(145) and subdivided into autonomic, neuroglycopenic and general malaise groups (6).
These are summarised in table 1.2 alongside Fletcher and Campbell's original classification.
The concept that symptoms can be divided into different groups is supported by evidence
from two different but complementary experimental approaches: statistical analyses of
symptom reports and physiological/pharmacological studies. The main statistical technique
employed in the classification of hypoglycaemic symptoms is that of Principal Axis Factor
Analysis. Reports of hypoglycaemic symptoms have been collected from people with
(146.147) and without (147) insulin-treated diabetes in both laboratory (147) and field (146)
studies. These have been analysed by principal components analysis, also known as factor
analysis, which confirmed that symptoms segregate into three distinct groups:
neuroglycopenic, autonomic and general malaise (6,146,147). The eleven common
hypoglycaemic symptoms contained within this 'three factor' validated model make up the
'Edinburgh Hypoglycaemia Scale' (6) which allows each symptom to be given an intensity
score from 1 to 7 on a visual analogue scale, allowing for comparison of symptoms between
different episodes of hypoglycaemia.
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Table 1.2
Comparison of different classifications of hypoglycaemic symptoms. Compiled from data in
Hypoglycaemia in clinical diabetes 2nd edition (2007) (eds Frier BM. Fisher BM) (144).
flypoglycaemic symptoms described Eist of symptoms Symptom categories (6)
by Fletcher and Campbell (2) described by Deary (6)
Sweating Sweating
Tremulousness Shaking
Feeling of hot or cold Warmth Autonomic
>
Change in pulse rate Palpitations
Excessive hunger H linger
Dysarthria, sensory and motor aphasia Speech difficulty ~N
Incoordination Incoordination
Nervousness, anxiety, excitement, Odd behaviour
emotional upset






Emotional instability V Malaise
Pallor
J
Statistical studies demonstrate that symptoms cluster into groups and allow researchers to
develop hypotheses as to how these symptoms are generated. For example, it seems intuitive
to label a group of symptoms that includes confusion, decreased concentration and
drowsiness as neuroglycopenic while a symptom that comprises sweating, anxiety and
pounding heart would seem to represent an autonomic group.
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However, statistical techniques can only demonstrate the association between symptoms but
cannot absolutely confirm their physiological origin. In order to demonstrate that these
symptoms do indeed have an either an autonomic or neuroglycopenic origin, differing
pharmacological blockades have been employed in healthy non-diabetic individuals.
Subjects were clamped on 4 different occasions in random sequence during euglycaemia.
hypoglycaemia (2.5 mmol/1), hypoglycaemia and combined alpha- and beta-adrenergic
blockade and hypoglycaemia with full autonomic blockade. Phentolamine and propranolol
were used to achieve alpha- and beta-blockade respectively while atropine was added to
achieve full-autonomic blockade. This study demonstrated that tremulousness. anxiety and
racing heart are all mediated by the adrenergic system (7), while sweating and hunger are
generated by sympathetic cholinergic stimulation (7,8). Those symptoms that were provoked
by hypoglycaemia but not reduced by complete autonomic blockade were designated as
neuroglycopenic in nature and included confusion, drowsiness and weakness (7). Evidence
that adrenalectomised individuals exhibit typical autonomic symptoms suggests that these
largely arise from sympathetic neural activation rather than release of epinephrine from the
adrenal medulla (9).
When individuals with diabetes have previously been asked to indicate which symptoms they
most associate with hypoglycaemia, the commonest symptoms were sweating, difficulty
concentrating, decreased coordination and weakness (80%, 80%, 75% and 70% of
respondents respectively) (148). The earliest symptoms to develop when blood glucose falls
into the hypoglycaemic range are trembling, sweating, tiredness, decreased concentration and
hunger (149). The symptoms which correlate most accurately with blood glucose levels are
hunger, trembling and weakness (53%, 33% and 27% of people respectively) (150).
Surprisingly, the relationship between symptomatic and biochemical hypoglycaemia is not as
robust as might be expected. During stepped clamps, blinded individuals with type 1 diabetes
were asked to rate their symptoms at blood glucose levels of 8.9, 5.6 and 2.2 mmol/i on a
hypoglycaemic clamp and at 8.8, 14.4 and 21.1 mmol/1 during a hyperglycaemic clamp (151).
They were also asked to estimate their blood glucose levels at each step of the clamp. During
the hypoglycaemic clamp, 34% of subjects had no awareness of autonomic symptoms while
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1 5% had no symptoms at all. Hypoglycaemia and hyperglycaemia were frequently confused,
with potentially serious errors made by 66% patients at blood glucose levels of 21.1 mmol/1
and 17% of subjects at 2.2 mmol/1 (151). Earlier field studies examining the relationship
between symptomatic and biochemical hypoglycaemia also found that they were unreliably
linked, with biochemical hypoglycaemia (defined as < 3mmol/l) present in only 29% of
symptomatic episodes and symptoms present in only 16% of episodes of biochemical
hypoglycaemia (20).
Even when symptoms are present at the time of biochemical hypoglycaemia, there is no
guarantee that an individual will translate their symptoms into appropriate actions such as the
measurement of capillary glucose and the ingestion of carbohydrate to correct the
hypoglycaemia. This is because multiple factors such as patient knowledge, distractors and
symptom beliefs can affect an individual's response to hypoglycaemic symptoms (152). For
example, a standing position augments the autonomic but not the neuroglycopenic symptoms
associated with hypoglycaemia (75).
Lack of knowledge can also be an important factor influencing the ability to respond
appropriately to hypoglycaemia, particularly amongst elderly people with type 2 diabetes
(153,154) and their relatives and carers (155). However, even in young adults, knowledge of
diabetes and its treatment declines with time (156) and regular educational reinforcement on
interpretation of hypoglycaemic symptoms is seldom undertaken in clinical practice.
It has been suggested that in daily life, people with diabetes tend to rely predominantly on
autonomic rather than neuroglycopenic symptoms to warn them of the onset of
hypoglycaemia (7). However, neuroglycopenic symptoms are as closely related to blood
glucose concentrations as autonomic symptoms (148) and, at the onset of hypoglycaemia,
people with insulin-treated diabetes report symptoms from both groups with equal frequency
(147). Thus, both autonomic and neuroglycopenic symptoms are of equal value in warning
people with type 1 diabetes of the onset of hypoglycaemia, provided that the symptoms
peculiar to the individual are identified and interpreted correctly. This reinforces the
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importance of educating individuals to be aware of their own individual constellation of
hypoglycaemic symptoms.
When educating patients about the recognition of hypoglycaemia. it is also important to be
aware of factors that may cause variation in the symptom profile. Hypoglycaemic symptoms
are idiosyncratic and age-specific (145). For example, young children have difficulty
recognising hypoglycaemia and distinguishing between autonomic and neuroglycopenic
symptoms (157) and they often exhibit behavioural changes as part of their symptom profile
(158,159). In elderly patients, neurological symptoms, such as visual disturbance and
decreased coordination, are prominent and general malaise symptoms are less frequently
reported (160). The neurological symptoms and signs generated in response to
hypoglycaemia in elderly people may masquerade as other conditions, such as a transient
ischaemic attacks or vaso-vagal episodes.
In a study comparing hypoglycaemia generated by tolbutamide and insulin (161), the
symptoms reported were unaffected by the causative agent. In an analysis of multiple studies
by the same group, the symptoms of hypoglycaemia did not appear to be affected by the
method of induction of hypoglycaemia (insulin infusion versus hypoglycaemic clamp) (162).
However, while the symptoms generated by insulin and sulphonylureas may not differ in
nature, a stepped glucose clamp study suggested that in patients treated with sulphonylureas,
hypoglycaemic symptoms are more intense and occur at higher blood glucose concentrations
that in patients with insulin treated type 2 diabetes, even when the two groups are matched
for glycaemic control and duration of diabetes (163). While this may offer some additional
protection from severe hypoglycaemia for those treated with sulphonylureas, it may also act
as a barrier to the achievement of tight glycaemic control in this group. Retrospective recall
of symptoms in field studies (164,165) and symptom measurement during experimental
hypoglycaemia (162,166) suggest that the symptom profile does not differ between type 1
diabetes and insulin-treated type 2 diabetes.
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Although there are gender differences in the extent of the symptomatic and counterregulatory
responses to hypoglycaemia (104,106.108.114). symptoms of hypoglycaemia develop at
similar blood glucose thresholds in men and women with type 1 diabetes (62). A study
reviewing symptoms recorded during experimentally-induced hypoglycaemia in 160 adults
(with and without diabetes) did not find any evidence of a gender effect on the nature of the
reported symptoms (167).
Prospective field studies have demonstrated that some hypoglycaemia-related symptoms may
be more reliably associated with a patient's blood concentration than others, but a given
symptom is not equally predictive of hypoglycaemia in everyone (150). This points to the
existence of between-subject variability in the reporting pattern of symptoms and it is widely
accepted that each individual's symptom complex is idiosyncratic (145). However, an
additional important issue is the degree to which individuals report similar patterns of
hypoglycaemia-related symptoms across episodes. The reliability with which hypoglycaemic
symptoms occur will influence an individual's ability to detect the onset of hypoglycaemia.
People who have at least one reliable symptom of hypoglycaemia detect blood glucose levels
below 3.9mmol/l correctly on 50% of occasions, whereas individuals with four or more
reliable symptoms recognize similar blood glucose levels on 75% of occasions (148).
The symptoms reported by children exhibit marked within-subject (or intra-individual)
variability between episodes of hypoglycaemia (157) but it is not known whether the same is
true of adults. This is a relevant issue because many of the studies which have informed us
about the nature and classification of hypoglycaemic symptoms have relied on patients
documenting their 'typical' hypoglycaemic symptoms. These studies partly rest on the
assumption that each individual will have a group of hypoglycaemic symptoms which is
reasonably constant at an intra-individual level. While the idiosyncrasy of an individual's
hypoglycaemic symptoms is widely accepted (144), the intra-individual consistency of
symptom reporting has not been formally studied so far.
The effects of alcohol on symptom generation have been studied. In one clamp study, seven
subjects with type 1 diabetes and eight healthy volunteers consumed either ethanol or placebo
prior to undergoing clamped hypoglycaemia. At euglycaemia, ethanol caused a transient
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increase in systolic blood pressure, a sustained increase in heart rate and a slowing in reaction
time. During hypoglycaemia, ethanol was associated with a more marked slowing of reaction
time, and a greater increase in sweating and finger tremor than on the placebo study (120).
Furthermore, following ethanol, only 2 out of the 15 subjects were aware of symptoms during
hypoglycaemia as compared to 11 out of 15 subjects following placebo (120).
Antecedent exercise also affects symptomatic responses to hypoglycaemia. In a study
involving 27 individuals with type 1 diabetes, subjects were clamped on three occasions, 1
day after either no exercise or after two 90-minute exercise sessions at 30%VO2max or two-90
minute sessions at 50%VO2max- These repeated episodes of both low and moderate intensity
exercise were found to the blunt hypoglycaemic symptoms on both days compared to the
control clamp with no antecedent exercise (117).
In conclusion therefore, hypoglycaemic symptoms can be grouped into autonomic,
neuroglycopenic and general malaise categories and they are usually initiated at blood
glucose levels of approximately 2.8-3.2 mmol/1. However, multiple factors can affect an
individual's perception of symptoms and their ability to act appropriately in response to them.
Although it is accepted that each individual has an idiosyncratic set of hypoglycaemia
symptoms, the degree to which these vary from one episode of hypoglycaemia to the next is
unknown.
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1.6 Awareness of hypoqlycaemia
1.6.1 Definition
Awareness of hypoglycaemia can be defined as "the initial perception of any symptom of
hypoglycaemia, irrespective of whether this is autonomic, neuroglycopenic or simply a vague
sensation of apprehension or loss of well-being" (168). The clinical syndrome of impaired
awareness of hypoglycaemia has long been recognised and was clearly described by
Lawrence in 1941 (169). There is no universally accepted definition of impaired awareness
of hypoglycaemia but it is clear that with increasing duration of type 1 diabetes, many
individuals experience a change in symptom profile and/or a reduction in symptom intensity
such that they are less aware of the onset of hypoglycaemia. An increase in the frequency of
asymptomatic biochemical hypoglycaemia during routine blood glucose monitoring
(170.171) or continuous glucose monitoring (172) can be suggestive of impaired awareness.
Despite the lack of consensus over a precise definition, the term "impaired awareness" of
hypoglycaemia is more useful than "hypoglycaemia unawareness" because loss of awareness
is not an all or none phenomenon. Total absence of all warning symptoms is rare (170.171).
1.6.2 Classification and prevalence of impaired awareness
Several systems of classifying impaired awareness are in use (21,170.171,173). The method
developed by Clarke and colleagues consists of 8 questions to document the individual's
exposure to moderate and severe hypoglycaemia as well as their threshold for developing
hypoglycaemic symptoms and the nature of these symptoms, with a score of 4 or above
suggesting impaired awareness of hypoglycaemia (171). The method by Gold and colleagues
poses the question "do you know when your hypos are commencing?" The subject gives
their answer on a 7-point Likert scale where 1 represents "always aware" and 7 represents
"never aware". A score of 4 or above suggests impaired awareness of hypoglycaemia (170).
The method by Pedersen-Bjergaard and colleagues asks the question "can you feel when you
are low?" The patient can reply either "always", "usually", "sometimes" or "never". Patients
answering anything other than "always" are considered to have impaired awareness.
These three methods have been directly compared in one study where 80 participants with
type 1 diabetes completed all 3 methods of assessment in random order and then complete 4-
point daily blood glucose monitoring for a 4 week period (174). Any documented blood
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glucose reading below 3 mmol/1 was accompanied by an assessment of symptoms using the
Edinburgh Hypoglycaemia Score (6). The prevalence of impaired awareness of
hypoglycaemia was 26%, 24% and 62.5% using the Clarke, Gold and Pedersen-Bjergaard
methods respectively (174). There was a strong correlation between the results using the
Clarke and Gold methods (r=0.868. p=0.001) with the Pedersen-Bjergaard method appearing
to overestimate the prevalence of impaired awareness of hypoglycaemia (174). The
prevalence in this study using the Clarke and Gold methods is similar to figures in previous
population studies, suggesting a prevalence of 20-27% in unselected individuals with insulin-
treated diabetes (4,175-177). The clinical history is of paramount importance in assessing
awareness as individuals who feel that they have impaired hypoglycaemic warnings are
usually correct (171).
The prevalence of impaired awareness of hypoglycaemia has been re-examined more
recently. Earlier prevalence data was based on retrospective cohorts prior to the introduction
of insulin analogues and it was therefore postulated that the rates of hypoglycaemia and
impaired awareness of hypoglycaemia might have fallen with more modern treatment
regimens. In a cohort of 518 people with type 1 diabetes recruited randomly from a hospital
clinic over a two year period, the prevalence of impaired awareness using the Gold method
(170) was 19.5% (178), compared to prevalence figures of 20-27% in earlier studies (4,175-
177). Those with impaired awareness were older with a longer duration of diabetes and had a
six-fold greater incidence of severe hypoglycaemia in the preceding year (1 78). Older studies
have also shown that impaired awareness of hypoglycaemia is associated with a six-fold
increase in the incidence of severe hypoglycaemia (170,171) and studies employing CGMS
confirm that those with impaired awareness have a much higher rate of undetected daytime
hypoglycaemia than those with intact awareness (172). Impaired awareness of
hypoglycaemia becomes more common with increasing duration of insulin therapy (175) and
by the time individuals have been treated for 25 years, up to 50% will have impaired
awareness (4). 0.48, 2.83
It is important to identify impaired awareness of hypoglycaemia in view of its association
with increased risk of severe hypoglycaemia. Retrospective studies suggest that the
prevalence of severe hypoglycaemia in this group is 90%, compared to 18% in individuals
with normal awareness (175). Prospective studies suggest that individuals with impaired
awareness have a six-fold increased frequency of severe hypoglycaemia (170).
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1.6.3 Pathogenesis of impaired awareness of hypoglycaemia
Impaired awareness predisposes to severe hypoglycaemia for a number of reasons, including
changes in the blood glucose thresholds required to trigger symptoms and counterregulatory
responses. A study that compared the thresholds for the onset of symptoms and
counterregulation during hypoglycaemia in non-diabetic subjects and in people with type l
diabetes who had either normal or impaired awareness of hypoglycaemia found that those
with impaired awareness developed neuroglycopenic symptoms and counterregulatory
hormone secretion at lower blood glucose levels than in those with normal awareness and
non-diabetic control subjects respectively (78).
There is also evidence for functional cerebral changes in response to hypoglycaemia.
Adaptation in brain glucose uptake following recurrent or prolonged hypoglycaemia has been
demonstrated in non-diabetic people and in subjects with type l diabetes (17,179) and
neuroimaging studies have demonstrated permanent alterations in regional cerebral blood
flow in those with a history of severe hypoglycaemia, with increased perfusion of the frontal
cortex and a decrease to caudal regions (180).
Central nervous system adaptation and exposure to recurrent hypoglycaemia are not the only
potential factors implicated in the pathogenesis of impaired awareness. It has been observed
that impaired awareness of hypoglycaemia often co-exists with counterregulatory
deficiencies in individuals with long-standing type 1 diabetes (181). It has therefore been
suggested that there may be a common aetiology for counterregulatory failure and impaired
awareness of hypoglycaemia. Individuals who experience frequent hypoglycaemia can
develop a condition that has been termed Hypoglycaemia Associated Autonomic Failure
(HAAF) (14,102,103). The underlying premise is that antecedent hypoglycaemia results in
attenuation of the epinephrine response to hypoglycaemia in individuals who have already
lost their glucagon response. This results in defective counterregulation and reduced warning
symptoms. Supporting evidence for this suggestion comes from evidence that both awareness
of hypoglycaemia and the epinephrine response can be partially restored by avoidance of
hypoglycaemia for 2 or more weeks (11,62,182,183). While antecedent hypoglycaemia
42
underlies the counterregulatory defects and impaired awareness observed in I1AAF, both of
these problems themselves predispose to recurrent hypoglycaemia, thus setting up a vicious
self-perpetuating cycle.
Although it is clear that antecedent hypoglycaemia moves the thresholds for sympathoadrenal
responses to lower blood glucose levels, the mechanisms underlying these threshold shifts are
less well understood. Several hypotheses exist to explain the potential central nervous system
alterations that might underlie the altered glucose thresholds observed in HAAF, antecedent
hypoglycaemia and impaired awareness of hypoglycaemia (184).
The first of these is the systemic mediator hypothesis, which postulates that antecedent
hypoglycaemia increases levels of a systemic factor, such as Cortisol, which acts on the brain
to reduce the sympathoadrenal responses to hypoglycaemia (185). There are data from
animal studies to support this theory. Corticotrophin-releasing hormone (CRFI) acts at key
sites in the brain involved in autonomic activation. CRH delivered to the VMH and acting
via the CRH-1 receptor amplifies the counterregulatory response to hypoglycaemia (186)
while local delivery of urocortin, acting via the CRH-2 receptor, suppresses counterregulation
(187).
The potential for Cortisol to be implicated in the development of impaired awareness of
hypoglycaemia is also supported by human data. In healthy subjects, Cortisol infusions
during euglycaemia reduce epinephrine and muscle sympathetic responses to hypoglycaemia
the following day, in a manner analogous to that of antecedent hypoglycaemia (185).
Infusions of ACTH resulting in supraphysiological Cortisol levels similarly led to diminished
symptom responses to hypoglycaemia the following day (116). It has therefore been
hypothesised that elevations of Cortisol in the context of hypoglycaemic counterregulation
blunt subsequent responses to hypoglycaemia. In a clamp study of individuals with primary
adrenocortical failure (who cannot mount a Cortisol response during hypoglycaemia),
participants' usual glucocorticoid therapy was replaced by a continuous Cortisol infusion
designed to mimic the normal circadian variation. When the adrenocortical failure group and
healthy controls underwent hyperinsulinemic clamps on two consecutive days, the control
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group demonstrated blunted counterregulation on the second day while the adrenocortical
failure group had preserved counterregulation. The authors suggest that the lack of a rise in
Cortisol during the first clamp resulted in preservation of counterregulation during the second
clamp (188). However, these findings have been challenged by Phil Cryer;s group, who
demonstrated that low dose Cortisol infusions, at a level similar to that present during
systemic hypoglycaemia. do not reduce the symptom response to hypoglycaemia the
following day (189). Furthermore, CRI1 knockout mice, who are unable to mount a Cortisol
response, still develop counterregulatory changes in response to recent antecedent
hypoglycaemia (190). These latter studies therefore question the role of Cortisol in the
pathogenesis of impaired awareness and HAAF.
The brain fuel transport hypothesis suggests that the brain up-regulates blood-brain barrier
transporters, such as GLUT-1. in response to recent antecedent hypoglycaemia. This allows
increased transport of glucose and other metabolic fuels into the brain, which in turn reduces
the sympathoadrenal responses to subsequent hypoglycaemia. Studies in rodents undergoing
3 days of hypoglycaemia demonstrate increases in brain GLUT-1 and protein and glucose
uptake (191-194). Similarly, humans undergoing 2 days of hypoglycaemia demonstrate
preserved glucose uptake during subsequent hypoglycaemia (17,179). However, in healthy
subjects undergoing 24h of experimental hypoglycaemia, sympathoadrenal and autonomic
responses were attenuated, as in HAAF, but brain glucose transport, as measured by [1-
"Cjglucose positron emission tomography, was not altered (195). Furthermore, the features
of HAAF can begin to become evident after just a few hours of hypoglycaemia (101,196,197)
so the relevance of studies of prolonged hypoglycaemia to our understanding F1AAF and
impaired awareness is unclear.
According to the brain metabolism hypothesis, recent antecedent hypoglycaemia alters brain
metabolism in a way which reduces sympathoadrenal responses to subsequent
hypoglycaemia. The difficulty with verifying this hypothesis is that, although certain areas
such as the VMH are key to cerebral glucose-sensing (45,51,53-55), counterregulation
involves widespread brain activation (198), making this a difficult area to study. A number
of possible alterations in metabolism have been examined, including glucokinase activity.
Glucokinase is thought to mediate glucose-sensing in the VMFI (41), where its expression has
44
been demonstrated (199). In one study, the infusion of fructose, given to modulate
glucokinase activity, resulted in near-normalisation of the epinephrine response to
hypoglycaenria in patients with type 1 diabetes (200).
Finally, the brain glycogen supercompensation hypothesis posits that reduced
sympathoadrenal responses are caused by a rebound increase in astrocyte glycogen levels
following antecedent hypoglycaemia (201). However, there is little concrete evidence for a
hypothesis which relies heavily on the concept of supercompensation, given that brain
glycogen turnover is a small fraction of total glucose consumption measured in rats (202) and
brain glycogen stores are orders ofmagnitude lower than stores in muscle and liver.
Regardless of whether antecedent hypoglycaemia alters glucose thresholds via a systemic
mediator or by affecting brain metabolism, delivery of brain fuel or storage of brain
glycogen, the final effects may well be mediated by changes in the cross-talk between GI and
GE neurones (42). Both sets of neurones function over a range of glucose values with
considerable overlap but hypoglycaemia favours activity of GI neurones (which act to
promote counterregulation) while hyperglycaemia favours activity of GE neurones (which
suppress counterregulation). Recurrent hypoglycaemia is associated with reduced AMPK
activity in the VMH and AMPK is implicated in the functioning of GI neurones (203). Thus,
glucose counterregulation would be expected to commence at a lower blood glucose level
due to reduced activation ofGI neurones.
1.6.4 Conclusions on impaired awareness of hypoqlycaemia
Although there is a clear appreciation of impaired awareness of hypoglycaemia as a clinical
problem, current understanding of its pathogenesis and our ability to treat and correct it is
limited. Hypoglycaemia will activate a number of defence systems and, while individual
studies may help elucidate fragments of this system, our understanding of the cross-talk
between these various defence systems remains restricted. Clearly, ongoing work is needed
in this field in view of the fact that patients with impaired awareness represent one of the
groups who are most vulnerable to the potentially devastating effects of hypoglycaemia.
45
1.7 Epidemiology of hypoqlycaemia in type 1 and type 2 diabetes
mellitus
The studies in this thesis all relate to hypoglycaemia in type 1 diabetes so this section will
focus on the frequency of hypoglycaemia in type 1 diabetes. However, the frequency of
hypoglycaemia in type 2 diabetes will also be mentioned because some studies consider
insulin-treated patients with both types of diabetes and other studies in type 2 diabetes
contribute to the debate on the safety of tight glycaemic control and the dangers of
hypoglycaemia in general.
In people with type 1 diabetes, several studies have recorded that, mild hypoglycaemia occurs
on average around twice weekly (4,173,204). However, calculating the frequency of mild
hypoglycaemia can be difficult for a variety of reasons including the fact that recall of mild
hypoglycaemia is unreliable after an interval of one week (4,21). Furthermore, mild episodes
may be unnoticed or the symptoms may be misinterpreted without this leading to any obvious
consequences. Definitions of mild hypoglycaemia differ between studies, hampering
comparison. Finally, inclusion and exclusion criteria in some studies may limit the
generalisability of their data on hypoglycaemia. For example, one study reporting an
extremely low rate of mild hypoglycaemia of eight episodes per person per year (205)
included patients with insulin-treated type 2 diabetes and examined a cohort with poor
glycaemic control (mean HbAlc 9.1%), factors which would be expected to reduce the
frequency of observed hypoglycaemia. Similarly, participants in the Diabetes Control and
Complications Trial (DCCT) (3,206) were excluded if they had experienced more than one
episode of severe hypoglycaemia in the last two years, which would probably result in a
lower rate of hypoglycaemia than would be observed in an unselected population (207).
By contrast, recall of severe hypoglycaemia is relatively robust over a period of one year and
severe hypoglycaemia is therefore easier to record accurately. In studies in northern Europe
of unselected populations with type 1 diabetes, the estimated incidence of severe
hypoglycaemia ranges from 1.0 to 1.7 episodes/patient/year (4,173,204,208-210). The annual
prevalence is around 30% (206,208,211) but can be as high as 40.5% (209). Flowever, the
frequency of severe hypoglycaemia is skewed with many people with type 1 diabetes never
experiencing severe hypoglycaemia and a small minority experiencing repeated episodes. In
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the UK Hypoglycaemia Study, individuals were stratified according to type and duration of
diabetes. In subjects with less than 5 years duration of type 1 diabetes, the incidence of
severe hypoglycaemia was 1.1 episodes per person per year, with a prevalence of 22%.
However, in subjects with greater than 15 years duration of type 1 diabetes, the incidence was
3.2 episodes per patient per year with a prevalence of 46% (212). Thus, the incidence of
severe hypoglycaemia is higher in certain groups, such as those with a longer duration of
diabetes (212) or those with impaired awareness of hypoglycaemia (170,171). By
comparison, those with insulin-treated type 2 diabetes of greater than 5 years duration had a
much lower mean incidence of severe hypoglycaemia of 0.7 episodes per person per year
with a prevalence of 25% (212).
One of the strengths of the UK Hypoglycaemia Study is the subdivision of subjects according
to treatment modality and disease duration. The United Kingdom Prospective Diabetes Study
(UKPDS) (213), which reported the prevalence of hypoglycaemia in different treatment
groups of people with type 2 diabetes, is frequently cited in discussions of the frequency of
hypoglycaemia in type 2 diabetes. A higher frequency of hypoglycaemia was associated with
intensive compared to conventional treatment, with either sulphonylureas or insulin. With
intensive insulin treatment, the prevalence of severe hypoglycaemia was 2.3%. One of this
study's main strengths is its duration. However, although it subdivides subjects by treatment
modality, the oral agents used (glibenclamide and chlorpropamide) are no longer in
mainstream use in the UK and there is no stratification by disease duration. Furthermore, it
lacks accurate incidence data because only the most severe episode of hypoglycaemia was
documented at each four monthly review.
Similarly, hypoglycaemia data from the Diabetes Control and Complications Trial (DCCT)
(3,206) are frequently cited in the context of type 1 diabetes. However, these figures must be
interpreted with caution for a number of reasons. Firstly, this was an interventional trial so
the figures are not a true reflection of the frequencies of hypoglycaemia observed in routine
clinical practice. Secondly, patients at high risk of hypoglycaemia were excluded from the
DCCT (207), which explains the lower incidence of severe hypoglycaemia observed (0.19 to
0.62 episodes/patient/year) (3). The risk of severe hypoglycaemia was higher in the
intensively managed arm of the trial, which serves as a reminder that the ambient level of
glycaemic control will affect hypoglycaemic risk. This fact further limits the generalisability
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of the DCCT hypoglycaemia data to a contemporary patient cohort because of the
anachronistic definition of intensive management in the DCCT. This trial shaped the way
that diabetes is currently managed such that the level of glycaemic control that was formerly
considered to be strict would now be viewed as desired management. The DCCT therefore
does not give any indication of the risk of severe hypoglycaemia for unselected patients who
are treated intensively by modern standards, and the same criticism could be applied to the
UKPDS for data in type 2 diabetes.
More recently, two large randomised controlled trials were published in the same issue of the
New England Journal of Medicine comparing modern-day intensive management with
conventional management of blood glucose in type 2 diabetes. Although their reported
frequencies of hypoglycaemia are not directly relevant to individuals with type 1 diabetes,
these trials sparked extensive debate over the safety of tight glycaemic targets and their effect
on overall mortality as well as on the frequency of hypoglycaemia. They therefore merit
brief discussion here.
The ACCORD trial (Action to Control Cardiovascular Risk in Diabetes) (214) included
intensive and conventional blood pressure, lipid and glycaemic control arms. The intensive
glucose control arm, which aimed for an HbAlc <6%, was terminated early because of an
increase in cardiovascular and all-cause mortality. In contrast, there was no increase in
mortality in the intensive glycaemic control arm in the ADVANCE trial (Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modfied Release Controlled Evaluation)
(215), which aimed for HbAlc <6.5%. Although both trials achieved a median HbAlc of
6.4%, baseline HbAlc values differed so that the intensive group in ACCORD had an
absolute HbAlc reduction of 1.4% within 4 months, while participants in the intensive arm of
ADVANCE had an absolute decrease in HbAlc of 0.6% at 12 months. Furthermore, the use
of thiazolidinediones, alone or in combination with insulin, was much higher in ACCORD.
The prevalence of severe hypoglycaemia was 3.1% in the intensive arm of ACCORD
compared to 0.7% in the intensive arm of ADVANCE. Nineteen of the 41 excess deaths in
ACCORD were attributed to "unexpected or presumed cardiovascular disease. It has been
suggested that the excess mortality may have been precipitated by severe hypoglycaemia,
although this cannot be confirmed.
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Although the frequency of hypoglycaemia in these studies is much lower than that quoted in
studies of unselected patients with type 1 diabetes, these patients with type 2 diabetes were
older with more extensive comorbidities and they may therefore have been less able to
tolerate hypoglycaemia. Consideration of the other potential contributors to the differences
in mortality, such as the use of particular oral agents, is beyond the scope of this discussion.
However in the wake of these studies, it seems sensible to avoid lowering HbAlc levels
below 6% (with the exception of pregnancy) as this may increase mortality, possibly by
increasing the risk of severe hypoglycaemia.
The true frequency of hypoglycaemia is difficult to estimate for the reasons discussed above.
This is particularly true in type 2 diabetes where both the disease and treatment modalities are
highly heterogeneous (63). However, even within type 1 diabetes there is extensive evidence
that the risk of hypoglycaemia is not uniform. For example in a cross-sectional survey of
1076 consecutive adults with type 1 diabetes, the self-reported incidence of severe
hypoglycaemia was estimated at 1.3 episodes per patient per year with a prevalence of 36.7%
(204). However, 54% of all episodes of severe hypoglycaemia were accounted for by 5% of
patients (204). Clearly, certain patient sub-groups are more vulnerable to frequent and
debilitating hypoglycaemia. It is therefore useful to consider the factors which moderate risk
of hypoglycaemia, particularly severe episodes requiring third party assistance.
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1.8 Risk factors for hypoqlycaemia
There are a number of established moderators of risk of hypoglycaemia. listed in table 1.3,
which will be discussed briefly. Subsequently, more detailed consideration will be given to a
recently proposed moderator of hypoglycaemia risk, serum ACE level, which is the subject of
one of the studies in this thesis.
Table 1.3
Established risk factors for hypoglycaemia.
Moderator of hypoglycaemia References
Low HbAlc, intensive glycaenric control (3,206)
Impaired awareness of hypoglycaemia (170,171,175)
Duration of diabetes (3,173,205,212,216).
Antecedent hypoglycaemia (11-15)
Hypoglycaemia Associated Autonomic Failure (14.102,103)
Extremes of age (3,216)
Negative C peptide levels (3,173)
Sleep (217)
Pregnancy (218-220)
1.8.1 Intensive qlycaemic control
Studies such as the DCCT demonstrate that low ElbAlc and intensive treatment increase the
risk of hypoglycaemia in type l diabetes (3,206). In the DCCT, 77% of the episodes of
severe hypoglycaemia occurred in intensively treated subjects, with a recorded incidence of
severe hypoglycaemia that was two to six times higher in the intensive compared to the
conventional arm (221).
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1.8.2 Impaired awareness of hypoqlycaemia
In a one-year prospective study, the frequency of hypoglycaemia in individuals with type l
diabetes was compared between 29 patients with impaired awareness and 31 patients with
normal awareness of hypoglycaemia, matched for age, duration of diabetes, age at onset of
diabetes and level of glycaemic control (170). In the impaired awareness group, the
incidence of severe hypoglycaemia was 2.8 episodes per person per year with a prevalence of
66%. In contrast, the incidence in the normal awareness group was only 0.5 episodes per
person per year with a prevalence of 26%.
In a 6 month prospective study by a different group, the subjects with impaired awareness of
hypoglycaemia had an incidence of severe hypoglycaemia of 2.6 episodes per patient per year
while the group with normal awareness only experienced 0.87 episodes of severe
hypoglycaemia per person per year (171). A retrospective survey of the prevalence of severe
hypoglycaemia found that 90% of individuals with impaired awareness experienced an
episode of severe hypoglycaemia the previous year, compared to just 18% or individuals with
normal awareness (175).
1.8.3 Duration of diabetes
Impaired awareness of hypoglycaemia is associated with increased duration of diabetes, so it
is not surprising that increased disease duration also increases hypoglycaemia risk
(3,173,205,212,216).
1.8.4 Antecedent hypoqlycaemia
As previously discussed (sections 1.4.3.2 and 1.6.3), one episode of severe hypoglycaemia
can cause blunting of warning symptoms and therefore increase the likelihood of further
episodes (11-15). This cycle of hypoglycaemia begetting hypoglycaemia is thought to
underlie HAAF (14,102,103).
1.8.5 Age
The extremes of age are associated with an increased risk of hypoglycaemia (3,216), with
under-reporting occurring frequently in both the very young and the very old. A number of
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large prospective studies examining the frequency of severe hypoglycaemia in children have
indicated an increased risk of hypoglycaemia in younger children (35,222-224).
In older patients, hypoglycaemia can produce neurological symptoms (160,225) which may
masquerade as alternative conditions such as transient ischaemic attacks or vaso-vagal
episodes (63), complicating the recognition of hypoglycaemia. In addition, the elderly report
lower symptom scores than younger patients (133) with some studies suggesting that the
diminished symptom response is a result of diminished autonomic activation, which is a
feature of increasing age, independent of any effects of diabetes (132,226). In addition, the
blood glucose thresholds for symptom generation and cognitive dysfunction occur almost
simultaneously in the elderly (134), which limits the time available for self-treatment before
progression to severe hypoglycaemia. Thus, an altered symptom profile, lower symptom
intensity and altered glycaemic thresholds combine to increase the risk of progression to
severe hypoglycaemia in the elderly.
1.8.6 C peptide levels
Individuals who are C peptide negative have no endogenous insulin secretion and this confers
a two to four times increased risk of severe hypoglycaemia (3,173). For this reason, severe
hypoglycaemia is uncommon within the first year of type 1 diabetes (227).
1.8.7 Sleep
Nocturnal hypoglycaemia is common (217), with 55% of severe hypoglycaemic episodes
occurring while individuals were asleep (221). This is because during sleep, both
counterregulatory and symptoms are diminished (143).
1.8.8 Pregnancy.
During pregnancy, the peak incidence of hypoglycaemia occurs during the first and second
trimesters . In one study, 84% of severe hypoglycaemic episodes resulting in loss of
consciousness occurred within the first 20 weeks of pregnancy (220). In a large study
comparing the incidence of severe hypoglycaemia in different stages of pregnancy, there
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were almost 2.5 times as many episodes in the first trimester as compared to the third
(218,219).
1.8.9 Serum ACE levels
More recently, a number of studies have examined serum angiotensin-converting enzyme
(ACE) as a potential marker for risk of severe hypoglycaemia. Although three recent papers
from Scandinavia suggest that increased serum ACE levels are associated with an increased
risk of hypoglycaemia, this has not been validated in a non-Scandinavian population and is
therefore an area that requires exploration. The first study in this thesis examines the
potential role of serum ACE as a marker of risk of severe hypoglycaemia and the background
to this study will now be discussed.
The controversy surrounding ACE dates back to the early 1990s when case reports suggested
improvements in insulin sensitivity in patients on ACE inhibitors (228.229). Studies
formally examining the relationship between ACE inhibitors and insulin sensitivity produced
mixed results, with some suggesting an increase in sensitivity (230) while others did not
(231). Further observational studies have examined the relationship between ACE and
hypoglycaemia. A nested case control study employing the Dutch PFIARMO database
included 300,000 residents of 6 Dutch cities and examined hospital admissions and drug
dispensing for this group between 1986 and 1992 (232). There were 94 patients with diabetes
admitted to hospitals with hypoglycaemia over this period. Following adjustment for
potential confounders and after 654 controls were assigned, ACE inhibitors were the only
drugs found to be associated with an increased risk of hypoglycaemia with an odds ratio of
2.8 (95% confidence interval 1.4-5.7). However, it should be noted that this study was a
retrospective analysis and as such it can only demonstrate an association, not causation. In
addition, the study did not adjust for renal impairment, which is both a risk for
hypoglycaemia and an indication for ACE inhibition in patients with diabetes. There were
also problems with the matching of cases and controls and factors such as duration of
treatment were poorly matched. Control patients were selected from amongst the diabetic
population admitted to hospital for other reasons, but the fact that many of these admissions
may have related to hyperglycaemic emergencies such as diabetic ketoacidosis would suggest
that this group may be been inherently less likely to experience hypoglycaemia. Finally,
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most cases of severe hypoglycaemia do not require hospital admission so this study only
examines a subset of those with significant hypoglycaemia.
A more recent nested case control study in Scotland examined the same question using the
DARTS database (233). They matched 440 controls for sex and age to 64 patients admitted
to hospital with severe hypoglycaemia. This study also found an association between ACE
inhibition and severe hypoglycaemia with an odds ratio of 3.2 (95% confidence interval 1.2-
8.3, p=0.023). Although there were differences between cases and controls in terms of
diabetes duration, treatment type and comorbidities such as the presence of congestive
cardiac failure, adjusting for these potential confounders only strengthened the observed
association with an adjusted odds ratio of 4.3 (95% confidence interval 1.2-16.0). However,
only 7 out of the 64 patients admitted with severe hypoglycaemia were taking ACE
inhibitors, which probably accounts for the wide confidence intervals reported. Creatinine
measurements were only available for 49% of patients and after adjusting for creatinine, the
odds ratio linking ACE inhibitors with severe hypoglycaemia was no longer statistically
significant.
Other studies have not supported the proposal that ACE inhibitor drugs are associated with
hypoglycaemia. For example, the EUCLID study was a randomised controlled trial
comparing lisinopril with placebo on albumin excretion in 530 individuals with type 1
diabetes (234). No difference in hypoglycaemia was observed in the treatment and control
arms, although it should be noted that clinical trials often select patients at low risk of ill-
health or complications and they are not the optimal way to seek unintended effects of a drug.
More recently, a new avenue of research opened up with studies exploring the role of serum
ACE in exercise physiology. The ACE gene is located in chromosome 17q23. Individual
variation in serum ACE levels is partly mediated by a gene polymorphism via I (insertion)
and D (deletion) alleles. The insertion polymorphism consists of a 287 base pair Alu element
in intron 16, with an insertion frequency of 50% in European populations. The II genotype is
associated with low serum ACE activity while the DD genotype is associated with high
serum ACE activity (235,236). Studies in elite athletes demonstrated an association between
low serum ACE and the II genotype with enhanced athletic performance in events requiring
stamina (237-240). Further studies examined body composition in 123 army recruits before
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and after a 10 week training programme. When participants with the II genotype were
compared to participants with ID or DD genotypes, the former group displayed a greater
anabolic response in both fat and non-fat mass with relative sparing of fat stores during
structured physical training (241). This suggests that ACE may have effects on energy
balance and on the efficiency with which oxidative fuel is used for metabolism.
On the basis of these studies, it has been postulated that a lower ACE activity confers a
greater ability to function effectively during periods of metabolic substrate deprivation. If
this theory was extrapolated to the arena of hypoglycaemia, it could be hypothesised that
those with high ACE activity and the DD genotype might have a more limited functional
capacity when challenged by glucose deficiency. In people with type 1 diabetes with high
ACE activity, this may be manifest by greater cognitive impairment during hypoglycaemia
than in those with low ACE activity. This might explain the variable risk of developing SH
within a population with type 1 diabetes. Those who are unable to maintain reasonable
cognitive function during mild to moderate hypoglycaemia will be less likely to treat low
blood glucose in a timely fashion which in turn makes it more likely that third party
assistance will be required. Interestingly, if this hypothesis were correct, it would point to the
potential to use ACE inhibitors to lower ACE levels and reduce the frequency of severe
hypoglycaemia, despite the earlier concerns that ACE inhibitors might increase the risk of
hypoglycaemia.
Two Danish studies in adults and one Swedish study in children and adolescents, all with
type 1 diabetes, have examined the relationship between serum ACE and risk of severe
hypoglycaemia. In a retrospective study of 207 consecutive adults with type 1 diabetes,
participants were asked to record the number of episodes of mild hypoglycaemia experienced
in the preceding week and the number of episodes of severe hypoglycaemia experienced each
year for the last 2 years (173). Individuals treated with ACE inhibitors or angiotensin 2
receptor blockers (ARBs) were excluded. Awareness of hypoglycaemia was graded on a 4
point visual analogue scale and blood was sampled for C peptide, HbAlc, serum ACE and
ACE genotype. Patients with the DD genotype had a relative risk of severe hypoglycaemia
of 3.2 (95% confidence interval 1.4-7.4) compared to the II group (173). Other significant
determinants of severe hypoglycaemia risk were impaired awareness of hypoglycaemia,
degree of residual beta cell function as reflected by C peptide levels and duration of diabetes
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above 20 years. The same group followed this study with a one year observational
prospective study of 171 adults with type 1 diabetes, which demonstrated a relative risk of
severe hypoglycaemia of 2.9 in individuals in the top quartile of ACE activity when
compared to those in the bottom quartile (210).
A Swedish group examined this relationship in children and adolescents. In this prospective
study of 86 patients aged 7-19 years old (median 12.8), incidence and prevalence of severe
hypoglycaemia were calculated and serum ACE was measured. The incidence of severe
hypoglycaemia in those with serum ACE levels below the median was 0.5 episodes per
patient per year compared to 3 episodes per patient per year in those with ACE levels above
the median (p=0.008) (242). The high ACE group had a prevalence of severe hypoglycaemia
of 61% compared to a prevalence of 40% in the low ACE group (p=0.053) (242).
Although these results appear to demonstrate a strong association between serum ACE and
risk of severe hypoglycaemia, these results have not been validated in a non-Scandinavian
population. It is possible that the relationship between serum ACE levels and severe
hypoglycaemia may differ between ethnically different groups of people with diabetes.
There are other potential difficulties in interpreting the Danish data. For example, previous
work has suggested that the predictive value of serum ACE is strongest in patients whose
defence against SH is compromised, such as those with impaired hypoglycaemia awareness
(173). The Danish method of assessing hypoglycaemia awareness probably over-estimates
the prevalence of impaired awareness of hypoglycaemia as being 60% (21) compared to a
prevalence of around 25% in other population studies (168) and this may hamper comparison
of their study population with other cohorts of patients with diabetes. It is therefore still
premature to add serum ACE to the list of conventional moderators of hypoglycaemia risk
such as impaired awareness of hypoglycaemia, duration of diabetes and antecedent severe
hypoglycaemia. This association should be validated in a non-Scandinavian population using
a method of assessment of hypoglycaemia awareness which correlates well with other
validated methods (174). This forms the basis of the first original study in this thesis and is
discussed in chapters 3 and 4.
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1.9 Summary on the clinical and physiological effects of
hypoqlycaemia
Hypoglycaemia is a common and much-feared iatrogenic complication of diabetes therapy.
There is a lack of consensus over a precise definition of mild hypoglycaemia but agreement
that severe hypoglycaemia constitutes any episode requiring third party assistance. Several
factors, such as disease duration and the presence of impaired awareness of hypoglycaemia,
are known to increase the risk of hypoglycaemic episodes. The recent emergence of serum
ACE as an additional putative factor requires further exploration and this forms the basis of
the first study in this thesis, which is discussed in chapters 3 and 4.
Although we have a reasonably good understanding of the physiology of hormonal
counterregulation, our understanding of brain glucose sensing remains incomplete. Similarly,
although the symptoms of diabetes have been thoroughly classified and grouped into
autonomic, neuroglycopenic and general malaise categories, we have next to no knowledge
of the extent of intra-individual variation in hypoglycaemic symptoms. The second study in
this thesis, discussed in chapters 3 and 5, explores the within-subject variability of
hypoglycaemic symptoms.
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Chapter 2: Effects of hypoglycaemia on cognitive
FUNCTION
2.1 Testing cognitive function
The symptoms of hypoglycaemia include some, such as confusion and difficulty with speech,
which indicate an effect on cognitive function. Any decrement in cognitive function can
affect an individual's ability to self-treat an episode of hypoglycaemia and the greater the
degree of neuroglycopenia, the greater the risk that severe hypoglycaemia will ensue. The
effects of hypoglycaemia on cognition have therefore been studied in an attempt to
characterise the cognitive domains affected by hypoglycaemia and the glycaemic thresholds
at which cognitive function is disrupted.
2.1.1 Methodological issues
Comparison of different studies is hampered by methodological and statistical
inconsistencies, the effects of which have been reviewed previously (243,244). The
inaccuracies inherent in the method of inducing and measuring hypoglycaemia have been
discussed in chapter l. Inconsistencies in the method of cognitive function testing will now
be considered.
Some issues, such as variability in performance by study volunteers, must be considered
regardless of the study methodology. Hypoglycaemic clamp studies suggest that intra-
individual variability is not a major issue, with diabetic individuals exhibiting reasonably
reproducible glycaemic thresholds for impaired performance on psychomotor tests when re¬
assessed after a 4-6 week interval (245). However, a significant degree of m/er-individual
variation exists with respect to performance on cognitive tasks (243,245,246). It is therefore
important to ensure that studies are adequately powered to minimise the possibility of the
performance of one or two individuals skewing the overall results. Practice effects must also
be considered as performance on most tests improves with familiarity (245,247). A robust
study design should therefore allow sufficient practice sessions on the day of testing such that
a stable plateau in performance has been achieved at baseline and subsequent testing during
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hypoglycaemia is assessing the effects of low blood glucose without practice effects
confounding the results.
Some methodological problems can be minimised by attention to subject selection and study
design. Previous studies have suggested that factors such as higher IQ (246) and male gender
(248) can be associated with a greater decrement in cognitive function. Studies should
therefore ensure an equal gender spread and always include a euglycaemic control arm, with
participants being blinded to the experimental condition (hypoglycaemia versus
euglycaemia).
The order in which subjects undergo each arm of the study should be randomised and
counterbalanced. In other words, half the participants should undergo the euglycaemic arm
while the other half undergo hypoglycaemia on their first study session. This study design
allows each participant to act as their own control. This minimises the effect of potentially
confounding effects such as boredom and tiredness as it can be assumed that each individual
will become fatigued at around the same point during each experimental condition. There
should be an opportunity to practise the tests first to avoid practice effects and tests should be
administered in the same order on both study sessions. In addition, the choice of cognitive
test is also important.
2,1,2 Choice of cognitive test
Some researchers favour testing individual cognitive domains while others prefer the use of a
broad battery of tests to assess cognitive function as a whole. When a comprehensive test
battery is employed, researchers sometimes present their findings as z scores (also known as
a standard score). This score indicates how many standard deviations an observation is above
or below the mean. The score is obtained by subtracting the population mean from an
individual score and dividing the difference by the population standard deviation. The unit of
the z score is therefore the standard deviation, which allows scores on different tests to be
standardised and amalgamated into a composite score.
Clearly, if a battery of tests is employed, it is important to report results of individual tests
rather than a z score alone as performance on one test unaffected by hypoglycaemia could
mask the decrement in a different test score when results are combined. For example, in one
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study by Mitrakou and colleagues (61), a battery of cognitive tests was applied repeatedly
during a stepped glucose clamp. The overall Z score implied that hypoglycaemia affected
performance at a glucose threshold of 2.4 mmol/1. However, the published raw scores
suggest that some of the tests were affected at much higher blood glucose levels (choice
reaction time affected at a threshold of approximately 3.7 mmol/1; Stroop test affected at an
approximate threshold of 3.1 mmol/1).
The number of tests employed is also a relevant consideration. It could be argued that
increasing the number of tests will increase the sensitivity of the test battery but it will also
increase the chance that boredom and fatigue may affect performance. Furthermore,
increasing the number of tests also increases the risk of introducing a type 1 statistical error.
In other words, the larger the number of tests employed in any given study, the greater the
likelihood of performance on one test being affected simply by chance.
One of the criticisms levelled against cognitive function tests is that they assess isolated
domains in an abstract fashion and may not represent cognitive function with respect to
everyday activities. For example, the p300 brain evoked potential is taken to be a sensitive
indicator of cognitive dysfunction (249) but there is no intuitive way to correlate changes in
p300 potentials to the ability to perform daily tasks. By contrast, one of the tests frequently
used in clamp studies is the choice reaction time test (182,250-253), which is simple and
quick to administer and reflects skills used in daily life such as psychomotor function and
reaction time.
Tests which are specifically designed to reflect "real-life" situations are described as having
"ecological validity" (254). For example, the prospective memory test designed by Titov and
Knight (255) and adapted by Warren and colleagues (256) requires subjects to memorise a
list of tasks that have to be conducted at specific establishments on a shopping thoroughfare.
Later, they are asked to recall the list of tasks while viewing a video of the same shopping
street. Compared to traditional memory tests which involved rote learning of lists, this is
probably a more accurate reflection of the use ofmemory in routine life, where circumstances
and surroundings can act as prompts and reminders and other cognitive processes, such as
planning and vigilance, become relevant to the task in hand. Perhaps the best example of an
ecologically valid test is the driving simulator, which will be discussed later.
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2.2 Effects of hypoqlycaemia on cognitive function
Notwithstanding the methodological challenges involved in cognitive function testing during
hypoglycaemia, there is a broad literature in this area which has attempted to answer a
number of pertinent questions. For example, which cognitive domains are affected by
hypoglycaemia? Are they all equally affected? At what blood glucose thresholds are
different cognitive functions impaired? I low long does it take for cognitive function to
recover following hypoglycaemia? Can the brain adapt to recurrent hypoglycaemia? How
can results of laboratory studies be extrapolated to routine activities such as driving? These
questions will be considered in turn.
2.2.1 Cognitive domains affected by hypoqlycaemia
Specific aspects of cognitive function are essential for various everyday tasks including work
and leisure activities. It has been demonstrated that acute hypoglycaemia affects multiple
aspects of cognitive function including simple auditory processing (257,258), attention (259),
concentration (260), visual information processing (261,262), multiple aspects of memory
(256,263,264), higher level cognitive function (265),psychomotor function (174) and spatial
awareness (266). Unpublished data from our group also suggests that language processing is
affected by hypoglycaemia (personal communication, Dr Kate Allen). Table 2.1 summarises
the effects of hypoglycaemia on various domains of cognitive function, with test scores given
for hypoglycaemia and euglycaemia. Studies in this table are limited to those published by
our group. This is because methodological differences (such as the use of whole blood versus
plasma, discussed in section 2.1.1) hamper comparison between studies and our group has
employed consistent methodology throughout all the studies cited here. The extent of the
effect of hypoglycaemia on each cognitive domain (effect size) is given by Cohen's d, which
is the difference between two means divided by the standard deviation of the data.
Comparison of the mean scores during hypoglycaemia and euglycaemia in this way conveys
the extent of the effect of hypoglycaemia in a more meaningful way than the simple reporting
of a p value. The greater the Cohen's d value, the greater the effect of hypoglycaemia on the
domain being tested. The CRT and TMB tests have negative Cohen's d values because the
results are completion times where a better (quicker) result is represented by a lower number.
For these tests, the lower the Cohen's d, the greater the effect of hypoglycaemia.
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While it is possible to document all the individual areas of cognitive function affected
by hypoglycaemia, it is perhaps more useful to draw some general conclusions from
published studies. In laboratory studies, controlled mild hypoglycaemia causes
rapidly reversible cognitive dysfunction, both in diabetic and non-diabetic humans,
with no deterioration in level of consciousness (144). Although the laboratory studies
confirming these findings have been undertaken only in the last 20 years, this fact was
apparent to observers long before researchers began formally studying hypoglycaemia
(2). Simple motor and cognitive tasks tend to be relatively well preserved during
moderate hypoglycaemia in comparison to more complex, attention demanding tasks
(144), such as those involving working memory (267). Speed is often sacrificed in
order to preserve accuracy during hypoglycaemia, as demonstrated in studies where
subjects achieved the same proportion of correct answers but completed fewer Stroop
tasks and mathematical calculations during hypoglycaemia (269,270).
To date, studies have tended to assess specific and discrete areas of cognitive
function. However, it is known that all mental tests show a universal positive
covariation such that performance during one task can predict performance during
another (271). Spearman noted a positive correlation in children's test scores across
apparently unrelated subjects and proposed the presence of an underlying dominant
general intelligence factor, termed "g" (271,272). It is unknown whether
hypoglycaemia causes a deterioration in mental performance by affecting this general
factor shared by all tests or through specific effects on different aspects of cognitive
function.
2.2.2 Thresholds for cognitive dysfunction
Various studies have employed a "stepped clamp" methodology to lower blood
glucose in defined decrements and establish the thresholds at which various changes
occur. These studies have examined the effects of hypoglycaemia on cognitive
function in diabetic and non-diabetic individuals and found that the glycaemic
threshold for developing cognitive dysfunction ranges between a blood glucose of 2.3
and 3.3 mmol/1 (61,62,112,252,253,273-276). The thresholds for different cognitive
tests are summarised in table 2.2. As discussed in chapter 1, in people who have
normal hypoglycaemia awareness, symptom generation and counterregulatory
hormone release generally occur at higher blood glucose levels than the development
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of neuroglycopenia (60,61,112). These thresholds are not fixed and in the subsequent
sections on recovery of cognitive function and cerebral adaptation to hypoglycaemia,
it is discussed how these thresholds can be modified.
Tabic 2.2
Blood glucose thresholds for deterioration of performance in cognitive function tests
during acute hypoglycaemia. All studies in this table employed a "stepped clamp"'
Test (reference) Blood glucose(mmol/l) Subjects
Four choice reaction time (253)
o ->




Four choice reaction time (252) 3.2 Type 1 diabetes with normal awareness
and healthy volunteers
Four choice reaction time (253) 3.1 Healthy volunteers
Four choice reaction time (252) 3.0 Type 1 diabetes and impaired awareness
Four choice reaction time (182) 2.8 Type 1 diabetes
2.8 (62) Type 1 diabetes and impaired awareness:
hypoglycaemia avoided 3 months- 1 year
2.7 (62) Healthy volunteers
Z score for cognitive battery 2.6 (273) Healthy volunteers
2.6 (62) Type 1 diabetes and impaired awareness:
hypoglycaemia avoided for 2 weeks
2.4 (62) Type 1 diabetes and impaired awareness
2.3 (61,274) Healthy volunteers
Cognitive battery of 12 tests 2.9 (7 out of 12 tests*) Healthy volunteers
(112) 2.5 (all tests*) Healthy volunteers
Immediate recall (274) 2.5 Healthy volunteers
Late recall (274) 2.5 Healthy volunteers
* Test battery consisted of trail-making A and B, verbal fluency, Stroop test (interference subtest, word
and colour subtest), simple and choice reaction time, digit vigilance test, verbal memory test and
forward and backward digit span. Details not given as to which of these tests deteriorated at the higher
blood glucose level.
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2.2.3 Recovery of cognitive function
Recovery of cognitive function following hypoglycaemia has only been partially
explored. Anecdotal accounts from individuals with diabetes suggest that the
recovery of cognitive function can lag behind the restoration of biochemical
euglycaemia. Some of the early studies on hypoglycaemia and cognitive function
also supported this suggestion (277) although these findings were not universally
replicated (278). However, this early work is limited by methodological constraints,
such as the use of an insulin infusion rather than a glucose clamp technique to induce
hypoglycaemia (278) or the use of tests such as simple reaction time (277,279,280)
and finger tapping (278), which are not consistently affected by hypoglycaemia.
More recently, further attempts have been made to quantify the time taken for
cognitive recovery but these studies have also had limitations. For example, in some
studies, non-diabetic volunteers were recruited rather than subjects with type 1
diabetes (279,281,282), or a small sample of subjects was studied (282), or the study
lacked a euglycaemic control arm in its design (281,283) or neurophysiological
measurements were used rather than direct tests of cognitive function (279-281,284).
Furthermore, precise measurement of the time taken for recovery requires repeated
testing, but many studies have restricted cognitive testing to just one or two time
points (282-285). Finally, the interval between the restoration of euglycaemia and the
testing of cognitive function has not been clearly defined in several studies and it is
therefore difficult to be certain whether the timing of cognitive testing between
different participants was consistent (279,280,283,284).
Some of the limitations with earlier studies may relate to the fact that several were not
specifically designed to assess recovery. For example, the study by Herold el al was
designed to study cognitive function during hypoglycaemia rather than in the
recovery phase. In four of the subjects, reaction time was still prolonged at the end of
the study after 40 minutes of euglycaemia but no further measurements were made
(277). The choice of cognitive tests was also flawed as testing was restricted to
measurements of simple reaction time in response to a red light visual stimulus; a test
which is now known not to be consistently affected by hypoglycaemia (277).
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Some studies did set out specifically to examine recovery time. Evans et al (282)
clamped 8 healthy volunteers and assessed cognitive function serially with 4 choice
reaction time (4CRT), Stroop word and colour word tests and Trail Making B (TMB).
The 4CRT test remained impaired up to 20 minutes after restoration of euglycaemia
and TMB did not show consistent deterioration during hypoglycaemia so recovery
could not be assessed. Stroop tests showed no impairment at 20 minutes after
euglycaemia was restored. However, recovery was only assessed immediately after
restoration of euglycaemia and just once more after 20 minutes of euglycaemia. It is
therefore impossible to ascertain whether there was a brief lag in the recovery of the
Stroop tests or whether 4CRT remained impaired beyond 20 minutes. Similarly, a
more recent study in subjects with type 2 diabetes assessed hormonal, symptomatic
and cognitive responses (reaction time) to 30 minutes of hypoglycaemia and found a
prolonged reaction time 30 minutes after euglycaemia was restored (286). However,
as no subsequent measurements were taken it is not possible to conclude how long it
took for recovery to be complete.
Investigators in Sweden also looked specifically at restoration of cognitive function,
in non-diabetic men alone (281) and in diabetic versus non-diabetic men (284).
However, these investigators employed purely neuropsychological tests (EEGs, P300
latency and somatosensory evoked potentials in the median nerve) and the ecological
relevance of these measurements is unclear. Furthermore, these investigators
employed a 0.9% sodium chloride infusion for the control arm whereas it would have
been more appropriate to use a euglycaemic clamp. Finally, the diabetic subjects also
underwent a longer period of hypoglycaemia than the control subjects.
Similarly, Blackman el al clamped healthy volunteers (279) and people with poorly
controlled type 1 diabetes (280) in two separate studies and measured simple reaction
time, which is not reliably affected by hypoglycaemia, and P300 latencies, which are
considered to be an electrophysiological marker of decision-making processes but do
not clearly relate to the ability to perform routine daily tasks. Like the Swedish
investigators, Blackman and colleagues found that there was a delay in normalisation
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of P300 potentials ranging from 45 to 75 minutes after restoration of euglycaemia but
the timing of the recovery period was not clearly defined.
A previous study from our centre comparing the effects of hypoglycaemia on
cognitive function in 20 people with type 1 diabetes and either normal or impaired
awareness of hypoglycaemia applied a cognitive battery of 20 minutes duration
during hypoglycaemia and then during the recovery period at a single time point 10
minutes after euglycaemia was restored (285). Performance during the recovery
period remained impaired on the trail-making B and rapid visual information
processing tests, although there was no persistent impairment in the paced auditory
serial addition and digit symbol substitution (DSST) tests (285). However, as no
further testing was conducted after lOminutes into the recovery period, this study
could not fully define the duration of cognitive impairment in the recovery period
after hypoglycaemia.
So far, all of the studies discussed have examined immediate recovery. Some
investigators have examined longer term recovery after hypoglycaemia but have not
found strong evidence of persistent cognitive impairment. For example, one hour of
nocturnal hypoglycaemia (2.3-2.7mmol/l) does not affect cerebral function the
following morning in subjects with type 1 diabetes (287,288).
Most studies assessing the recovery period have examined mild hypoglycaemia but
one study from our centre examined cognitive function and mood prospectively in 20
people with insulin-treated diabetes who had recently experienced severe
hypoglycaemia (SH) and 20 matched controls with insulin-treated diabetes and no
recent episodes of SH (289). One subject in each group had type 2 diabetes and the
others had type 1 diabetes. An extensive cognitive battery was administered 1.5, 9
and 30 days after SH but recovery was already complete at the first time point so it is
not possible to conclude precisely when cognition returned to normal after SH, or
even to conclude whether or not there was any lag in recovery of cognition (289).
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Thus, it is apparent that there is a delay in the recovery of cognitive function
following hypoglycaemia but this has not been well defined and there is no evidence
of any long-term impairment.
2.2,4 Cerebral adaptation to hypoqlycaemia
It has been demonstrated previously that glycaemic thresholds for cognitive
dysfunction differ depending on the state of hypoglycaemia awareness. A study that
compared the thresholds for the onset of cognitive impairment during hypoglycaemia
in non-diabetic subjects and in people with type 1 diabetes who had either normal or
impaired awareness of hypoglycaemia found that those with impaired awareness had
a threshold for cognitive impairment of (mean±SE) 2.39±0.07 mmol/1 compared to
thresholds of 2.69±0.06 mmol/1 and 2.65±0.06 mmol/1 in those with normal
awareness and non-diabetic control subjects respectively (78). The thresholds for
neuroglycopenic symptoms and for counterregulatory hormone secretion were also set
at lower blood glucose levels in the impaired awareness group compared to the other
two groups. (78). Clamp studies by a different group also confirmed that cognitive
dysfunction is milder and begins at lower blood glucose levels in those with impaired
awareness of hypoglycaemia compared to non-diabetic individuals (62,274).
Previous exposure to hypoglycaemia in individuals with type 1 diabetes and normal
awareness can also cause the thresholds for cognitive dysfunction to shift to lower
blood glucose levels, regardless of whether the antecedent hypoglycaemic episodes
occur by day (12,290) or night (11,291). Neurophysiological changes, such as
alterations in p300 event-related potentials, are also shifted to lower blood glucose
levels by antecedent hypoglycaemia (249). Glucose clamp studies in non-diabetic
individuals have shown that 90-150 minutes of hypoglycaemia the day before
cognitive testing attenuates the deterioration in short term memory, reaction time and
auditory-evoked brain potentials (292-294), although performance on some
parameters such as DSST and some elements of event-evoked brain potentials did not
show evidence of adaptation (293,294). In a small study of adults with type 1
diabetes, twice weekly episodes of experimentally-induced hypoglycaemia over one
68
month resulted in preservation of cognitive function across a range of cognitive tasks
(12).
Prolonged hypoglycaemia has also been shown to affect thresholds for cognitive
dysfunction in a series of studies by Boyle and colleagues. Non-diabetic volunteers
underwent cognitive testing during two hypoglycaemic clamps, separated by a 56h
period of controlled hypoglycaemia where mean blood glucose levels were
maintained at 2.9 mmol/1, including during post-prandial periods. Following
prolonged hypoglycaemia, the glucose level at which performance on the Stroop test
deteriorated shifted from 3.3 mmol/1 to 2.5 mmol/1 (179). Details of functional
cerebral changes in response to hypoglycaemia give insights into possible
mechanisms for these observed alterations in the thresholds for cognitive dysfunction.
Total brain glucose utilisation can be estimated from measurements of cerebral blood
flow and blood glucose concentrations in jugular venous and arterial blood. In this
study by Boyle and colleagues, brain glucose uptake was augmented following
prolonged hypoglycaemia (179).
In a different study by the same research group, brain glucose uptake was observed to
fall during hypoglycaemia by around 20% in healthy volunteers and individuals with
poorly-controlled diabetes whereas it was preserved in those with strict glycaemic
control (17), raising the possibility of adaptation to repeated exposure to
hypoglycaemia. Although this study cannot confirm that increased exposure to
antecedent hypoglycaemia was the mechanism of preserved brain glucose
metabolism, it is certainly a plausible explanation.
Neuroimaging studies also demonstrate relevant alterations in regional cerebral blood
flow, with increased perfusion of the frontal cortex and decreased blood flow to
caudal regions observed during hypoglycaemia (295). These changes become
permanent in those with a history of severe hypoglycaemia (180) or impaired
awareness of hypoglycaemia (296). Neuropathological studies suggest that the
brain's sensitivity to hypoglycaemia decreases in a rostro-caudal direction, (297) so
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preservation of cerebral blood glucose delivery to more sensitive anterior areas of the
brain can be viewed as an adaptive response to hypoglycaemia.
It is unclear whether adaptation of cerebral function can occur acutely. In one study
by Kerr and colleagues, symptoms and choice reaction time values reverted towards
baseline by the end of a 2hour period of clamped hypoglycaemia, although this study
was limited by its lack of a euglycaemia control arm (298). The apparent
improvement could therefore have been caused by a practice effect. A glucose clamp
study by Gold and colleagues did not report any difference in performance on a
battery of tests at the start and end of an hour of clamped hypoglycaemia (299),
although it is possible that an improvement in performance may have been detected if
the period of hypoglycaemia had lasted longer as in the study by Kerr. A single
episode of antecedent hyperglycaemia does not affect physiological responses to
subsequent hypoglycaemia (300).
It has been postulated that repeated episodes of hypoglycaemia in those with impaired
awareness may lead to a degree of cerebral adaptation by allowing the body to
"acclimatise" to low blood glucose, with counterregulation, symptoms and cognitive
impairment being initiated at successively lower blood glucose levels. This
hypothesis is partly suggested by the fact that individuals with impaired awareness
have an increased incidence of both asymptomatic (170.172) and severe
hypoglycaemia compared to those with normal awareness (170,171).
It may also seem that people with impaired awareness are in some way protected from
hypoglycaemia in that they can function cognitively at blood glucose levels that
would affect people with normal awareness of hypoglycaemia. However, several
studies have demonstrated that the alteration of symptom thresholds can result in the
development of significant neuroglycopenia before autonomic symptoms develop
(78,301-303). For example, in a clamp study of 19 individuals with type 1 diabetes,
in those with stricter glycaemic control and diminished awareness of hypoglycaemia,
the blood glucose level associated with impaired four choice reaction time was
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0.5mmol/l lower than the corresponding threshold in individuals with poorer
glycaemic control, better hypoglycaemia awareness and a presumed lower exposure
to repeated hypoglycaemia. In contrast, the blood glucose level at which autonomic
and neuroglycopenic symptoms were initiated and epinephrine (adrenaline) was
released was 0.6-0.8 mmol/1 lower in those with better glycaemic control and poorer
hypoglycaemia awareness (304). Therefore, although all thresholds shift in response
to hypoglycaemia, it appears that that symptom and counterregulatory thresholds shift
to a greater extent than the thresholds for cognitive dysfunction. Any protective
effects on cognitive function are insufficient to compensate for the fact that changes
in symptom thresholds result in a much narrower window of opportunity to treat
clinically apparent hypoglycaemia before severe neuroglycopenia develops. In fact,
on occasions, neuroglycopenia can ensue before symptoms and counterregulation are
fully generated. Far from being protective, these threshold shifts should be viewed as
maladaptive, given that they increase the risk of developing severe hypoglycaemia. It
is therefore reassuring that avoidance of hypoglycaemia can restore symptoms (183)
and glucose thresholds for cognitive dysfunction to higher levels in individuals with
type 1 diabetes (62,274) and in non-diabetic individuals following treatment of an
insulinoma (273).
Despite the large body of literature supporting the concept of adaptation to repeated
episodes of hypoglycaemia, this finding is not universal. For example, one study
found no change in the threshold for cognitive dysfunction (4 choice reaction time
test) after avoidance of hypoglycaemia for 4 months, despite the fact that the
thresholds for hormone and symptom responses did shift to higher blood glucose
levels (182). In two studies, one hour of nocturnal hypoglycaemia (2.3-2.7mmol/l)
did not affect cognitive function the following morning in subjects with type 1
diabetes, despite the fact that mood, well-being and the ability to cope with
subsequent exercise were adversely affected (287,288).
A different clamp study has also shown that although individuals with type 1 diabetes
and impaired awareness experience symptoms of hypoglycaemia at blood glucose
levels of 2.3 mmol/1 while those with normal awareness become symptomatic at
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blood glucose levels of 3.0 mmol/1, both groups experience a deterioration in choice
reaction time at similar blood glucose levels (3.2 mmol/1) (252).
In another clamp study, individuals with type 1 diabetes were grouped together on the
basis of either good (HbAlc 8% ±0.2%, n=8) or poor (HbAlc 11.8% ±0.4%. n=9)
glycaemic control and assessed with a small battery of cognitive tests. There was no
significant difference in performance between the two groups despite the fact that the
well-controlled group developed counterregulatory changes at a lower blood glucose
level than those with poor glycaemic control (275). However, this study could be
criticised for its small size as there were only 8-9 individuals in each group.
Finally, in a study of 20 men and 22 women with insulin-treated diabetes, the effects
of glycaemic control and gender on cognitive function during hypoglycaemia (2.2
mmol/1) were examined. HbAlc values ranged from 5.8% to 18%. The observed
cognitive impairment was not correlated to level of glycaemic control (248).
However, no information was given on the state of awareness of the individuals with
good glycaemic control and it is possible that preservation of cognitive function might
have been observed if a group with well-categorised impaired awareness of
hypoglycaemia had been examined.
Thus, no consensus exists as to whether either impaired awareness of hypoglycaemia
or recurrent antecedent hypoglycaemia are associated with the relative preservation of
cognitive function (11,62,78,273,274,290,292,304) or an exacerbation of the
decrement in cognitive performance associated with hypoglycaemia
(182,252,275,285,287,288). Although different studies have produced apparently
discrepant results, several explanations can be offered for this. For example, inter-
individual variation in the degree to which hypoglycaemia affects cognitive function
is very wide (243) and this may explain why cognitive function appears preserved in
those with impaired awareness in some studies and not in others. Furthermore,
impaired awareness is not an all or none phenomenon so subjects in different studies
may have differed in the extent to which awareness was impaired. Different studies
have also employed different tests and it is accepted that not all cognitive functions
are equally affected by hypoglycaemia. Different tests will assess different parts of
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the brain and it is possible that some areas of the brain may be more capable of
adaptation to recurrent hypoglycaemia than others. It is also possible that adaptation
may occur more rapidly in some individuals than in others and that a more prolonged
hypoglycaemic stimulus in some of these studies might have produced evidence of
cerebral adaptation to hypoglycaemia.
Therefore, these various studies need not necessarily contradict each other and their
discordant results may be explained by differences in degree of awareness, depth and
duration of hypoglycaemic nadir, choice of cognitive function tests and inter-
individual variability between subjects.
2.2.5 Driving and related skills
One recurring criticism of studies of cognitive function during hypoglycaemia is that
they lack ecological validity and that their results may therefore not reflect how
individuals cope with hypoglycaemia in real life. For instance, most daily tasks
involve the use of multiple cognitive domains and may therefore be more complex
than cognitive tests in a research laboratory. However, there will also be a degree of
automaticity to certain daily tasks with familiar surroundings and possessions
providing cues to the individual undertaking the task.
Driving is one area of particular interest because hypoglycaemia in a driver may have
an impact on their driving licence, insurance, safety and, potentially, their livelihood,
as well as having broader issues regarding public safety if an accident occurs as a
consequence of low blood glucose levels. A survey undertaken across 11 diabetes
centres in the US and Europe highlighted increased driving mishap rates in drivers
with type 1 diabetes, compared to those with type 2 diabetes and non-diabetic spouses
(305). More drivers with type 1 diabetes reported episodes of hypoglycaemia while
driving than those with type 2 diabetes (305), raising the possibility that the increased
rate of driving mishaps observed in type 1 diabetes relates to hypoglycaemia. In a
survey of 202 insulin-treated diabetic drivers in Edinburgh, 25% did not consider that
a blood glucose of above 4 mmol/1 was prerequisite for safe driving, 60% would not
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routinely test blood glucose before driving and only 14% of participants would wait
longer than 30 minutes after correction of hypoglycaemia before resuming driving
(306).
Some studies have examined cognitive functions relevant to driving, such as visual
perception. It is known that hypoglycaemia affects contrast sensitivity, inspection
time, visual change detection and visual movement detection (261), which could
affect vision in relatively poor light or when visual discriminations must be made
rapidly. However, colour discrimination does not appear to be affected (307).
Attention (259,268) and volume discrimination (257,258) are also affected and all of
these skills are required for driving. Nonetheless, none of these aforementioned
studies examines the totality of skills required for driving.
Several studies, most notably from the group led by Dan Cox in Virginia, USA, have
employed complex driving simulators during clamped hypoglycaemia to ensure
greater ecological relevance than studies of isolated cognitive domains. Although
most simulator studies have examined the effects of hypoglycaemia on driving, one
glucose clamp study assessed the effects of driving on the development of
hypoglycaemia (308). Heart rate, epinephrine and dextrose infusion rates were
compared on two occasions in individuals with type 1 diabetes who either watched a
driving video or drove a simulator while undergoing clamped hypoglycaemia. Higher
dextrose infusion rates were needed while using the simulator, suggesting that driving
makes significant metabolic demands which may in themselves contribute to
hypoglycaemia (308).
Driving simulator studies suggest that driving ability is not significantly affected by
mild hypoglycaemia (3.6 mmol/1) while moderate hypoglycaemia (2.6 mmol/1) is
associated with disrupted steering, increased swerving, increased spinning and
increased time spent over the midline of the road as well as time spent completely off
the road (309). Clearly, the problem here is that neuroglycopenia does not simply
impair driving ability but also affects the ability to judge whether it is safe to drive.
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Field studies where hand-held computers were used to record information over 3-4
weeks, including details of symptoms, blood glucose levels and decision to drive,
suggest approximately 50% of drivers with type 1 diabetes will drive at least 50% of
the time when blood glucose is below 3.9 mmol/1 (310). Even more worryingly,
subjects made a decision to drive on at least 38% of occasions when blood glucose
levels were below 2.2 mmol/1 (310).
Awareness of hypoglycaemia also affects the decision to drive. For example those
with diminished warning symptoms are less likely to self-treat an episode of
hypoglycaemia while driving on a simulator (311). Regardless of the state of
awareness, individuals with type 1 diabetes being tested on a driving simulator under
hypoglycaemic conditions will be aware of impaired driving at moderate levels of
hypoglycaemia (2.8-4 mmol/1) but will often not treat hypoglycaemia till blood
glucose falls below 2.8 mmol/1 (312). When individuals with type 1 diabetes and
either normal or impaired awareness of hypoglycaemia were asked whether they felt
hypoglycaemic and whether they would drive during clamped euglycaemia (5.0
mmol/1) and hypoglycaemia (2.7 mmol/1), 43% of subjects in the impaired awareness
group decided to drive during hypoglycaemia as compared to just 4.2% of those with
normal awareness (313). Perhaps surprisingly, in one study middle-aged men with
type 1 diabetes were more likely to deem themselves safe to drive during a stepped
hypoglycaemic clamp than middle-aged women or subjects under 25 years of age
with type 1 diabetes, reinforcing the importance of education on driving safety for all
patients with diabetes and not just those in the stereotyped high risk groups such as
young males (314).
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2.3 Conclusions on cognitive function
Although statistical and methodological considerations complicate comparison
between different studies, it is clear that acute hypoglycaemia can affect cerebral
function without impairing consciousness at blood glucose levels below 3.3 mmol/1
(144). Complex tasks and those requiring rapid responses are more significantly
affected than simple tasks (144) and speed is often sacrificed at the expense of
preserving accuracy during hypoglycaemia (269,270). It is not clear whether
hypoglycaemia affects multiple cognitive domains individually or via its effects on a
general intelligence factor. The recovery of cognitive function is delayed following
restoration of biochemical euglycaemia but the timing of the recovery period has
previously been ill-defined. Although previous studies have produced mixed results,
a significant body of evidence suggests that repeated hypoglycaemia leads to a degree
of cerebral adaptation. However, this is insufficient to protect from severe
hypoglycaemia and simply serves to narrow the window of opportunity for
intervention between the onset of symptoms and the development of severe
neuroglycopenia. Both the recovery period after hypoglycaemia and the potential for
cerebral adaptation to recurrent hypoglycaemia merit further study.
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Chapter 3: Hypotheses for studies
Despite advances made in the last three decades, there are still gaps in our knowledge
of both the physiological and cognitive consequences of hypoglycaemia. Over the
last 25 years, our research group has made a substantial contribution to the existing
literature on hypoglycaemia and the studies presented here pick up on unanswered
questions from previous research studies.
This thesis consists of three studies which investigate in turn the risk factors for
developing severe hypoglycaemia, the variability of symptoms reported during
hypoglycaemia and the rate of cognitive recovery from hypoglycaemia.
3.1 Serum Angiotensin Converting Enzyme and frequency of
severe hypoqlycaemia in type 1 diabetes: does a relationship
exist? (Chapter 4)
While many patients rarely experience severe hypoglycaemia, a small subgroup
experiences recurrent episodes (170,171,212). Recovery from severe hypoglycaemia
is usually complete, but it is very disruptive to daily life and may be dangerous, for
example if it occurs when the individual is driving. It is therefore of direct clinical
relevance to identify risk factors for severe hypoglycaemia. Established risk factors
include intensive treatment (3,206), impaired awareness of hypoglycaemia
(170,171,175), increased disease duration (3,173,205,212,216), antecedent
hypoglycaemia (11,12,14,15,315), extremes of age (3,216), negative C peptide levels
(3,173), sleep (217), renal insufficiency and pregnancy.
Studies in the last 8 years have suggested that serum angiotensin converting enzyme
(ACE) activity, which is largely influenced by ACE genotype, may also influence the
risk of hypoglycaemia. Scandinavian studies have reported a direct association
between elevated serum ACE activity and an increased risk of severe hypoglycaemia
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in both adults and children with type 1 diabetes (173,210,242). However these studies
have methodological limitations and had not been reproduced outside Scandinavia at
the time that the present study was designed. Study one (chapter four) examines the
putative association between severe hypoglycaemia and serum ACE levels in a
population of 300 Scottish adults with type 1 diabetes.
3.2 Consistency of symptom reporting during hypoqlycaemia
(Chapter 5)
It is known that the symptoms of hypoglycaemia are idiosyncratic and age-specific
(145). Statistical techniques have previously been used to show that these symptoms
cluster into three categories in young adults: autonomic, neuroglycopenic and general
malaise (6,146.147). While it is accepted that each individual will experience a
different range of symptoms during hypoglycaemia, no studies have assessed the
extent of any intra-individual variability in adult symptom reporting. The ability to
predict which individuals will report a consistent group of symptoms and which
individuals will experience a more variable pattern of symptoms would assist patient
education and allow clinicians to better inform patients about how to anticipate and
recognise hypoglycaemia.
Study two (chapter five) prospectively examines the symptoms reported by a cohort
of 350 people with type 1 and type 2 diabetes with different disease durations and
varying treatment modalities over a period of nine to twelve months. In those with a
substantial number of recorded hypoglycaemic episodes, reported symptom clusters
were analysed using a novel statistical model to assess the consistency of symptom
reporting for each individual.
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3.3 Recovery of cognitive function following hypoqlycaemia
in adults with type 1 diabetes and the effect of impaired
awareness of hypoqlycaemia (Chapter 6)
This study examines the time taken for full cognitive recovery from hypoglycaemia
and the possible effect of the clinical syndrome of impaired awareness of
hypoglycaemia on this process. The effects of acute insulin-induced hypoglycaemia
on cognitive function have been investigated extensively but the recovery period after
hypoglycaemia has not been rigorously assessed due to methodological limitations of
previous studies. It is also unclear whether impaired awareness of hypoglycaemia is
associated with the relative preservation of cognitive function during hypoglycaemia
(62,78.273,290,292,316,317) or an exacerbation of the decrement in cognitive
performance associated with hypoglycaemia (65,285,31 8). The objective of this third
study (chapter 6) is to measure the recovery time for various domains of cognitive
function in a large group of patients with type 1 diabetes who have either normal or
impaired awareness of hypoglycaemia. The findings of this study will have important
clinical implications and help to advise patients how long to wait after restoration of a
normal blood glucose before resuming activities such as driving.
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Chapter 4: Serum Angiotensin Converting Enzyme
AND FREQUENCY OF SEVERE HYPOGLYCAEMIA IN TYPE 1
Diabetes: Does a relationship exist?
The data in this chapter have been published as a multi-author paper in a peer-
reviewed journal (See appendix). The first draft of this chapter was written entirely
by me and I coordinated all subsequent editing. Dr Riccardo Marioni did the
statistical analysis involving the negative binomial model but I did the remaining
statistical work and wrote up the results. Co-authors on this paperprovided editorial
input, corrections and comments but did not write any individual sections of this
paper.
4.1 Introduction
Hypoglycaemia is a common side-effect of insulin therapy. In type l diabetes most
events are mild (self-treated) with an average frequency of 2.0 episodes per week
(4,204). In northern European studies of unselected individuals with Type 1 diabetes,
the estimated incidence of severe hypoglycaemia (defined by the need for assistance
for recovery) ranges from 1.0 to 1.7 episodes/patient/year (204,205,208,209), with an
annual prevalence between 30% (208,211) and 40.5% (205), similar to the Diabetes
Control and Complications Trial (DCCT) (3). The frequency of hypoglycaemia
varies considerably, with most people never or rarely developing severe
hypoglycaemia, while a small subgroup frequently experience severe hypoglycaemia
(204).
Several risk factors for severe hypoglycaemia have been identified (3,319), including
strict glycaemic control and impaired awareness of hypoglycaemia (320,321). More
recently, serum angiotensin-converting enzyme (ACE) activity has emerged as a
possible marker for risk assessment. Individual variation in serum ACE levels is
mediated in part by gene polymorphism, via I (insertion) and D (deletion) alleles. The
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II genotype is associated with low serum ACE activity (235) and in type 1 diabetes
has been linked to a lower frequency and risk of severe hypoglycaemia; the DD
genotype is associated with higher serum ACE activity and an increased risk of severe
hypoglycaemia (173,210). Low serum ACE and the II genotype are associated with
enhanced athletic performance in events requiring stamina (237-239). It has therefore
been postulated that a lower ACE activity confers greater ability to function
efficiently during periods of metabolic substrate deprivation. Conversely, those who
have a high ACE activity have more limited functional capacity when challenged by
glucose deficiency.
In people with type 1 diabetes with high ACE activity, this may be manifest by
greater cognitive impairment during hypoglycaemia than in those with low ACE
activity. This might explain the variable risk of developing severe hypoglycaemia
within a population with type 1 diabetes. Two Danish studies in adults, and one
Swedish study in children and adolescents, all with type 1 diabetes, have suggested
that a high serum ACE activity is associated with an increased risk of severe
hypoglycaemia (173,210,242). However this observation has not been replicated in
non-Scandinavian countries. The present study therefore examined the relationship
between serum ACE levels and frequency of severe hypoglycaemia in a cohort with




Three hundred adults with type l diabetes attending a hospital outpatient clinic were
selected at random. Inclusion criteria consisted of type 1 diabetes of at least two years
duration and being over 16 years of age. Exclusion criteria consisted of pregnancy,
sarcoidosis or treatment with drugs affecting the renin-angiotensin system (RAS),
such as ACE inhibitors or angiotensin 2 receptor antagonists. The local medical
ethics committee approved the study, and informed consent was obtained from all
participants.
4.2.2 Methods
Each participant completed a questionnaire quantifying the frequency of mild
hypoglycaemia (self-treated) and severe hypoglycaemia (requiring external
assistance). Participants were asked to estimate the total number of episodes of severe
hypoglycaemia in their lifetime (using the following categories: 0, 1-2, 3-5 or >5
episodes of severe hypoglycaemia) and the specific number of episodes during each
of the previous two years. Awareness of hypoglycaemia was assessed using a
validated seven point visual analogue scale (170).
Information regarding microvascular complications was obtained from medical
records. Screening for retinopathy was performed by non-mydriatic digital retinal
photography in line with the standards demanded by the national retinal screening
programme and was classified as absent, background, pre-proliferative, or retinopathy
that had required laser treatment. The standard practice in our centre is to identify
peripheral neuropathy as being present or absent based on clinical assessment with a
10-gram monofilament, while autonomic neuropathy is confirmed by autonomic
function tests (322). Nephropathy is identified by the presence of microalbuminuria
(urinary albumin: creatinine ratio >3.5mg/mmol) or frank proteinuria on two separate
early morning urine samples or raised serum creatinine. It should be emphasised that
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none of these assessments were repeated as part of the study and information in the
medical records was accepted as accurate.
Serum ACE activity was measured using a continuous monitoring spectrophotometric
assay (Sigma Diagnostics, St Louis, MO USA) (323). HbA|C was measured by ion
exchange high performance liquid chromatography via the Bio-Rad Variant II
Haemoglobin testing system. The results are DCCT-aligned and the local non-
diabetic range for HbAlc is 5.0-6.5%
4.2.3 Statistical analyses
Primary end points were the number of events of severe hypoglycaenria reported
retrospectively over the previous two years and the proportion of participants
reporting such events. Frequency of severe hypoglycaemia was compared between
the top and bottom quartiles of ACE activity using Mann-Whitney U-tests (assuming
non-normal distribution). Serum ACE levels were compared between those with a
high number of severe hypoglycaemia events in the previous year (four or more) and
those with no severe hypoglycaemia in the previous year. Spearman rank correlations
were calculated for the associations between serum ACE activity and both frequency
of severe hypoglycaemia and awareness of hypoglycaemia.
The association between severe hypoglycaemia and serum ACE was also examined
with a negative binomial model using the statistical package R 2.4.1 (324). This
model takes into account the large number of zero values in the data (325). Other
analyses were performed using SPSS version 12.0 for Windows.
A p value of less than 0.05 was considered to be statistically significant. A formal
power calculation could not be conducted as there are no data on the distribution of
serum ACE levels within a Scottish population. However, the present study is larger
than previous published studies on this subject.
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4.3 Results
The clinical characteristics of the 300 participants are shown in table 4.1, alongside
those of the participants of the three previous relevant studies. In the present study,
the mean (SD) incidence of severe hypoglycaemia in the previous year was 0.93
(2.86) episodes per patient per year. However, the frequency of severe
hypoglycaemia was markedly skewed (figure 4.1), with 207 subjects experiencing no
severe hypoglycaemia, while only 44 individuals had experienced two or more
episodes of severe hypoglycaemia in the previous year.
Figure 4.1
Frequency distribution of severe hypoglycaemia occurring in the previous year in 300
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Table 4,1
Clinical characteristics of participants in the present study and in earlier Scandinavian
studies examining an association between serum ACE and severe hypoglycaemia
(SH).
Characteristics Present study Pedersen-Bjergaard Pedersen-Bjergaard. Nordfeldt. 2003
2001 (173) 2003(210) (242)
Location and type of study Scotland. Denmark, Denmark. Sweden,
retrospective. retrospective, prospective. prospective,
adults adults adults paeds/adolescent
Number of subjects 300 207" 171 86
Incidence of SI I (episodes/patient/year) 0.93 11 I.I 1.8
Prevalence of SH 31% 31% 39% 39% 51%
Age (years) Mean 38.1 43.1 44 13.0
SD 13.0 Not reported Not reported 3.1
Median 36 Not reported Not reported 12.8
Range 16-88 12.8 12 7.1-18.5
HbAlc (%) Mean 8.4 8.6 8.4 6.9
SD 1.4 1.3 1.0 1.0
Median 8.2 Not reported Not reported 6.8
Range 5.2-12,8 Not reported Not reported 4.7-10.2
Diabetes Mean 16.4 18.4 19 5.5
duration (years) SD 10.4 10.9 1 1 3.3
Median 14.5 Not reported Not reported 5.3
Range 2-49 Not reported Not reported 1.2-14.7
Male/Female (%/%) 53%/47% 54% / 46% 54%/46% Not reported
Retinopathy Number (%) 95 (32%) 92 (46%) Not reported (45%) Not assessed
Peripheral. Number (%) 17(6%) 52 (26%) Not reported (26%) Not assessed
Neuropathy
Autonomic. Number (%) 10(3%) 12 (9%) Not reported (7%) Not assessed
Neuropathy
Nephropathy Number (%) 9 (3%) 19(10%) Not reported (6%) Not assessed
Awareness of Normal: 196:104 92:115 70:101 Not assessed
hypoglycaemia** impaired (65:35%) (44:56%) (41:59%)
No. (%) with > 1 SH in previous year 93 (31%) Not reported 66 (39%) 44 (51%)
* 55/256 patients in this study were taking ACE inhibitors or angiotensin-II receptor
antagonists. Their data are excluded from this table.
** Different methods were used to estimate awareness of hypoglycaemia in the Scottish
and Danish studies
ACE = Angiotensin Converting Enzyme SH = Severe Hypoglycaemia
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The relationship between serum ACE activity and frequency of severe hypoglycaemia
over the previous year is shown in Figure 4.2. Data on incidence of hypoglycaemia
for the previous year and lifetime frequency of hypoglycaemia are available for all
300 subjects but the two year data on severe hypoglycaemia frequency was available
in only 257 subjects as several individuals felt that their recall was unreliable. One
subject claimed to have experienced 175 episodes of severe hypoglycaemia during the
preceding year and his data (which could not be verified) is reported as >30 episodes
of severe hypoglycaemia. The median (range) serum ACE level was 39.4 iU/L (<12-
129 iU/1).
Figure 4,2
The relationship between number of episodes of severe hypoglycaemia (SH)
experienced by individual participants during the previous year and their serum
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The correlation between serum ACE levels and frequency of severe hypoglycaemia
was examined using Spearman's test (table 4.2). There was a small (in effect size)
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but statistically significant correlation between serum ACE activity and the number of
episodes of severe hypoglycaemia in the previous year (p=0.047, p=0.115). The
correlations between serum ACE activity and all other estimates of frequency of
hypoglycaemia all failed to reach statistical significance (table 4.2). No significant
association was observed between serum ACE level and the hypoglycaemia
awareness score (p=0.701).
Table 4.2
Correlations between serum Angiotensin Converting Enzyme (ACE) activity and
various measures of frequency of severe hypoglycaemia (SH).
Serum ACE
Correlation coefficent (r) P
SH in previous year 0.115 0.047
SH in penultimate year 0.022 0.725
Mean annual incidence of SH (over 2 years) 0.079 0.175
Lifetime frequency of SH 0.013 0.816
Hypoglycaemia awareness score -0.022 0.701
The association between serum ACE levels and frequency of severe hypoglycaemia
was further examined using a negative binomial model. The subject with 175
episodes of severe hypoglycaemia was treated as an outlier and omitted from the
analysis, but the association remained statistically significant (p=0.002). Elowever,
the frequency of severe hypoglycaemia is very skewed, as illustrated in figure 4.1. In
order to assess the effect of the few individuals who experienced a high frequency of
severe hypoglycaemia, the data were reanalysed using a negative binomial model but
excluding two further subjects who had reported 20 and 24 episodes of severe
hypoglycaemia respectively over the previous year. When the subject with 24
episodes was excluded, the association remained significant (p=0.039), but when the
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subject with 20 episodes was also excluded, the result no longer achieved significance
(p=0.141). Adjustments were made to the model to consider stratification by age and
gender. However, neither had a significant impact upon the relationship between
serum ACE and frequency of severe hypoglycaemia.
The incidence of severe hypoglycaemia was determined for each quartile of ACE
activity (table 4.3) and compared between top and bottom quartiles using the Mann
Whitney U test. The frequency of severe hypoglycaemia did not differ significantly
between these two groups (p=0.075). The median serum ACE levels were compared
between the subset of people who had experienced no severe hypoglycaemia (n=207)
over the previous year and the small group who had experienced four or more
episodes of severe hypoglycaemia (n=18). The serum ACE levels were significantly
different between the two groups, (p=0.009) with median (range) ACE levels of 40.5
(12.0-129.0) iU/1 and 49.3 (56.4-96.9) iU/1 in the groups with low and high frequency
of severe hypoglycaemia respectively (p=0.008).
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Table 4.3
Number of episodes of severe hypoglycaemia (SH) in previous year for each quartile










Number of subjects 77 75 73 75
ACE Minimum 12 28.0 39.5 51.5
Maximum 27.9 39.4 51.4 129.0
















Median (range) episodes of SH 0 (0-6) 0(0-12) 0 (0-7) 0(0-30)
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4.4 Discussion
Previous studies have reported that high serum ACE activity is strongly associated
with an increased risk of severe hypoglycaemia. as demonstrated in adult cohorts with
type 1 diabetes in retrospective (173) and prospective (210) studies in Denmark and in
a prospective study of children and adolescents in Sweden (242). In the present study,
a statistically significant relationship was observed between serum ACE activity and
the incidence of severe hypoglycaemia, but this association was weak, with a low
correlation coefficient.
When the data were analysed using a negative binomial model, the statistical
significance of the relationship was determined by three individuals who reported a
very high frequency of severe hypoglycaemia. If the data from these three subjects is
omitted from analysis, this relationship is not statistically significant. The serial
removal of outliers is not a recommended statistical technique. However, it illustrates
how the relationship between ACE and severe hypoglycaemia may be
disproportionately affected by a small minority who have a very high incidence of
hypoglycaemia.
The incidence of severe hypoglycaemia did not differ significantly between subjects
in the top and bottom quartiles of ACE activity, but when the 18 subjects who
reported four or more episodes of severe hypoglycaemia over one year were
compared with those who had no severe hypoglycaemia, the serum ACE levels of
these two subgroups did differ significantly. The present study examined more
people than any of the Scandinavian studies and excluded those receiving treatment
with RAS-blocking drugs, as did two of the Scandinavian studies (210,242). A
significant number of individuals with type 1 diabetes are treated with such drugs and
their exclusion from this study may limit the generalisability of these findings.
However, we believe that the exclusion of these individuals is necessary to avoid
confounding of serum ACE data.
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Various possibilities can be proposed to reconcile the much weaker association
between serum ACE and severe hypoglycaemia observed in the present study with the
results of the three studies originating from Scandinavia. Retrospectively collected
data may be subject to recall bias, although recall of severe hypoglycaemia over a
period of one year has been shown to be robust and reproducible (4,21). It is possible
that the relationship of ACE to hypoglycaemia risk differs fundamentally between
Danish and Scottish populations, although they share similar cultural, ethnic and
genetic backgrounds and both countries have a similar prevalence of type 1 diabetes.
Even if this is a genuine difference, it does not appear to alter the rates of severe
hypoglycaemia observed in these national populations, possibly because the aetiology
of severe hypoglycaemia is multifactorial and a subtle difference in one factor might
be insufficient to alter the overall frequencies of hypoglycaemia. Previous studies in
Denmark (4), Scotland (205.208), England (204) and the Netherlands (209) have
reported very similar frequencies and distributions of severe hypoglycaemia within
populations of people with type 1 diabetes.
The discrepant results could relate to the processes of selection and assessment rather
than differences between the background populations from which subjects are
recruited. Differences between the three Scandinavian studies and the present study
are summarised in Table 4.1 and will now be discussed in more detail.
For example, although the present study differs from the others in the ages of the
subjects, the two Danish studies included participants who were older than those in
the present study (173,210), and the Swedish study examined adolescents and
children (242), which suggests that age was not contributory. While the much
younger Swedish patients had a shorter duration of diabetes and better glycaemic
control (242), no consistent differences were observed between the adult participants
of the present study and those in the Danish (173,210) studies, either in duration of
diabetes or HbAlc. However marked differences were present in the frequencies of
microvascular complications in the Danish groups compared with the present study
cohort. Information about microvascular complications was not provided in the
Swedish study, and these are rare in a paediatric age-group.
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Previous work has suggested that the predictive value of serum ACE is strongest in
patients whose defence against severe hypoglycaemia is compromised, such as those
with impaired hypoglycaemia awareness (173). The Danish method of assessing
hypoglycaemia awareness probably over-estimates the prevalence of impaired
awareness of hypoglycaemia as being 60% (21) compared to a prevalence of around
25% in other population studies (321). If the patients in the Danish studies (173.210)
had a higher frequency of impaired hypoglycaemia awareness than the present group
they would certainly have a greater vulnerability to developing severe hypoglycaemia
(170).
However, a study from our centre has compared three different methods of assessing
impaired awareness of hypoglycaemia. The Danish method (173) requires the patient
to answer the question "can you always feel when you are low?"' using the responses
"always", "usually'", "sometimes" or "never" and they are classified as having
impaired awareness if they answer anything other than "always". The Gold method
uses a 7 point likert scale to grade awareness, with 1 representing "always aware of
hypoglycaemia" and 7 representing "never aware". Prospective validation of this
method was undertaken by recruiting 2 groups of patients: one with awareness scores
of 1 -2 (normal awareness, n=31) and one group with awareness scores of greater than
4 (impaired awareness, n=29). The impaired awareness group had an almost 6-fold
increase in the incidence of hypoglycaemia over a 12 month follow-up period
compared to those with normal awareness (2.83 episodes per person per year
compared to 0.48 episodes per person per year, p<0.001) (170). The Clarke method
includes questions to characterise previous exposure to hypoglycaemia and an
assessment of the glycaemic threshold for and symptomatic responses to
hypoglycaemia (171). Comparison of these three methods in a cohort of 80 patients
with type 1 diabetes demonstrated good concordance between the Gold and Clarke
methods (correlation coefficient rs = 0.868, p = 0.001), which estimated prevalences
of impaired awareness of 24 and 26% respectively, compared to a prevalence of
62.5% using the Danish method (174). It therefore appears that the Danish method of
assessing impaired awareness may not be sufficiently specific or discriminatory.
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While it could be suggested that the difference in complication rates relates to the
exclusion from the current study of individuals treated with RAS-blocking drugs, only
one of the previous studies included individuals treated with these medications (173).
It could also be argued that exclusion of these individuals excludes those at higher
risk of severe hypoglycaemia, but as both the Danish studies reported a frequency of
hypoglycaemia of 1.1 episodes per patient per year, despite the fact that one study
excluded (210) while the other included (173) people treated with these agents, this
does not seem to be a likely possibility. In the latter study, the characteristics and risk
of severe hypoglycaemia in those treated with RAS-blocking drugs did not differ from
those of the other study participants so the investigators concluded that ACE
inhibition exerted no overall significant effect (173). However, patients in the
present study were often taking other antihypertensives including beta-blockers and
thiazide diuretics, which are known to exert an effect on the renin-angiotensin system.
For example, beta-blockers lower renin while thiazides, like RAS-blocking drugs,
increase renin. Calcium channel blockers reduce aldosterone. We did not control for
the presence of these other antihypertensives in our study and given that they all have
the potential to modulate components of the renin-angiotensin system, they may have
affected the measured serum ACE activity.
An alternative possibility is that there are differences in ACE genotype between the
different study populations, as the participants in the current study were not
genotyped. It has been noted previously that there is a close correlation between ACE
genotype and phenotype (173,235) and that the effect of the genotype is mediated by
the serum ACE levels (173), so when this study was designed a decision was made to
measure serum ACE alone. There would have been some potential advantages to an
assessment of ACE genotype in that it would have given a constant assessment of
each individual's renin-angiotensin system unaffected by factors such as concomitant
antihypertensive medication. It would also have simplified analysis in that we would
have been assessing the effect of a dichotomous variable (high risk versus low risk
genotype) rather than a continuous measurement (serum ACE level). Had patients
been genotyped, it would have been possible to study them in a case-control manner
by comparing the frequency of severe hypoglycaemia between those with high and
low risk genotypes rather than the rather more arbitrary subdivisions of ACE activity
into quartiles.
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However, there would also have been some drawbacks to this approach. It has been
accepted that if there is an increased risk of hypoglycaemia associated with the ACE
DD genotype that this is mediated by an increase in serum ACE levels. It was
therefore hoped that agents such as ACE inhibitors would reduce that risk by lowering
serum ACE levels. On that basis, it seemed rational to assess the phenotype rather
than the genotype because having a high risk genotype would not necessarily translate
to increased risk if the patient was taking a medication which lowered the ACE levels.
However, these are assumptions which cannot be proven and measurement of ACE
genotype would also have allowed a potentially interesting 3 way stratification of
patients into high risk genotype plus phenotype (ie DD genotype and high ACE
activity), high risk genotype and low risk phenotype (DD genotype and low ACE
activity) and low risk genotype plus low risk phenotype. This type of information
would have been a valuable addition to the present study as it would have provided
further data on the relationship between genotype and phenotype so it must be
acknowledged that the lack of genetic data is a limitation of this study.
Two other studies outside Scandinavia have addressed the relationship between serum
ACE levels and severe hypoglycaemia. The first of these is a study of 308 people
with type 2 diabetes in the UK, 124 of whom were treated with insulin while the
remaining 124 were treated with a combination of oral agents that included a
sulphonylurea (326). ACE genotype was checked in all subjects, who were divided
into two groups depending on whether or not they had ever experienced severe
hypoglycaemia. A total of 12% of subjects had previously experienced at least one
episode of severe hypoglycaemia and this proportion did not differ between ACE
genotype subgroups. The group carrying the D allele (including DD homozygotes
and DI heterozygotes) had an odds ratio of experiencing severe hypoglycaemia of
0.79 (95% confidence interval .035-1.78) relative to the II homozygotes. The authors
therefore found no evidence for a relationship between carriage of the ACE D allele
and an increased risk of severe hypoglycaemia in type 2 diabetes (326).
Similarly, a large prospective study in Western Australia concluded that the DD
genotype (which is associated with higher serum ACE activity) did not predict a
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significantly higher risk of severe hypoglycaemia in children and adolescents with
type 1 diabetes (327). A total of 585 children and adolescents with type 1 diabetes
were included in the study and the frequency of severe hypoglycaemia was assessed
prospectively over a 13 year period from 1992 to 2004. However, in this study, the
definition of severe hypoglycaemia was restricted to episodes resulting in loss of
consciousness. Children were seen with their parents every three months during the
study period and all subjects had their ACE genotype analysed. Of the 32% of
children who experienced at least one severe hypoglycaemic event, 28% had the II
genotype, 49% had the ID genotype and 23% had the DD genotype. The overall
incidence of severe hypoglycaemia was 14 episodes per 100 patient-years with no
significant increase in risk for those in the DD genotype group (incidence rate ratio
relative to II genotype = 0.97, 95% confidence interval 0.61-1.55)
In the present study the incidence of severe hypoglycaemia did not differ significantly
between subjects in the top and bottom quartiles of serum ACE activity, suggesting
that serum ACE is not sufficiently specific as a marker to allow hypoglycaemia risk
stratification of people with type 1 diabetes. Although serum ACE levels differed
significantly between people who had no history of severe hypoglycaemia and those
who had experienced four or more episodes, this has limited clinical applicability with
respect to screening for risk of severe hypoglycaemia. A previous history of severe
hypoglycaemia is a recognised risk factor for further severe hypoglycaemia. A
retrospective finding of high serum ACE levels in people who have already been
identified as having a high risk of severe hypoglycaemia based on their previous
history, has no prognostic value.
Thus, in the present study, the association between serum ACE and severe
hypoglycaemia in type 1 diabetes (173,210,242) was influenced disproportionately by
a few individuals who reported a high frequency of severe hypoglycaemia, raising
doubt as to the clinical significance of this finding. The present study suggests that
serum ACE is not sufficiently specific to serve as a prognostic indicator of increased
risk of severe hypoglycaemia. Further work is required to establish whether the
association is present in ethnically different (non-Caucasian) populations.
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Chapter 5: Modelling the consistency of
hypoglycaemic symptoms: high variability in diabetes
The data in this chapter have been published as a multi-author paper in a peer-reviewed
journal (See appendix). The first draft of this chapter was written by me. with the exception
of section 5.2.2 (Model for intra-individual consistency), which was drafted by Dr Streftaris
and edited by me. The other co-authors on this paper provided editorial input, corrections
and comments but did not write any individual sections of this paper. Dr Streftaris designed
the statistical model and undertook the statistical analyses. The idea to devise a model to
quantify between episode intra-individual variability in hypoglycaemia symptom reporting
was mine.
5.1 Introduction
Hypoglycaemia is a common side effect of insulin treatment which can have a
substantial morbidity. Rapid perception of the symptoms of hypoglycaemia is
essential to permit early corrective action. Field studies in which adults with insulin-
treated diabetes have reported symptoms experienced during hypoglycaemia have
allowed the most common symptoms to be identified (145) and subdivided into
autonomic, neuroglycopenic and general malaise groups (6).
When educating patients about the recognition of hypoglycaemia, it is important to
consider factors that may cause variation in their symptoms. The symptoms of
hypoglycaemia are age-specific, in that young children have difficulty recognising
hypoglycaemia (157) and often exhibit behavioural changes (157-159). In the elderly,
neurological symptoms are prominent and the signs of hypoglycaemia may mimic
those of a transient ischaemic attack, a stroke or a vasovagal episode (160). The
causative agent does not appear to influence hypoglycaemic symptoms, as
demonstrated in a study comparing hypoglycaemia generated by tolbutamide and
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insulin (161), where the symptoms reported were similar, irrespective of the
hypoglycaemic trigger. Retrospective field studies (164,165) and studies of
experimental hypoglycaemia (166) suggest that the symptom profile does not differ
between type 1 diabetes and insulin-treated type 2 diabetes. Gender does not
influence the nature of the symptoms experienced during hypoglycaemia (167).
Some hypoglycaemia-related symptoms may be more reliably associated with blood
glucose levels than others and a given symptom is not equally predictive of
hypoglycaemia in everybody (150). These observations suggest a degree of between-
subject variability in the reporting of symptoms. It is accepted that each individual's
symptom complex is idiosyncratic (145). However, an additional important issue is
the degree to which individuals report similar patterns of hypoglycaemia-related
symptoms across episodes. The reliability with which particular hypoglycaemic
symptoms occur in an individual's experience of hypoglycaemia influences the
person's ability to detect the onset of hypoglycaemia. People who have at least one
reliable symptom of hypoglycaemia correctly detect blood glucose levels below 3.9
mmol/1 on 50% of occasions, whereas individuals with four or more reliable
symptoms recognise similar blood glucose levels on 75% of occasions (148). In a
study where 100 children with type 1 diabetes and their parents completed a
questionnaire on their experiences of hypoglycaemia, the symptoms reported by
children exhibited marked variability between episodes of hypoglycaemia (157). It is
not known whether adults exhibit similar intra-individual variability.
The aim of the present study was to examine the symptoms of hypoglycaemia
recorded prospectively over 9-12 months by adults with type 1 and type 2 diabetes, to
develop a model for quantifying the consistency of the symptom complex recorded on
each occasion by every individual and to examine what factors might produce inter-
individual differences in the consistency of symptom reporting.
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5.2 Methods
Data for this study were collected during an epidemiological study examining the
effects of type of diabetes and treatment modality on the frequency of hypoglycaemia
(212). A total of 381 patients were followed for 9-12 months in six secondary care
diabetes centres in the UK. Participants aged 17-75 years were recruited into five
groups:
1. Type 2 diabetes treated with oral agents (which had to include a
sulphonyl urea)
2. Type 2 diabetes treated with insulin for <2 years
3. Type 2 diabetes treated with insulin for >5years
4. Type 1 diabetes with <5 years duration
5. Type 1 diabetes with >15 years duration
The clinical diagnosis of type 1 and type 2 diabetes was corroborated by ELISA
measurements of glucagon-stimulated C-peptide. HbAlc was assessed in a central
laboratory by a DCCT-aligned method. The presence of retinopathy was assessed
using digital retinal photography. Serum Angiotensin Converting Enzyme (ACE),
considered to be a putative marker for increased risk of severe hypoglycaemia at the
time that the study was designed (173,210,242), was also measured in a central
laboratory.
Subjects treated with insulin had to be taking at least two injections a day. Exclusion
criteria were: HbAlc >9%, severe diabetic complications, history of seizures,
malignant disease, severe systemic disease or pregnancy. The protocol received
multi-centre ethics approval. Subjects gave informed consent.
Subjects performed regular capillary glucose monitoring using a Medisense G glucose
meter (Abbott Laboratories). Subjects were asked to record every episode of
hypoglycaemia on standard forms, noting the date, time, duration, symptoms,
treatment received and concurrent blood glucose. Biochemical criteria for
hypoglycaemia were not stipulated and it was left to subjects' discretion to report any
episodes that they perceived to represent hypoglycaemia. However, subjects were
98
specifically asked to record any episodes associated with a capillary glucose <3.0
mmol/1 regardless of whether or not these were associated with symptoms. Subjects
were encouraged to measure blood glucose for every report form completed but
episodes were accepted as valid, even if no blood glucose measurement was available,
provided that symptoms resolved with ingestion of carbohydrate. All episodes
associated with a blood glucose level <4.0 mmol/1 were accepted as valid, even if
subjects reported no symptoms in association with these readings. Symptoms were
recorded using a standard list (table 5.1).
Table 5.1
List of symptoms on patients' report forms.
Symptom Description Symptom Description
l Confusion 14 Blurred vision
2 Sweating 15 Hunger
3 Drowsiness 16 Thirst
4 Weakness 17 Nausea
5 Dizziness 18 Anxiety
6 Feeling warm 19 Tiredness
7 Difficulty speaking 20 Tingling
8 Pounding heart 21 Trembling
9 Impaired concentration 22 Headache
10 Shivering 23 Malaise
11 Unsteady 24 Irritability
12 Non-specific awareness 25 Other
13 Double vision 26 None
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The state of hypoglycaemia awareness was assessed at entry to the study using a
validated scale (170). Each month, subjects returned forms recording all
hypoglycaemic episodes. If no form was received, the patient was contacted by
telephone. As the intensity of hypoglycaemic symptoms is diminished following
antecedent hypoglycaemia (12,14,101), any episode of hypoglycaemia occurring
within 24 hours of a preceding episode was excluded from further analysis.
5.2.1 Modelling and analysis
In the statistical model developed, individuals report specific symptoms with a
probability that depends on a random threshold being crossed. The behaviour of
thresholds is modelled through a probability distribution whose degree of
concentration around a central value provides a measure of an individual's symptom-
reporting consistency.
Under a Bayesian approach, following observation of binary indicators of symptom
experience (i.e. whether or not an individual experiences a given symptom),
information on unobserved latent factors and the variability of the thresholds becomes
available through their posterior distribution which is obtained using Markov Chain
Monte Carlo (MCMC) methodology (328). Bayesian methods and MCMC
techniques are used in the analysis of latent variable models in psychology (329,330).
Latent variable and threshold models are commonly used in the behavioural sciences
(331) and stochastic methods have been employed in diabetes to model the decision¬
making processes that lead to treatment of hypoglycaemia (332).
Computations were performed using the statistical package R (324). MCMC
techniques were implemented using winBUGS software (333). The lack of previous
similar analyses prevented formal power calculations. A pragmatic decision was
made that participants should have experienced at least 2 episodes of hypoglycaemia
per month on average. As follow-up ranged from 9-12 months, participants were only
included if they had reported more than 18 episodes of hypoglycaemia. The data
were checked for sample bias resulting from patients with more frequent episodes
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potentially experiencing lower number of symptoms, but no such association was
found ( p = -0.09)
5.2.2 Model for intra-individual consistency
The random threshold determining the probability of an individual reporting a set of
specific symptoms relates to latent variables that govern the intensity of a given
symptom on a given occasion and the individual's propensity to experience that
symptom. Therefore within our statistical model, assessment of intra-individual
consistency is based on a principle of hierarchical symptom reporting where order is
imposed by both propensity and intensity. Thus, a symptom is more likely to be
reported if it is intense (e.g. profuse versus mild perspiration) and if the individual has
a strong tendency to experience that symptom.
This modelling approach can be represented graphically by regarding each subject's
responses as a J x K matrix of indicator variables (J = number of symptoms; K =
number of episodes) where each reported symptom is represented by a marked cell.
Figure 5.1a represents a hypothetical completely consistent patient who reports the
same five symptoms on every episode of hypoglycaemia.
Rearranging the rows according to the frequency with which symptoms are
experienced and the columns according to the number of symptoms per episode (both
following a descending order from the top left corner; figure 5.1b), we obtain a
representation where the degree of clustering of marked cells can be regarded as a
measure of consistency and the relative frequency of embedded empty cells provides
evidence of lack of consistency.
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Figure 5.1 a
Example of a ,/ x K matrix of indicator variables (J = symptoms; K = episodes) for
hypothetical subject with symptoms 1-26 listed vertically and hypoglycaemic
episodes listed horizontally. Each reported symptom is marked with a square.





























Rearrangement of the matrix rows and columns: rows now appear according to the
frequency with which symptoms are experienced and columns according to the
number of symptoms per episode (both following a descending order from the top-left
corner of the table).



























In contrast to the hypothetical completely consistent patient who reports the same
symptoms on every occasion, the JxK matrix for subject number 6010 (figure 5.2)
illustrates the way that symptoms for a less consistent patient cluster to a lesser extent.
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Figure 5.2 a
Example of a JxK matrix of indicator variables (,/ = number of symptoms; K =
number of episodes) for subject 6010 with symptoms 1-26 listed vertically and
hypoglycaemic episodes listed horizontally. Each reported symptom is marked with a
square.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
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Rearrangement of the matrix rows and columns: rows now appear according to the
frequency with which symptoms are experienced and columns according to the
number of symptoms per episode (both following a descending order from the top-left
corner of the table).
9 2 7 4 8 6 11 10 16 19 12 18 1 5 3 14 17 15 13
2 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
9 ■ ■ ■ ■
6 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■
1 ■ ■ ■ ■ ■ ■ ■
20 ■ ■ ■ ■ ■ ■





















This graphical representation of symptom reporting consistency can be expressed
within a parametric framework using a logistic-type latent variable model. We
assume that the unobservable random thresholds r(associated with individual i
reporting symptom j at episode k) follow a log - normal(0, cr2) distribution, under




i = 1y=l,....J, k = 1 where al} and fiik represent the propensity for
symptom / and the intensity of episode k respectively for individual i, and<f>() denotes
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the cumulative distribution function of a standard normal variable. Therefore, the
model implies that occurrence of symptoms across and within episodes depends on
the relevant propensity (a,j) and also on the underlying episode intensity (/?,*) which
introduces associations among symptoms through the imposed hierarchical structure
of occurrence. The information available on the frequency with which symptoms are
reported through all episodes and on the total number of symptoms per episode,
allows estimation of both au and /?,* in our model.
The precision parameter cr~2 of the threshold distribution provides a measure of the
symptom reporting consistency of an individual. Consistent symptom profiles are
associated with low variance of the threshold distribution. For ease of interpretation
(7~~ is converted to a consistency parameter ci = 100/(1 + cr,2), which has range (0-
100) with increasing values corresponding to higher symptom consistency.
5.2.3 Association between consistency and patient-specific factors
Generalised linear model (GLM) methodology was used to investigate the effect of
the following ten patient-specific covariates on consistency: gender, age, type of
diabetes (1 or 2), duration of diabetes, presence of retinopathy, hypoglycaemia
awareness score (1 to 7, with higher scores corresponding to diminishing awareness
of hypoglycaemia), body mass index, stimulated C-peptide, FIbAlc, and serum ACE
activity. For modeling purposes retinopathy was sub-divided into no retinopathy,
background retinopathy and proliferative retinopathy (ret 1-3 respectively). A GLM
with gamma errors (see appendix) was used to link estimates of the precision
parameter <x,~2with the covariates, through the function
log{£(a,"2)} = b0 + bgen x GEN, + bagc, x AGE, + blype x TYPE, + bdur x DUR,
+ bren x RET 1, + brel2 x RET2, + brel3 x RET3, + bawar x AWAR,
+ bhm, x BM I, + bcpep x CPEP, + bhha x FIBA, + bacex x ACE,
and the effect of each covariate was assessed using 95% equal tailed Bayesian
intervals of the corresponding b coefficients.
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5.3 Results
A total of 3.474 episodes of hypoglycaemia from 59 patients were examined, of
which 91% were confirmed by capillary glucose readings. After exclusion of
hypoglycaemic episodes occurring within 24 hour of a previous event, 2699 episodes
remained for analysis. Table 5.2 summarizes the subject characteristics and
hypoglycaemic episodes within each group. The most commonly recorded symptoms
were weakness, decreased concentration, sweating and hunger (reported in 28.7%,
28.2%. 21.8%, and 21.1% of episodes, respectively).
The precision parameter crj2 quantifies the degree to which a patient reports a similar
set of symptoms on every episode of hypoglycaemia. The distribution of the
estimated values, cx ~2, is skewed, with most subjects having low consistency (fig
5.3a). Estimates of the converted consistency parameter, c/ = 100/(1 + <r2), have
mean 50.3 and standard deviation 16.7 (figure 5.3b). The main sample quartiles of c,
are cjo = 18.0, 70.25 = 37.6, <70.5 = 50.2, 70.75 = 62.7and 7\ = 96.7. Posterior estimates of
c, were derived for each subject in the analysis using Markov chain Monte Carlo
(MCMC) methodology (328). and are displayed in Table 5.3. Credible intervals for c,
were wide for some patients, reflecting limited information in the occurred episodes.
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Table 5.2
Subject characteristics and hypoglycaemic episodes within each group. Data are given as
median (range) unless otherwise stated. (T2tabs: Type 2 diabetes treated witli oral agents;
T2Ins<2: Type 2 diabetes treated with insulin for <2 years; T2lns>5: Type 2 diabetes treated
with insulin for >5years; T11ns<5: Type 1 diabetes with <5 years duration; T11ns> 15: Type 1
diabetes with >15 years duration)
T2tabs T2Ins<2 T21ns>5 Tllns<5 T1Ins> 15 Total
Number in original study (212) 108 89 77 50 57 381
No. of subjects with > 19 hypos 1 4 9 21 24 59
Hypos per group 25 113 476 1385 1475 3474
Hypos per group after hypos 25 104 370 1095 1 104 2699
<24h of each other excluded
Number of hypos per patient 25 28.5 37 49 44.5 42
(25) (20-36) (27-146) (19-210) (19-300) (19-300)
Hypos per patient after hypos 25 25 31 44 37 37
<24h of each other excluded (25) (20-34) (25-105) (19-134) (19-138) (19-135)
Percentage of hypos confirmed 100% 95.2% 89.1% 95.1% 87.8% 91.0%
biochemically
Asymptomatic episodes per
group (% ) after hypos <24h of 36% 0% 9.3% 0.9% 4.5% 11.3%
each other excluded
No. (%) male 1 (100%) 4 (100%) 8 (89%) 14 (67%) 1 1 (46%) 39 (65%)
Age (years) 51 65 65 39 58 57.5
(51) (60-74) (57-72) (22-70) (34-72) (22-74)
No. (%) with impaired awareness 0 (0%) 0 (0%) 2 (22%) 7 (33%) 13 (54%) 22 (37%)
BMI (kg/m2) 23.7 27.8 27 24 25.3 25.0
(23.7) (26-30.2) (21.9-33) (19.5-29.6) (21.6-42.7) (19.5-42.7)
C peptide (nmol/1) 2.22 0.85 0.24 0.45 0.09 26
(2.22) (0.27-1.58) (0.05-0.21) (0.06-0.87) (0.05-0.85) (0.05-2.51)
HbAlc (%) 7.1 8.3 7.6 7.2 7.8 7.55
(7.1) (7.8-8.8) (6.3-8.9) (5.6-10.1) (6.1-9.7) (5.6-10.1)
ACE (11J/I) 20 13.5 39 34 31.5 32.5
(20) (7-24) (4-71) (18-94) (3-98) (3-98)
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Table 5.3 Posterior estimates of consistency (mean ci — E(c, \y ), std dev =
^var(cv |y ) and 95% equal-tailed interval) for all subjects.
Group Subject No. of
hypos
No. of hypos excluding
those < 24h of previous
No(%) of asymptomatic
episodes
c, Std dev 95% interval
T2 tabs 3046 25 25 9 (36%) 68.84 7.682 53.19. 83.24
3016 23 22 0 (0%) 73 7.495 56.95. 86.2
12 Ins 6002 34 34 0 (0%) 41.3 6.986 28.9. 55.93
<2yrs 6056 36 28 0 (0%) 64.92 7.89 49.38. 80.02
6058 20 20 1 (5%) 74.29 7.048 59.25, 86.65
1055 27 27 9(33.3%) 74.05 7.207 58,69. 86.46
3048 37 31 0 (0%) 67.46 7.562 51.48, 80.93
3052 146 105 14 (13.3%) 49.5 5.25 39.36. 59.91
3057 92 51 0 (0%) 39.81 6.287 28.22, 52.48
T2 Ins 3065 27 26 7 (26.9%) 55.09 8.411 38.84. 71.92
>5yrs 3067 32 26 2 (7.7%) 42,47 7.742 28.42, 58.19
4072 42 39 I 5 (38.5%) 57.57 7.333 43.14. 72.22
4076 33 29 0 (0%) 52.96 8.252 36.7, 69.27
5009 40 36 0 (0%) 25.9 4.974 17.44.36.98
1009 93 74 0 (0%) 53.16 5.902 41.57. 64.58
1021 49 43 0 (0%) 47.72 7.065 34.3,62.27
1036 42 24 3 (12.5%) 51.14 8.395 35.42, 67.65
2012 42 37 0 (0%) 29.72 6.09 19.44.43.08
2027 26 22 3(13.6%) 68.52 8,179 51.53. 83.29
3001 35 31 20(6.5%) 56,94 8.089 41.18. 72.31
3024 30 27 0 (0%) 52.05 8.046 36.88. 67.78
3029 78 69 0 (0%) 64.71 5.951 52.68. 75.89
3050 54 44 1 (2.3%) 49.04 6.941 36.29. 62.96
T1 Ins
<5yrs
4023 210 134 0 (0%) 22.07 2.988 16.75,28.65
4034 61 55 0 (0%) 59.98 6.523 46.97, 72.87
4049 23 22 2 (9.1%) 60.79 8.303 44.17, 76.63
4063 45 42 0 (0%) 33.95 6.241 22.85.47.46
5029 47 45 0 (0%) 62.07 6.905 48.07, 75.02
5044 88 70 36(51.4%) 40.38 5.579 29.69. 51.7
5045 79 68 12 (17.6%) 47.46 5.902 35.97.59.12
5088 102 87 7 (8.0%) 24.33 3.813 17.73, 32.64
6010 19 19 0 (0%) 63.97 8.463 46.91, 79.94
6019 93 64 1 (1.6%) 38.13 5.327 28.27, 49.26
6038 125 79 12 (15.2%) 28.43 4.34 20.67. 37.63
6065 44 39 0 (0%) 50.17 7.443 36.11, 64.75
1008 124 95 14 (14.7%) 30.07 4.123 22.57.38.78
1015 35 27 0 (0%) 37.11 7.649 24.02, 53.68
1025 26 25 5 (20%) 63.36 8.222 47.1, 78.24
1028 45 42 42 (100%) 96.65 1.535 92.88, 98.65
1039 47 43 0 (0%) 30.64 5.68 20.75,42,81
1086 91 67 0 (0%) 39.72 5.53 29.52, 50.89
2009 101 86 3 (3.5%) 30.46 4.34 22.65. 39.38
2010 102 89 32 (36.0%) 33.4 4.478 25.33.42.55
2013 300 138 0 (0%) 18.01 2.556 13.41.23.37
2015 44 32 14 (43.8%) 53.02 7.695 38.25. 68.16
2021 33 24 4 (16.7%) 58.05 8.683 41.19, 74.89
T1 Ins
>]5yrs
2022 41 36 0 (0%) 43.41 7.338 30.09, 58.72
3015 19 19 1 (5.3%) 58.93 9.166 40.84, 76.37
3022 23 20 1 (5%) 66.05 8.198 49.04, 81
4003 26 23 18 (74.1%) 75.86 6.818 60.73, 87.59
4008 67 59 0 (0%) 31.24 4.825 22.74.41.81
4013 55 39 0 (0%) 49.62 7.283 35.8,64.12
4043 36 34 0 (0%) 39.05 6.796 26.5, 52.88
4045 46 38 0 (0%) 48.41 7.506 34.24,63.57
5004 28 26 3 (11.5%) 61.33 8.093 45.33, 76.98
5023 22 20 5 (25%) 72.85 8.022 55.42. 86.8
5026 26 24 0 (0%) 74.24 7.2 58.61, 86.96
6018 62 39 0 (0%) 29.94 5.703 19.96. 42.12
6023 76 59 14(23.7%) 32.67 5.174 23.36, 43.41
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Figure 5.3
Histograms of estimated precision parameter a~2 (5.3a) and estimated consistency
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Some subjects in the study merit individual consideration. Subject 1028 (type 1
diabetes >15 years) was asymptomatic during all of his 45 recorded episodes. He had
reported a hypoglycaemia awareness score (170) of 7, denoting total loss of warning
symptoms, and had the highest estimated consistency (96.7 with 95% Bayesian
interval 92.9 to 98.7). In Bayesian statistics, the credible or Bayesian interval plays a
similar role to confidence intervals in frequentist statistics. Subject 4003 (also type 1
diabetes >15 years) had the second highest consistency score (75.86 with 95%
Bayesian interval 60.7 to 87.6), was asymptomatic during 74.1% of his reported
episodes and was the only other subject with an awareness score of 7. Subject 5044
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(type 1 diabetes <5 years duration) had no symptoms during 51% of her reported
episodes of hypoglycaemia but had a hypoglycaemia awareness score of 2, implying
good awareness. Her consistency score was 40.4 (95% Bayesian interval 29.7-51.7).
During the asymptomatic episodes, her median (range ) blood glucose readings were
3.4 (2.4-3.9). All other subjects were symptomatic during at least 50% of their
reported hypoglycaemic episodes. The single subject treated with oral agents was
asymptomatic on 36% of episodes, all of which were confirmed biochemically
(median blood glucose 3.4 mmol/1; range 3.1-3.5 mmol/1). All of these subjects were
included in the analysis as the presence or absence of symptoms was considered to
form part of the variability of their symptom profiles.
When the effect of specific covariates on the consistency measure was examined,
gender and hypoglycaemia awareness were the only factors which had a systematic
effect. Figure 5.4 shows 95% Bayesian intervals for all covariate coefficients. If both
endpoints of the interval are positive or negative, a corresponding effect of the
covariate on consistency can be inferred. The mean of the gender coefficient, b n,
was - 0.677 (95% Bayesian interval - 1.239, - 0.110). This suggests that female
subjects were less consistent than male subjects (gender was coded as 0=males and
l=females). The mean of the coefficient of awareness, b;mat, was 0.138 (95% interval
0.006, 0.284). As high values of the covariate indicate impaired awareness, the
significantly positive estimate of bawar implies that those with impaired awareness of
hypoglycaemia recorded lower variability in their hypoglycaemic symptoms than
those with higher awareness.
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Figure 5.4
Posterior means (circles) and 95% equal tailed Bayesian intervals (bars) for
standardised coefficients of patient-specific covariates (baci,: serum ACE activity;
bhha: HbAlc; hcpip: stimulated C-peptide; bhmi: body mass index; bawar:
hypoglycaemia awareness score; bren : no retinopathy; brel2: background retinopathy,
brel3: pre-proliferative retinopathy; bdur: duration of diabetes; blype: type of diabetes;
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However, if subjects 1028 and 4003 (asymptomatic on 100% and 74% of episodes
respectively) are excluded, only gender has a significant effect (females less
consistent than males; bgcn= -0.43, 95% Bayesian interval - 0.82. - 0.03) (figure 5.5).
Figure 5.5
Posterior means (circles) and 95% equal tailed Bayesian intervals (bars) for standardised
coefficients of patient-specific covariates after exclusion of subjects 1028 and 4003 (bace:
serum ACE; bhha: HbAlc; b : stimulated C-peptide; bhmi'. body mass index; bawar:
awareness score; brell: no retinopathy; bret2 : background retinopathy, brel3: pre-proliferative






















Whereas it has long been recognized that subjective symptoms can vary in different
circumstances, the present study has demonstrated and quantified episode-to-cpisode,
intra-individual variability in symptoms of hypoglycaemia reported by adults with
type 1 and type 2 diabetes. It has also sought and found some determinants of inter-
individual differences in this symptom (in)consistency. The statistical method that we
have developed allows patient consistency to be mapped on a continuous scale, taking
into account the involved statistical uncertainty. It is accepted that each individual's
hypoglycaemia symptom complex is characteristic. However, the wide range and
skewed distribution of the precision parameter cr~2 demonstrates that within-subject
symptom profiles vary substantially between episodes and that people show marked
individual differences with respect to their consistency of symptom reporting.
Conversion of the precision parameter to the normalised consistency parameter c. on
a (0, 100) scale facilitates between and within-patient comparisons of consistency
estimates, although there is no pre-defined cut-off to differentiate consistent and
inconsistent individuals
The most commonly reported symptoms in this study were weakness, decreased
concentration, sweating and hunger. In studies where patients have previously been
asked to indicate which symptoms they most associate with hypoglycaemia, the
commonest symptoms were sweating, difficulty concentrating, decreased
coordination and weakness (80%, 80%, 75% and 70% of respondents respectively)
(148). It has previously been noted that the earliest symptoms to develop when blood
glucose falls into the hypoglycaemic range are trembling, sweating, tiredness,
decreased concentration and hunger (149). The symptoms which correlate most
accurately with blood glucose levels are hunger, trembling and weakness (53%, 33%
and 27% of people respectively) (150). Thus the symptoms most frequently reported
in the present study are those that are appreciated to be the earliest perceived
symptoms of hypoglycaemia (149) and those that are most commonly (148) and
accurately (150) associated with hypoglycaemia. However, the main aim of this study
was not to study population similarities but rather to examine intra-individual
consistency of symptom reporting.
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The statistical models, methodology and analyses in the present study raise some
important points for patient education and hypoglycaemia research. Firstly, the
skewed distribution of the estimated precision parameter, <x~2 (fig 2a). demonstrates
that most subjects in this study exhibited low symptom reporting consistency. Thus,
when patients are taught that their own hypoglycaemic symptoms are idiosyncratic,
they should also be informed that their symptoms are likely to vary between episodes.
Reinforcing this point may reduce the possibility of failure to recognise
hypoglycaemia as a result of symptom variation.
Secondly, it is probably useful for patients to have an awareness of how consistent
their symptoms are, given that individuals with four or more reliable hypoglycaemic
symptoms are much more likely to correctly identify low blood glucose levels than
individuals with fewer reliable symptoms (148).
Finally, previous studies have relied on very few snapshots of the hypoglycaemic
symptom profile, either recorded during experimental hypoglycaemia (7.161,167,334)
or documented retrospectively by patients in what was thought to represent their
"typical" symptom profile (6,146,160,164,165). The findings of the present study
challenge the validity of the latter approach for the purpose of advising individual
patients, as the degree of between-episode variability is much greater than has
previously been appreciated.
Of the factors examined, only female gender and normal hypoglycaemia awareness
increased symptom variability in the initial analysis. Impaired awareness is usually
associated with loss of autonomic warnings and increased reliance on
neuroglycopenic symptoms. Individuals with impaired awareness therefore have a
more restricted range of symptoms which may explain why their symptom variability
is lower. In fact, the estimated consistency measure is negatively correlated to the
total number of symptoms reported throughout all episodes (^_y,Jk) for each
j,k
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patient, suggesting that higher symptom reporting activity (as would be expected with
normal awareness) may be associated with greater variation of reporting thresholds.
In order to assess the extent to which the two predominantly asymptomatic
individuals affected the observed results, the GLM analysis was repeated after
exclusion of the two individuals with awareness scores of 7 (subjects 1028 and 4003).
These two subjects were asymptomatic on 100% and 74% of occasions respectively.
Although impaired awareness was associated with increased symptom consistency in
the initial analysis, this effect was no longer observed once these two subjects were
excluded. This illustrates that one of the limitations of this analysis is that it cannot
distinguish between a completely consistent person with full symptom awareness and
a consistently asymptomatic individual. However, these subjects represent the
extreme end of the spectrum of impaired awareness of hypoglycaemia. For
individuals with fewer asymptomatic episodes, the presence or absence of symptoms
contributes to the consistency of their symptom profile and it was therefore felt
important not to exclude asymptomatic episodes completely from this analysis.
However, it is probably reasonable to conclude that female gender is the only factor to
systematically affect consistency and the observed effect of impaired awareness in the
original analysis is attributable to a consistent lack of symptoms rather than a
consistently reported set of symptoms.
It was surprising to find that the subject treated with oral agents was asymptomatic
during 36% of episodes, despite recording a normal hypoglycaemia awareness score
of 1. However, as all his episodes were confirmed with appropriate capillary glucose
readings, his symptom reports were regarded as valid. In the UK, patients treated
with oral agents are not routinely asked to check blood glucose levels. It is therefore
likely that he had not realised that his awareness was impaired prior to participation in
this study.
The relationship between consistency of symptom reporting and gender has not been
reported previously. However, it is recognised that differences exist between males
and females in their perception of hypoglycaemia. Symptoms of hypoglycaemia
develop at similar blood glucose thresholds in men and women with type 1 diabetes
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(62) but the magnitude of the counterregulatory response is lower in women (107)
which may influence the intensity of the symptomatic response of autonomic
symptoms, some of which are enhanced by catecholamine secretion. Female
counterregulatory responses are less affected by antecedent hypoglycaemia and
exercise than responses in men (335). It could be hypothesised that the gender
differences in this study relate to under-reporting by females as a result of lower
symptom intensity. In the present study, subjects were not asked to note the intensity
of symptoms, so it is not possible to establish whether symptom intensity differed
between males and females. Although there are gender differences in the magnitude
of the symptomatic and counterregulatory responses to hypoglycaemia, a study
reviewing symptoms that were recorded during experimentally-induced
hypoglycaemia in 160 adults (with and without diabetes) did not find any evidence of
a gender effect on the nature of the symptoms (167)
It is possible that other factors, such as the activities engaging the individual at the
time of the episode, may have an effect on symptom consistency but it would be
logistically difficult to study these in greater detail. Earlier work has classified
hypoglycaemic symptoms in physiological terms (6,158,160,164,165). Appropriate
grouping of symptoms may be able to account for additional sources of between-
group variation for an individual patient in the model, thus giving scope for including
relevant effects for symptom groups in future analyses.
Not all hypoglycaemic episodes in this study were confirmed biochemically.
Flowever, the presence of typical symptoms which resolve with ingestion of
carbohydrate is conventionally taken as evidence of hypoglycaemia. Insistence on
biochemical corroboration would have further restricted the number of episodes
available for analysis and most episodes (91%) were confirmed with capillary glucose
readings.
A difficulty also arises with the definition of hypoglycaemia according to biochemical
parameters when subjects are asymptomatic. Blood glucose and symptom data for
this study were obtained from a multicentre epidemiological study (212), where
subjects were asked to record all episodes associated with a capillary glucose <3.0
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mmol/1 or any episodes associated with symptoms typical of hypoglycaemia.
However, as hospital clinics frequently advise patients not to let blood glucose levels
drop below 4 mmol/1, patients did send in hypoglycaemia recording sheets with blood
glucose readings between 3 and 4 mmol/1 in the absence of symptoms. As these
episodes were considered valid and were included in the epidemiological study they
were also included in the statistical analysis in this study. It was felt that they could
not be excluded when similar blood glucose readings from symptomatic patients were
being included. However, it is possible that some of the asymptomatic readings
between 3 and 4 mmol/1 included in this study were essentially episodes of
normoglycaemia and this represents a potential limitation of this study. For future
work, a more robust approach would be to pre-define a more definite cut-off for
asymptomatic hypoglycaemia, such as a blood glucose level of 3.2 mmol/1 or less, as
this blood glucose level is known to be associated with neuroglycopenia
In subjects with normal awareness, it would be interesting to stratify episodes
according to blood glucose level to investigate whether this had an effect on symptom
reporting, as it could be hypothesised that the depth of the glucose nadir might affect
the range (and intensity) of the symptoms reported. However, this was not possible in
the present study for several reasons. Although a fall in blood glucose in a non-
diabetic adult triggers the secretion of counterregulatory hormones and the onset of
cognitive and symptomatic changes at reproducible blood glucose thresholds (60,62)
within a defined hierarchy (61), these thresholds become altered in diabetes and the
same blood glucose level may affect individuals with diabetes in different ways.
Secondly, data from field studies will never be as controlled as data generated in a
lab. In the present study, confirmation of hypoglycaemia may have occurred several
minutes before or after rescue carbohydrate was administered so blood glucose
measurement may not have coincided exactly with the blood glucose nadir or the peak
of symptom intensity. Finally, blood glucose meters are less accurate in the
hypoglycaemic range and it would not have been possible to confirm these readings
with venous samples outside the confines of a tightly regulated laboratory study.
The study has several strengths, including its size (2699 episodes of hypoglycaemia),
its prospective design and its duration (9-12 months). Although some previous
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studies have collected symptoms prospectively (4,150.336), they have not attempted
to compare symptoms between episodes or to compile a representative list of
symptoms from those reported during different episodes. Furthermore, prospective
field data could be regarded as more generalisable than hypoglycaemia data collected
under laboratory conditions.
The present study demonstrates that: intra-individual between-episode symptom
variability is much greater than has been previously appreciated and that there are
marked individual differences in this consistency. Caution should be exercised when
interpreting patients' retrospective recall of what they regard to be their "typical"
hypoglycaemic symptoms. Female gender was the only factor found to have a
systematic association with increased variability of the symptom complex. Given this
observed variability, clinicians should advise patients against being too dogmatic in
their perception of what constitutes their cardinal hypoglycaemic symptoms, as these
may vary considerably between episodes. This variability should also be considered
when interpreting hypoglycaemic symptom responses under different experimental
conditions or when comparing different therapeutic interventions.
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Chapter 6: Recovery of cognitive function following
HYPOGLYCAEMIA IN ADULTS WITH TYPE 1 DIABETES AND THE
EFFECT OF IMPAIRED AWARENESS OF HYPOGLYCAEMIA
The data in this chapter have been published as a multi-author paper in a peer-
reviewed journal (See appendix). The first draft of this chapter was written entirely
by me and 1 coordinated all subsequent editing. Professor Ian Deary provided advice
on statistical analysis but I performed the statistical analyses and wrote up the
results. Co-authors on this paper provided editorial input, corrections and comments
but did not write any individual sections of this paper.
6.1 Introduction
Clinical observation has suggested that the recovery of cognitive function following
hypoglycaemia often lags behind the restoration of biochemical euglycaemia.
Previous studies which have attempted to quantify the time taken for cognitive
recovery have been limited by factors such as recruitment of non-diabetic volunteers
(279,281,282), small sample sizes and consequent lack of statistical power (282), lack
of a euglycaemic control arm (281,337). the use of neurophysiological measurements
rather than direct tests of cognitive function (279-281,284) or the use of cognitive
tests which are not reliably affected by hypoglycaemia (277-280). Precise
measurement of the time taken for recovery requires repeated testing, but many
studies have restricted cognitive testing to just one or two time points (282,284,337)
and therefore cannot accurately define the recovery phase. Finally, the interval
between the restoration of euglycaemia and the testing of cognitive function has
mostly been ill-defined, and consistency of the timing of cognitive testing between
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different participants was not assured (279,280,284,337). Comparison of results from
different centres is frequently hindered by methodological variation in hypoglycaemia
studies (243) with relevant variables including method of measurement of blood
glucose (278) and the target level for. and duration of, hypoglycaemia (284).
In addition, it has been observed that the inter-individual variation in the degree to
which hypoglycaemia affects cognitive function is very wide (243). However, no
consensus exists as to whether either impaired awareness of hypoglycaemia or
recurrent antecedent hypoglycaemia are associated with the relative preservation of
cognitive function during hypoglycaemia (62,78,273,290.292,316,317) or an
exacerbation of the decrement in cognitive performance associated with
hypoglycaemia (65,285,318).
The present study has examined the time taken for recovery of tests representing
various domains of cognitive function in a group of individuals with type 1 diabetes,




The local medical research ethics committee approved the protocol. Subjects gave
informed consent for participation.
6.2.1 Subjects
Subjects were eligible for inclusion if they were between 18-45 years of age with a
diagnosis of type 1 diabetes of at least 2 years duration and HbAlc values between 7
and 10% within the preceding 12 months. Volunteers were excluded in the event of
pregnancy, co-existent systemic disease or malignancy, a past history of head injury,
epilepsy, hypoglycaemia-induced seizure, chronic alcoholism or psychiatric disorder.
Thirty-six subjects with type 1 diabetes were recruited, 20 with normal
hypoglycaenria awareness (NHA) and 16 with impaired hypoglycaemia awareness
(1HA), confirmed by documenting their hypoglycaemia history and using a validated
hypoglycaemia awareness scale (170). Each subject was asked "Do you get warning
of your hypos?" and asked to select a number on a scale from 1 ("Always") to 7
("Never"). People who chose 1 -2, and reported no history of severe hypoglycaemia
or subjective change in their glycaemic threshold for symptoms, were categorised as
having normal awareness. Those who scored between 3-7 were categorised as having
impaired awareness
The subjects' clinical characteristics are given in table 1. Microvascular
complications were defined as any clinical diagnosis of diabetic retinopathy,
neuropathy or nephropathy, the latter requiring urine albumin:creatinine ratio
persistently above the local reference maximum or serum creatinine > 150 prnol/1.
The presence of retinopathy was determined by digital retinal photography while the
presence of peripheral neuropathy was confirmed on the basis of clinical examination
using a tuning fork and lOg monofilament. HbAlc was measured by high-
performance liquid chromatography (Variant II haemoglobin Testing System; BioRad
Diagostics Group, Hercules, CA) with a local non-diabetic reference range of 4.3-
6.5%. The IHA group had a longer duration of diabetes (median [range] 33.5 [22-43]
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years) compared to the NHA group (29 [19-44] years; p<0.001) and a higher
prevalence of microvascular complications (6 patients in IHA group, 1 patient in
NHA group, x =5.994, p=0.013). Other comparisons (sex, age, HbAlc, BMI) were
non-significant.
Table 6.1.
Characteristics of participants with type 1 diabetes
unless stated otherwise.
in study. Data are mean (SD)
Hypoglycaemia awareness status Normal Impaired
Number 20 16
Male : female 12 : 8 6 : 10
Median age (range) (years) 29 (19-44) 33.5 (22-43)
Median duration of type 1 diabetes (range) (years) 3.8 (1.1-20) 15.5 (2-35)
HbAlc (%) (Non-diabetic range 4.0-6.5%) 7.8 (1.3) 8.4 (1.8)
BMI (kg m"2) 25.8 (2.2) 26.8 (3.6)
Number (%) with microvascular complications 1 (5) 6(38)
6.2.2 Glucose clamp procedure
Each subject underwent one hypoglycaemic and one euglycaemic clamp, separated by
at least two weeks. The order of the experimental condition (hypoglycaemia versus
euglycaemia) was randomised and counterbalanced and subjects were not informed of
the order of occurrence. Clamp sessions commenced at 08.00h after an overnight fast
from 22.00h and subjects were asked to omit their usual morning insulin dose on
study days. In order to avoid effects of antecedent hypoglycaemia, six studies were
postponed (2 NHA, 4 IHA) because of symptomatic hypoglycaemia or blood glucose
< 4.0mmol/l during the preceding 48h.
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An ante-cubital vein and a dorsal hand vein were cannulated in the non-dominant arm
for infusions and blood sampling. The dorsal hand vein was cannulated in a
retrograde fashion and the hand was wrapped in a heated blanket to arterialise venous
blood. Arterialised venous samples were drawn every 5 minutes, and whole-blood
glucose was measured using a Yellow Springs 2300 analyser (Yellow Springs
Instruments, Yellow Springs, Ohio).
The study design is illustrated in figure 6.1. Using a modified hyperinsulinaemic
glucose clamp technique (74), an infusion of soluble human insulin (Actrapid,
NovoNordisk) at 1.5 mU kg"' min"1 was commenced, and 20% glucose solution was
infused at a variable rate to achieve the target blood glucose levels. Blood glucose
was stabilised at 4.5mmol/l (euglycaemia) and maintained for 30 minutes while
subjects practised the cognitive tests (baseline phase). In the euglycaemic condition,
glucose was maintained at this level during the experimental phase. In the
hypoglycaemic condition blood glucose was lowered over 20 minutes to 2.5mmol/l,
where it was maintained for one hour (experimental phase). It was not always
possible to drop blood glucose in exactly 20 minutes so this interval is approximate.
Testing during the hypoglycaemic condition began once blood glucose dropped to 2.5
mmol/1 or below. Following the experimental phase, euglycaemia (>4.0mmol/l) was
then rapidly restored. The recovery phase start was defined by two consecutive
arterialized glucose readings > 4mmol/l, with blood glucose tested every 5 minutes
throughout the study. Cognitive testing in the recovery period commenced 10
minutes after the first of two consecutive euglycaemic readings.
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Figure 6.1
Study outline. Cognitive function and symptoms were tested at baseline, at the
beginning and end of the experimental condition and during the recovery period at 10,
20, 30, 40, 55, 70 and 85 minutes after euglycaemia was restored.
6.2.3 Symptom scores and cognitive function tests
The cognitive battery consisted of three tests which are sensitive to hypoglycaemia
(144) and are easy to administer repeatedly. The tests were:
1. Trail making B (TMB): This test is taken from the Halsted Reitan battery
(338) and assesses mental flexibility and executive function. A modified
version was used where the subject was presented with a hand-held computer
displaying a grid with randomly positioned numbers and letters (339). These
must be tapped sequentially using a hand-held pen, alternating between
numbers in ascending order and letters in alphabetical order. The score is the
time taken to complete the task.
2. Digit Symbol Substitution Test (DSST): Taken from the Wechsler adult
intelligence scale (340). This test of processing speed involves the
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substitution of symbols for digits using a given code. Subjects are scored for
the number of symbols correctly substituted within 2 minutes
3. Four Choice Reaction Time (CRT). In this test of processing speed, the
numbers 1-4 are presented repeatedly and in random order on a small screen.
Subjects are asked to press one of four numbered buttons corresponding to the
number on the screen. The speed of reaction and accuracy are recorded.
Symptoms were recorded using the Edinburgh Hypoglycaemia Scale (6), which lists
symptoms of hypoglycaemia and allows each to be graded in intensity on a visual
analogue scale of 1 -7. The cognitive battery and the Edinburgh Hypoglycaemia Scale
were applied at baseline, at the beginning and end of the experimental phase, and
during the recovery period at 10, 20, 30, 40, 55, 70 and 85 minutes after euglycaemia
was restored (figure 1).
6.2.4 Statistical analysis
Cognitive scores were compared using general linear modelling (repeated-measures
analysis of variance [ANOVA]). In the full model, including all subjects,
hypoglycaemia awareness status was the between-subjects factors. The
experimentally-induced state of hypoglycaemia versus euglycaemia was the within-
subjects factor. Age, sex, duration of diabetes and order of exposure to
hypoglycaemia had no significant effect on the results, so these fixed
effects/covariables were excluded from the final model. Individuals' test scores
within a single clamp study were corrected for baseline performance by subtracting
their baseline score from their scores at each time point. The model compared these
adjusted scores between the euglycaemic and hypoglycaemic conditions (repeated
measure). The effects of hypoglycaemia in NHA and IHA groups separately are also
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reported. Statistical significance was accepted at p<0.05. Partial rj was used to
indicate effect size. Analyses were performed using SPSS for Windows version 12.0.
With 20 subjects in each group, the power of the study in detecting a 0.5 standard
deviation change in any test (assuming a=0.05, reliability of test=0.8) is 94%. Using




6.3.1 Blood glucose results
During the euglycaemia studies, mean (SD) blood glucose concentrations were 4.5
(0.2) mmol/l in the NHA group and 4.5 (0.3) mmol/l in the IHA group (p=0.643).
During the hypoglycaemia condition, blood glucose was maintained at 2.5 (0.2)
mmol/l in both the NHA and IHA groups (p=0.468) (Figure 6.2).
Figure 6.2a
Mean blood glucose values during clamp study on euglycaemic and hypoglycaemic

























Mean blood glucose values during clamp study on euglycaemic and hypoglycaemic
sessions: Impaired awareness group
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Total symptom scores did not change during the euglycaemia condition. During the
hypoglycaemia condition the mean (SD) symptom scores rose in the NHA group
(baseline 23.2 (4.4) versus experimental 44.1 (22.2); p<0.001) and 1HA subjects
(baseline 22.9 (7.0) versus experimental 28.8 (8.3); p=0.001). The increment in
symptom scores was greater in the NHA group (p=0.002). Symptom scores reverted
to baseline immediately after euglycaemia was restored in both groups.
6.3.3 Cognitive tests
Tables 6.2, 6.3 and 6.4 show mean (SD) test scores corrected for baseline
performance (i.e. each score is the difference between the baseline score and the score
at that time point) for CRT, DSST and TMB test respectively. CRT and TMB scores
are completion times so a lower score represents better performance. The DSST score
is the number of items completed in two minutes so a higher score represents better
performance. The effects of glycaemic condition were first examined within NHA
and 1HA groups, and then for all subjects combined including interaction between
glycaemic condition and awareness status. A considerable practise effect was
apparent on the DSST task but not on the CRT and TMB tasks. The randomised
counterbalanced study design controls for practise effects.
6.3.3.1 NHA subjects
Performance on all cognitive tests was significantly impaired during hypoglycaemia
in NHA subjects (tables 6.2-6.4 and figures 6.3a, 6.4a, 6.5a). Performance on DSST
and TMB deteriorated significantly during hypoglycaemia but reverted to baseline as
soon as euglycaemia was restored (tables 6.3-6.4). CRT remained impaired after
restoration of euglycaemia, with significant differences between the hypoglycaemic
and euglycaemic conditions at 20, 30, 40 and 75 minutes (table 6.2 and figure 6.3a).
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Mean (SE) times on CRT test during hypoglycaemia and euglycaemia conditions in
individuals with normal awareness of hypoglycaemia.
Squares=EU Triangles=HYPO
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Mean (SE) times on CR T test during hypoglycaemia and euglycaemia conditions in




Mean (SE) times on TMB test during hypoglycaemia and euglycaemia conditions in
individuals with normal awareness of hypoglycaemia.
Squares=EU Triangles=HYPO
*= p<0.05 EU vs HYPO




Mean (SE) times on TMB test during hypoglycaemia and euglycaemia conditions in
individuals with impaired awareness of hypoglycaemia.
Squares=EU Triangles=HYPO
♦ Data for one subject was omitted at this time point as it skewed the data markedly
(required 212 seconds to complete the task during hypoglycaemia). The difference
between hypoglycaemia and euglycaemia was not significant regardless of whether























Mean (SE) times on DSST during hypoglycaemia and euglycaemia conditions in
individuals with normal awareness of hypoglycaemia.
Squares=EU Triangles=HYPO















Mean (SE) times on DSST test during hypoglycaemia and euglycaemia conditions in








In IMA subjects, cognitive tests did not show significant impairment during
hypoglycaemia, with the exception of the DSST task after 60 minutes of
hypoglycaemia (p=0.041; table 6.2, figures 6.3b. 6.4b, 6.5b). There were no
significant differences between the two experimental conditions during the recovery
phase. Compared with NHA subjects, trends towards a smaller deterioration in
performance and more rapid recovery following hypoglycaemia were observed.
6.3.3.3 All subjects
Poorer performance during hypoglycaemia versus euglycaemia was seen for all
cognitive tasks. This difference persisted for CRT at 20, 30 and 40 minutes after
euglycaemia was restored (p=0.04, r| =0.125) (table 6.2), and for TMB at 10 minutes
after euglycaemia was restored (p=0.024, r)2=0.158) (table 6.4). There was no
persistence of impairment of DSST performance (table 6.3).
6.3.3.4 Comparison of effect of hypoglycaemia in NHA and IHA subjects
DSST: The interaction between glycaemic condition and hypoglycaemia awareness
(hereafter termed the glycaemia-awareness interaction) was significant only at the
start of hypoglycaemia (table 6.3) (p=0.009), suggesting that hypoglycaemia caused
significantly greater impairment in NHA subjects than in IHA subjects.
CRT: Performance was impaired during hypoglycaemia and at 20, 30 and 40 minutes
after euglycaemia was restored (p=0.04, p =0.125). The glycaemia-awareness
2interaction was significant only at the end of hypoglycaemia (p=0.045, rfi=0.124)
(table 6.2). This infers that the NHA group were, relative to their baseline
performance, more affected during hypoglycaemia than the IHA group, but there were
no significant between-group differences during recovery.




Results from the present study suggest three conclusions. Firstly, in all subjects
combined, cognitive performance was significantly impaired during hypoglycaemia
by comparison with euglycaemia, consistent with numerous previous studies (144).
Secondly, when subjects were divided according to their state of hypoglycaemia
awareness, cognitive performance was significantly impaired in NHA subjects,
whereas only non-significant trends were seen in IHA subjects. This difference
appears to suggest that individuals with IMA are less affected by hypoglycaemia than
those with NHA. A formal NHA-IHA difference requires a significant interaction
between awareness status and glycaemic condition; this was seen for CRT at the end
of hypoglycaemia, and for DSST at the start of hypoglycaemia, without correction for
multiple comparisons. This study therefore provides the first, but limited, evidence
for a formally-tested difference in the cognitive effect of hypoglycaemia depending
on state of awareness.
Thirdly, choice reaction time remained significantly prolonged up to 75 minutes after
hypoglycaemia in NHA subjects (and up to 40 minutes in all subjects combined), and
TMB completion time remained significantly prolonged 10 minutes after
hypoglycaemia in all subjects combined. These data suggest that some aspects of
cognitive function remain impaired for a clinically significant time after correction of
hypoglycaemia.
The absolute differences in CRT between the groups were small. There was a trend
toward improvement in CRT during the euglycaemic condition in the NHA group
with a corresponding deterioration in the IHA group. This highlights the importance
of the euglycaemic control arm in that each group's performance during
hypoglycaemia is compared to performance during euglycaemia and not to that of a
different group, thus controlling for between-group differences that may not be
apparent.
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The present study has a strong power for within-subjects comparisons but is less
powerful at detecting between-subjects differences; high power for a medium effect
size difference between groups requires over 50 subjects per group. It is impossible
to exclude some overlap in hypoglycaemia awareness between the two groups,
because scoring methods require some degree of subjective self-assessment. The IHA
subjects also had longer duration of diabetes and more microvascular disease,
although as IHA appears to be strongly associated with diabetes duration, it may be
impossible to match for these characteristics. Finally, asymptomatic hypoglycaemia
prior to the study cannot be excluded, particularly in IHA subjects, despite the
frequent monitoring of blood glucose for the preceding 48h.
If the NHA-IHA differences are accepted, they suggest that IHA subjects develop
cerebral adaptation to hypoglycaemia. This interpretation may appear to be
counterintuitive as these individuals have a higher risk of severe hypoglycaemia than
those with NHA (170,171). However, this adaptation may increase their
susceptibility to severe hypoglycaemia by limiting the time to identify low blood
glucose and allowing progression to debilitating neuroglycopenia. The degree of
cognitive adaptation acquired by those with IHA is insufficient to compensate
completely for the loss of physical symptoms.
Individuals with IHA are at increased risk of frequent asymptomatic hypoglycaemia.
There is data to suggest that antecedent hypoglycaemia affects the subsequent
physiological responses to further hypoglycaemic stimuli. The effects of antecedent
hypoglycaemia on the counterregulatory responses to hypoglycaemia in people with
diabetes have been well studied. In one early clamp study of 13 adults with type 1
diabetes, blood glucose was lowered to 3mmol/l and maintained at that level for 2
hours. Normoglycaemia was restored for one hour before a further hour of clamped
hypoglycaemia (3mmol/l). Counterregulatory responses were reduced during the
second period of hypoglycaemia (341). Similarly, counterregulatory responses to
hypoglycaemia were attenuated in other studies when the interval between the
antecedent episode and the studied episode of hypoglycaemia were as long as two
(15) or even three days (342).
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Antecedent hypoglycaemia can also affect the cognitive responses to hypoglycaemia.
by shifting the thresholds for cognitive dysfunction to lower blood glucose levels in
adults with type 1 diabetes (11.12,290.291). In one study, the antecedent
hypoglycaemic stimulus consisted of twice weekly periods of clamped
hypoglycaemia (mean glucose 2.8mmol/l for one month) (12) while in another study
subjects' blood glucose was lowered to 2.6mmol/l for 3.5 hours during sleep (11).
The decrement in cognitive ability during the final episode of hypoglycaemia was
reduced in both these studies, indicating that a range of antecedent hypoglycaemic
stimuli can alter the thresholds for cognitive dysfunction and attenuate the effects of
subsequent hypoglycaemia. It has also been previously demonstrated that cognitive
dysfunction begins at lower blood glucose levels in people with T1DM and IHA
compared to those with NHA (78).
These effects of antecedent hypoglycaemia are not limited to individuals with
diabetes. Glucose clamp studies in non-diabetic individuals have shown that 90-150
minutes of hypoglycaemia the day before cognitive testing attenuates the deterioration
in short term memory, reaction time and auditory-evoked brain potentials (292-294)
and avoidance of hypoglycaemia can restore the glucose thresholds for cognitive
dysfunction to higher levels (62,273,274).
The suggestion therefore is that individuals with IHA experience frequent episodes of
hypoglycaemia (often without symptoms), which then attenuate the effects of future
episodes of hypoglycaemia. This would explain why cognitive function was not
significantly affected in the IHA group in this study when performance was compared
between the hypoglycaemic and euglycaemic conditions.
A smaller study from our centre by Gold and colleagues published in 1995 compared
the effects of hypoglycaemia on cognitive function in 20 people with T1DM with
either IHA or NHA and reported a trend towards poorer performance during
hypoglycaemia in IHA subjects (285). Methodological differences exist between the
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two studies, with the earlier study applying a cognitive battery of 20 minutes duration
at one time point only, 10 minutes after euglycaenria was restored. This study was
therefore unable to accurately quantify the time taken for recovery of cognitive
function. The effect of awareness was not significant for any of the tests employed
except for the Rapid Visual Information Processing (RV1P), where the results are
given for RV1P hits, misses and reaction time. The result was not significant for the
hits (ie correct answers) or reaction time but there was a significant effect on RVIP
misses (ie there were more false positive responses in the group with impaired
awareness). However, on this latter measure, the effect of the study condition (ie
euglycaemia versus hypoglycaemia) was not significant. The cognitive tests used
differed from the current study and CRT (the test yielding the most interesting results
in the present study) was not used.
However, the study in 1995 by Gold and colleagues did employ a more robust
definition of impaired awareness of hypoglycaemia than that used in the present
study. The earlier study in 1994 which validated the Gold method of stratifying
awareness of hypoglycaemia (170) established that people with type 1 diabetes had an
almost six-fold increase in the incidence of hypoglycaemia if they had an awareness
score of greater than four. In the 1995 study on the effects of hypoglycaemia
unawareness on hypoglycaemia-induced cognitive dysfunction, the impaired
awareness group scored 4 or more. However, in the present study, the median score
for awareness was 4 (range 3-6) with seven participants selecting scores of 3. These
participants clearly did not have full awareness of hypoglycaemia given that both the
1994 and 1995 Gold studies classified normal awareness as a score of 1-2. However,
this group with an intermediate level of awareness may behave differently to a more
clearly defined impaired awareness group. There may also be a significant degree of
heterogeneity in this group as three out of the seven participants with awareness
scores of 3 had not experienced any episodes of severe hypoglycaemia in the
preceding year, while the remaining 4 reported 2 or 3 episodes in the preceding year.
It is therefore difficult to fully ascribe the observed effects in the present study to
impaired awareness when there were a number of patients with partial levels of
hypoglycaemia awareness.
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In addition, the present study had intended to recruit 20 participants to each arm.
With 20 subjects in each group, the power of the study in detecting a 0.5 standard
deviation change in any test, (assuming a^O.05, reliability of test=0.8) would have
been 94%. Recruitment was halted after 16 participants were enrolled in the impaired
awareness arm of the study. At this point, every patient documented to have impaired
awareness on our hospital diabetes computer system had been invited to attend. In
order to recruit the planned 20 subjects it would have been necessary to recruit from
other centres and the result was that this study may have been slightly underpowered.
However, at 36 participants, it is still a one of the largest clamp studies examining the
effects of hypoglycaemia on cognitive function. For example, the 1995 study by Gold
and colleagues comparing the effects of impaired awareness on hypoglycaemia-
induced cognitive dysfunction only included 10 subjects with normal awareness and
10 with impaired awareness whereas the present study included a total of 36
participants.
There was inter-individual variability in the effects of hypoglycaemia on cognition,
consistent with anecdotal observations. The present study was not sufficiently large
to study the determinants of these differences formally. Thus, advice to individuals
should not be too dogmatic given the possibility of inter-individual differences.
Furthermore, although an hour of asymptomatic hypoglycaemia may occur frequently
in individuals with IHA, hypoglycaemia is probably perceived and corrected earlier in
those with NFIA. Exposure to a shorter period of hypoglycaemia should be examined
in a group of individuals with NHA to ascertain whether the duration of
hypoglycaemia affects the recovery of cognitive function. It would also be interesting
to examine whether other factors such as fatigue may have an additive effect on the
delayed recovery of choice reaction time following hypoglycaemia.
Finally, it is important to exercise some caution when extrapolating findings of
cognitive function studies to daily life. Although rapid reactions are undoubtedly
required for several daily activities, most notably driving, reaction time does not
operate in isolation. It is possible that other skills may be less affected following
hypoglycaemia (as was the case with the TMB results in the present study) and that
these may compensate for the slowing of reaction time. Recovery of cognitive
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function has not been formally tested in a driving simulator. Our centre lacks the
facilities to conduct such a study but a well-designed clamp study where performance
on a driving simulator is assessed during and after hypoglycaemia would provide
results of great ecological validity. Although these findings cannot be directly
extrapolated to driving performance, they certainly support the advice currently given
to patients by both the DVLA (Driver and Vehicle Licensing Agency) and health care
professionals to avoid driving immediately after a period of hypoglycaemia. It is
therefore of concern that in a survey of 202 insulin-treated diabetic drivers in
Edinburgh, only 14% of participants would wait longer than 30 minutes after
correction of hypoglycaemia before resuming driving (306).
The present study indicates that cognitive recovery is variable for different tasks but is
prolonged for four-choice reaction time. It also provides evidence to support the
concept of cognitive adaptation to hypoglycaemia in people with IHA, possibly as a
consequence of recurrent exposure to hypoglycaemia. The delay in recovery of
reaction time has implications for the safety of undertaking tasks requiring rapid
responses immediately after hypoglycaemia.
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Chapter 7: Conclusions and future directions
There is already an extensive body of literature on the risk factors for severe
hypoglycaemia, symptoms of hypoglycaemia and effects of hypoglycaemia on
cognitive function. It is therefore pertinent to ask what the work in this thesis adds to
previous studies in this area.
The first study was undertaken at a time when there was great interest in a potential
role for serum ACE levels in predicting the risk of severe hypoglycaemia. Three
Scandinavian studies (173,210,242) had previously suggested a strong link between
increased serum ACE levels, mediated by the DD ACE genotype, and an increased
risk of severe hypoglycaemia. Furthermore, it had been suggested that people with
high ACE levels might be less able to function efficiently during periods ofmetabolic
substrate deprivation. This could potentially be manifest by greater cognitive
impairment during hypoglycaemia than in those with low ACE activity, which might
partly explain the variable risk of developing severe hypoglycaemia amongst people
with type 1 diabetes.
The concept was an attractive one. Flad the link between serum ACE and severe
hypoglycaemia been confirmed, it would have been interesting to conduct
hypoglycaemic clamp studies in cohorts with high and low ACE levels to see whether
those with high ACE levels experienced greater decrements in cognitive function than
those with normal ACE levels. There are few therapeutic strategies available to
reduce the risk of severe hypoglycaemia, but ACE inhibitors would have been
interesting to investigate in this context.
However, the study reported in this thesis found that the association between serum
ACE levels and the risk of severe hypoglycaemia was statistically significant but
weak, with a low correlation coefficient. The statistical significance of the
relationship was largely determined by three individuals who reported a very high
frequency of severe hypoglycaemia. Furthermore, the incidence of severe
hypoglycaemia did not differ significantly between subjects in the top and bottom
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quartiles of serum ACE activity, suggesting that serum ACE is not sufficiently
specific as a marker to allow hypoglycaemia risk stratification of people with type 1
diabetes.
Shortly before this study was published (343), two other studies were published which
also suggested that there was no significant link between serum ACE levels and risk
of severe hypoglycaemia in children and adolescents with type 1 diabetes (327) and in
adults with type 2 diabetes (326). Although negative studies are often regarded as
being less worthy of publication than positive studies, these three published studies, in
different diabetic subgroups, are important in that they challenge the previously held
view that serum ACE might be useful as a marker of severe hypoglycaemia. This in
turn helps prevent unnecessary research into a putative link that is not strong enough
to be clinically relevant.
The second study in this thesis examines the intra-individual, between-episode
variability in the reporting of symptoms of hypoglycaemia. It is accepted that the
symptoms of hypoglycaemia are idiosyncratic but it has also been assumed that each
individual has a typical set of symptoms of hypoglycaemia. This study confirms that
adults with type 1 and type 2 diabetes are much more variable in terms of symptom
reporting than has previously been appreciated. This has implications for both
hypoglycaemia research and for patient education.
Previous research has relied on "snapshots" of a patient's hypoglycaemia symptom
profile, either recorded during experimental hypoglycaemia (7,161.167,334) or
documented retrospectively by patients, who reported what they regarded as their
"typical" symptom profile (6,146,160.164.165). The findings of the present study
challenge the assumption that patients have a consistently reported set of
hypoglycaemia symptoms because the degree of between-episode variability is much
greater than has previously been appreciated.
Notwithstanding, the present study does not necessarily undermine previous research
findings. For example, some of the studies where symptom profiles have previously
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been gathered have contributed to the physiological grouping of hypoglycaemia
symptoms in autonomic, neuroglycopenic and general malaise symptoms (6.146.160).
The validity of these groupings has been confirmed by pharmacological studies which
confirm the same symptom groupings. It is likely that a patient's summary of their
"typical" symptoms is reasonably representative but the key point is that they will not
express all these symptoms on every occasion and there may be some infrequently
experienced symptoms which they do not include in their "typical" profile. It would
be interesting to conduct further studies where subjects are asked to record their
typical symptom profile at the start, which could then be compared to prospectively
recorded symptoms over a period of time.
It is probable that the observed symptom variability is more relevant to patient education than
it is to interpretation of previous research. The skewed distribution of the estimated
precision parameter demonstrates that most subjects in this study exhibited low
symptom reporting consistency. Thus, when patients are taught about hypoglycaentic
symptoms, they should be informed that their symptoms are likely to vary between
episodes in order to avoid any failure to recognise hypoglycaemia as a result of
symptom variation. It is also useful for patients to have an awareness of how consistent
their symptoms are, given that individuals with four or more reliable hypoglycaemic
symptoms are much more likely to correctly identify low blood glucose levels than
individuals with fewer reliable symptoms (148).
Of the factors examined, only female gender was consistently associated with
increased symptom variability. It could be hypothesised that the gender differences in
this study relate to under-reporting by females as a result of lower symptom intensity.
In the present study, subjects were not asked to note the intensity of symptoms, so it is
not possible to establish whether symptom intensity differed between males and
females. It would be interesting to conduct further studies where subjects record both
the nature and intensity of symptoms to see whether symptom intensity is related to
the observed between-gender differences in the consistency of symptom reporting.
Given that earlier work has classified hypoglycaemic symptoms in physiological
terms (6,158,160,164,165), it would also be interesting to explore the effect of
appropriate grouping of symptoms within the statistical model to see whether this
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might account for additional sources of between-group variation for an individual
patient.
The study has approached symptom analysis in a novel way and developed a
statistical method of quantifying symptom variability. This study's size (2699
episodes of hypoglycaemia). its prospective design and its duration (9-12 months) are
all notable strengths. This study has recently been published (344) and there is the
potential to extend this work in future as discussed above.
The third study in this thesis examined the time taken for recovery of cognitive
function following hypoglycaemia in adults with type 1 diabetes and either impaired
or normal awareness of hypoglycaemia. It demonstrates a prolonged recovery for
reaction time, with delayed reaction time evident in those with normal awareness up
to 75 minutes after euglycaemia was restored. It also finds that subjects with
impaired awareness of hypoglycaemia were less affected by low blood glucose levels,
both during and after the period of hypoglycaemia. with only non-significant trends
towards impaired performance evident on cognitive testing. Although the question of
cerebral adaptation in those with impaired awareness remains a contentious issue,
these findings are consistent with previous studies which support the concept of
adaptation to hypoglycaemia as a result of repeated exposure to low blood glucose
levels (65,285,318).
This study was designed to avoid the methodological limitations of earlier studies in
this area. These robust results raise some further interesting questions. For example,
it could be argued that an hour of hypoglycaemia would not be typical for individuals
with normal awareness of hypoglycaemia, who would detect and treat the episode
promptly. It is pertinent to ask whether the time taken for recovery is affected if the
period of hypoglycaemia is brief. It could be hypothesised that a shorter period of
hypoglycaemia might be followed by more rapid recovery of cognitive function.
Following the publication of this study (250), our group is planning further clamp
studies to investigate this in the future, where the study protocol would be replicated
in individuals with normal awareness following a 20 minute period of hypoglycaemia.
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It would also reasonable to explore the clinical significance of the observed delays in
reaction time. While this study has demonstrated statistically significant delays in
reaction time for a prolonged period after correction of hypoglycaemia, it is difficult
to be certain what the practical relevance of these delays is. Driving is one activity
which involves rapid reactions but as it also involves other domains of cognitive
function, it is not possible to determine from the present study what the effect would
be on aspects of driving such as braking speed or the ability to avert a collision. It
would be interesting to explore the recovery of driving ability following
hypoglycaemia using a well-designed clamp study and a driving simulator, but
unfortunately our centre does not have the facilities to conduct such a study.
In conclusion, the current body of work adds to the existing literature on
hypoglycaemia in a number of ways. Firstly, it contributes to the debate in two
contentious areas by adding to the bodies of evidence which suggest that serum ACE
is not a sufficiently sensitive marker of severe hypoglycaemia for clinical use and that
adults with impaired awareness of hypoglycaemia can exhibit a degree of cerebral
adaptation to hypoglycaemia. In addition, the data demonstrating significant delays in
reaction time following restoration of euglycaemia and high intra-individual between-
episode variability in hypoglycaemia symptom reporting are relevant to patient
education. The work contained in this thesis has been published in high quality peer-
reviewed diabetes journals and interesting questions have been raised which should
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Appendix 1:
Statistics for Hypoglycaemia Symptom Analysis
Model for intra-individual consistency
We have assumed that an individual's symptom profile depends on latent factors expressing
the intensity of a given symptom on a given occasion and the individual's propensity to
experience that symptom. The model that we develop implies that assessment of intra-
individual consistency is based on a principle of hierarchical symptom reporting where order
is imposed by both propensity and intensity.
To account for various sources of uncertainty associated with the process of applying the
hierarchical structure described above to symptom propensity and episode intensity, a
logistic-type latent variable model is used. If we let Yyk denote the indicator random variable
taking the value 1 if subject i experiences symptom j at episode k and 0 otherwise, we assume
Yjjk~ Bernoulli(piJk) for / =1j = 1 k = 1 (in our data / = 59,./= 26 and K,
varies from 19 to 135), where pljk gives the corresponding reporting probability and is
derived as follows. We assume that individual i reports symptom / at episode k when
exceeds a threshold xyk, with latent variables ay > 0 and fi,k > 0 representing the propensity for
symptom j and the intensity of episode k respectively for individual /. The thresholds xyk are
considered to be random variables and we assume that for a given individual i they follow a
common log-normal distribution, i.e.
where pl and cr2 provide the mean and the variance of log(x,^). Therefore, the probability
pjjk of individual i reporting symptomj at episode k is given by
i = 1j=\,...,J, k = 1 where 0() denotes the cumulative distribution function of a
standard normal variable. The mean of the logarithm of the thresholds, E{log(r,/;(.)} = pi, is
Tjk ~ log - normal (/r .cr2), i = 1,...,/ [1]
[2]
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not of primary interest here and. without any loss of generality, we can set //, =0for all
subjects /.
Under this model Yjk are only conditionally independent, with occurrence of symptoms
across and within episodes depending on the relevant propensity (%), and also the underlying
episode intensity (/?,*) which introduces associations among symptoms through the imposed
hierarchical structure of occurrence. Also, as episodes of hypoglycaemia occurring within 24
hours of a preceding episode were excluded from this study, the model does not assume any
correlation structure between intensity levels of successive episodes.
The unknown variance parameter <x2 of the threshold distribution provides a measure of the
symptom reporting consistency of an individual patient. To simplify notation, we use
w; — a'2 to denote the precision parameter of the threshold distribution throughout this
appendix. Under the assumed log-normal model we have var(r ) = ea' (e°' -l)and
lim var(r„i.) = 0, as a, —> 0. Equivalently, lim var(r/Jt) = 0 as w, —* oo. Here, to facilitate
interpretation and comparisons, we use a function of erf2 given as the rescaled consistency
parameter c, = 100/(1+ er2), with range (0, 100). For large c, the thresholds get highly
concentrated around a constant value r, , resulting in consistent reporting of symptoms
• • • • • • *
associated with latent symptom propensity at] and episode intensity fyk such that a^jk > r, .
Therefore, consistent symptom reporting is associated with high concentration of the
threshold distribution, corresponding to increasing values of the consistency parameter c,.
Sensitivity to threshold distribution
The level of the consistency parameter for each subject was estimated under a Bayesian
approach. The thresholds r^can alternatively be assumed to follow other distributions. Here
we consider that, for patient i, they are drawn from a Weibull family, i.e.
Tijk ~ Weibull(v,,T,), i = 1,...,/
and the probability pijk of individual i reporting symptom j at episode k is is expressed
though the appropriate cumulative distribution function (cdf) as
P,jk = V<T,jk ^ a„P,k) = 1 - exp {-T, {ajp,k)}
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/ =1k = As with the mean parameter in the log-normal model, the
scale parameter of the threshold distribution is assumed known and set to X, = 1. The
unknown parameter of the threshold distribution provides a measure of the symptom
reporting consistency of an individual patient, with var(r^.) = T\l+2/v,) - {/"(7 + 7/ v,)}'. This
gives
implying that high v,- values correspond to consistent symptom reporting, as was the case
with c, under the log-normal threshold distribution. Again, rescaled versions of the parameter
can be used for convenience, e.g. ul = 100/(1 + v"1). There is close agreement between the
consistency parameter estimates under the two models, as shown in figure Al, verifying that
our analysis is robust to the choice of the threshold distribution.
Figure A1:
Estimated posterior mean of c, = 100/(1 + cr,2) against posterior mean of ui = 100/(1 + v~') .













Posterior estimates for individual subjects
Following a Bayesian approach, we consider independent prior distributions for the latent
variables ai} ~Gamma(ya,da), i = 1 1 ,j = 1ftjk ~Gamma(yp,dp), i = 1 1, k = 1 K„
with appropriate values for ya,Sa, yp and dp to express relative prior ignorance (here ya = yp =
1 and Sa = 8p = dB = 0.1). As in this work we do not focus on between-individual variability
of symptoms, it is not relevant to assume a hierarchical setting of common distributions for
the latent propensity variables («jy). Estimation of cc., and filk is informed by the frequency
with which a symptom is reported throughout all episodes and the number of symptoms per
particular episode. For identifiability and interpretation purposes, we have also imposed a
corner-type constraint on the logarithms of these parameters
(loga.j = logp:1 = 0,i = 1,
We also assign a relatively vague inverse gamma prior distribution to the variance parameter,
cr2 ~ lnv-Gamma(yff, da) , i = 1 1 where again ya = 1, da =0.1.
Posterior estimates of c, were derived for each subject in the analysis using Markov chain
Monte Carlo (MCMC) methodology. Credible intervals for c, were wide for some patients,
reflecting limited information in the occurred episodes. A histogram and the empirical
cumulative distribution function of ci, the posterior means of c„ are given in chapter 5 (figure
5.3).
Relationship between consistency measure and number of empty embedded
cells
In this work, the consistency of individual patients when reporting symptoms throughout a
series of hypoglycemic episodes has been associated with a principle under which symptoms
are experienced according to a hierarchical order determined by their latent propensity and
the latent intensity of episodes. The embedded empty cells in figures 5.1 and 5.2 (chapter 5)
provide evidence of deviation from this principle in the observed complex of symptoms for
each individual. Figure A2(a) illustrates that consistency, as estimated in our model, is related
to the number of embedded empty cells, and therefore the consistency parameter c, in our
approach is in agreement with the principle of hierarchical symptom reporting. Figure A2(b)
reveals that the estimated consistency is also negatively related to the total number of
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symptoms reported throughout all episodes jk ) for each patient. This points towards
J,k
potential presence of additional variation in the threshold level of individuals, suggesting that
an extended model may also be considered in the future to allow for random effects for
associated symptoms.
Figure A2:
(a) Number of embedded empty cells against ci





No. of embedded empty cells
SCO 200 400
Total no. of reported symptoms
GLM analysis for association between consistency and patient-specific factors
Generalised linear model (GLM) methodology was used to investigate the effect of the
following ten patient-specific covariates on consistency: gender, age, type of diabetes,
duration of diabetes, presence of retinopathy, hypoglycaemia awareness score, BMI,
stimulated C-peptide, HbAlc and serum ACE activity. Gender, type of diabetes and presence
of retinopathy were included in the model as categorical factors, while all other covariates
assumed numerical values.
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The estimated posterior mean of the precision parameter, vr = E(w/ \y ), is modelled as the
response variable in a Bayesian gamma GLM. This is a more appropriate measure to be
modelled as the GLM response variable, compared to c, for which a distribution on the






which gives E(uj) = ml and var(w,) = m] jX. The suitability of the gamma errors and
alternative GLM assumptions are discussed later in this Appendix. The mean consistency
response mi is linked to patient-specific categorical factors and continuous covariates through
a function of the form m, =exp(x,//?), i = 1 /, where b = (b0,b],...,b]2)1 is a vector of real
valued coefficients and x' = (l,x,x12/) is the covariate vector corresponding to the order
in which the covariates are given above (with the unit value giving the intercept, bQ, of the
linear function). Note that gender and type of diabetes account for one coefficient each (with
male patients and type 1 diabetes giving the base-line categories), while retinopathy accounts
for three coefficients using a sum-to-zero constraint for comparing effects to a mean level. As
before, we assume relative prior ignorance about the model parameters, using the
independent priors b, ~ N(0,oy2), / = 0, ..., 10,
X ~ Inv -Gamma(,8.) with = 104= fib = 1(T3. There are eight patients with
unspecified records in covariates retinopathy, C peptide and ElbAlc. Under a Bayesian
perspective, the missing values are included in the analysis by treating the covariates as
random variables to be estimated by the model. First their prior distribution is defined and
then estimates can be obtained from the joint posterior distribution of the model parameters
and missing values given the observed data (345). Here we assume vague prior distributions
for the three covariates. Posterior estimates of the 6, coefficients are obtained through
MCMC simulation. The effect of each covariate is assessed using 95% equal tailed credible
intervals based on the marginal posterior densities p(bt \ w) .
The gamma family was considered appropriate in the GLM analysis for two reasons: firstly,
the variance of vv( was found to be non-constant, and in particular var(vij)oc E2(w() (see
figure A3) - a typical feature of the gamma distribution; and secondly, the gamma density is
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a natural choice for modelling wt = a,2, that is the reciprocal of the variance of the normal
distribution of log(x^).
Figure A3:
Mean against variance of consistency measure vr = cr~". For clarity of presentation subject 1028 has
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«'i= EfVv'i/y)
An alternative GLM with log-normal errors was also considered for modelling the
consistency measure wi, with
w, ~LN(m,,cr^), i=\,...,I
where m, is associated to patient-specific covariates through the identity link mi =x'j b,
andx(' and b are as before. Again, relatively vague priors were assumed for all parameters.
This model did not provide better fit to the data compared to the gamma formulation (eq. [3]).
This is demonstrated by the lower values of both the posterior mean of the deviance and the
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deviance information criterion (DIC) for the gamma model - see Table Al. A discussion on
the use of these model assessment criteria is given in [3] in this Appendix (we note that since
the two models have the same number of parameters, both criteria give equivalent results).
Table A1:
Posterior mean of deviance and deviance information criterion (DIC) under the two
considered GLM error distributions.
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FIGURE1Frequencydistrib tioofsever hypoglycaemia(SH!oc urringinthprev yearin500peoplewithTypeId ab tes.
SerumACE(IU/1)
FIGURE2Therelationshipbetwenumber< episodesofseverehypoglycaemia(SH) experiencedbyindividualparticipa tsdu g
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angiotensin-convertinge zyme(ACE)level .
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recallofSHveraperiod1yh sbe nshownt robustandreproducible[1,24|.Itispossi lethaterelation¬ shipofACEtohypoglycaemiariskdiffersfundamentally betweenDanishandScottipopulations,althought ey sharesimilarcultural,ethnicandgeneticbackgrounds, bothcountrieshavsimilarprevalencefTyp1di b t s. Evenifthissagenuinediffer nce,onotappearlt r therat sofSHbservedint sn tionalpopulations,po ibly becausetheaetiologyofSHismultifactorialnds b le differenceno efactormightbinsuffici nttalt rhoverall frequenciesofhypoglycaemia.PrevioustudiesiD nmark 111,Scotland|3,4|Eng2antheNetherlands5|h ve reportedverysimilarfrequenciesadistribut onsofSH withinpopulatio sfeoplewi hTy1diab tes. Thediscrepantsultsco ldb latedtfferencesbetwe n thestudypopulations.Thesediffer nc s(Tabl1)marelate totheprocessesfselectionandss s mentrath rt a differencesbetweenhackgrou dpopulationsfromwhich subjectsarerec uited.Forexample,thD nishmethodf assessinghypoglycaemiaawar ne sprobablyover sti tes thepreval nceofimpair dawa enesshypoglycaemias being60%[241comparedwithaprevalencefarou25in otherpopulations udies[10].Iftpati ntsintDanish studies112,13]haigherfreq ncyofimpair dhyp gly¬ caemiaawarenessthanpr sentgroup,yuldc rtainly havegreatervulnerabilitytodevelopingSH|18|.Pre i us workhassuggestedthatpredictivevalufs r mACEi strongestinpatientswhosedefe cagai tSHi c mpro¬ mised,suchastho ewitimpairhypoglyca miaawaren ss |12|.Althoughthepres ntstudydiff rsfromt thersin agesofthsubjects,woD nishtudiesincl dparticipant
whoereolderthant osinthpr sentstudy112,131,and Swedishstudyexaminedadole centsnchildr117],which suggeststhaa ewnotcontributory.Whiltmuchyo nger Swedishpatientsh dshorterdur tionofiabetndbe e glycaemiccontrol]171,nc sistentdifferenc sw re observedbetw enthadultparticipantsfr s ts y andthoseineD ni h112,13]studies,eith ridura ionf diabetesorH Au.owever,mark ddifferenc srpres nt
inthefrequenciesofmicrovascularcomplicationsithDa h groupscomparedwiththpresentst yc hort.Info tion aboutmicrovascularcomplicationsw snpr idedith Swedishstudy,anthe earrari pa diatricg -group. Whileitcouldbesuggestedt athdiffer ncncomplica¬ tionrateselatesthxclusionfromtcurr ntstudyf individualstreatedwi hRAS-blockingdrugs,onlyefth previousstudiesinclu dindividualtr atew hheseme ¬ cations112].Iouldlsoberguedthatexc si nfe e individualsexcludesthosathigherriskofSH,butht Danishstudiesreportedfreq ncyofhypoglyca miaI.I episodesperatientry ar,despitthfactatonudy excluded1131whiletot erinclud|I2)peoplereat d withtheseag nts,isdonoseem:blik lyposs bilit . Inthela terstudy,tcharact isticsndriskofSHi ose treatedwi hRAS-blockingdrugsidn tifferfromthosef theoth rs udyparticipants,otinves igatorscon lu ed thatACEinhibitionexertednov allsignificantffect112]. Analternativeposs bilityith terrediffer cesCE genotypebetweenthdiff rentstudypopulations,as participantsinthecurr ntstudydidnore eiveg n typing. However,ithasbeennotedpr iouslythatrisclose correlationbetw eACEgenotypea dph noty(12,25]
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DIA-2010-0207-Zammitt_3P.3d03/16/117: 6Page HYPOGLYCEMIAS MPTOVARIABILITYINDIABET S symptom.Thismodelingapproachcanbere r se t d graphicallybyregardingeacsubject'sesponsea/xK matrixofindic orvari bles(J=num esymp m ; K=numberofepisodes)(Fig.1a),wherachreported symptomirepresentedbyamarkedcell.Re r a gingth rowsaccordingthefrequ ncywithhichsymp mar experiencedandthcolumnsccor ingnumberf symptomsperepisode(Fig.lb),weobtainarepres n ation wherethdegreeofclusteringmark dellsnbregard asmeasureofconsistency. Thisisexpressedwithinap rametricframeworkusi g logistic-typelatentvariablmodel.Wa sumethat unobscrvablerandomthresholdst„*(associatedw thindi¬ vidualireportingsym t mjaepisodek)follow log-normal(0,o2)distributionunderwhichthprob bility;»,;1 ofindividualreportingsym t mjaepisodekgivenby PiikPr(<*aPi )*|
log(*ij/W\
with/' -1,...,/,andk- .,K,-,wherea, -and//.j representthprop sityforsymptomjandint n ityf episodek,r s ectively,forindividual/and<1>()denotesth cumulativedistributionfun tioofastand rdnorm lvari¬ able.Therefore,thmod limpliest atoccurrcnceofsympt ms acrossndwithinepisodedepeothereleva tropen ity (or,,)andlsotheund rlyingepiso einte sitywhich introducesassociationsm ngsymptomth ugheimp s d hierarchicalst uctureofcc rrence.Thinformationavailabl onthefrequ ncywithwhicsymp omsarreport dth ug allepisodesnothetanumberfsympt msperepiso , allowsestimationofb thand/fi urmodel. Theprecisionpa ametera-'2ofthhresholddist ibut on providesameasureofthesymptom-reportingcons st ncy
anindividual.Consistentsymptomprofilesars ciat d withlowvariancefthehresholddistribut o .Forc se interpretationi ,2sconvertedac sistencyparamet r =100/(1+rr2),whichrangesfromt 0withinc easing valuescorrespondingthigh rsymptomconsist ncy. Associationbetweeconsistency andpatient-specificfac ors Generalizedlin armodelethodologyw susetinvesti¬ gatetheeff ctoftfoll wingpatient-sp cificc variateson consistency:gender,ag .diab t styp(1r2),uratiofi¬ abetes,retinopathy,hypoglyc miaawarenessscor(1-7,th higherscorescorrespondingtdimini hingawarenessofy¬ poglycemia),b dymassindex,stimulat dC-pcpti e,hemo¬ globinA e,andscrumangi tensiconvertinge zymectivity. Formodelingpurpos sretinopathywassubd vi edinn retinopathy,backgroundretin pathy,a dp oliferativet ¬ nopathy.Ageneralizedlin rm delwithgammaerrors(s SupplementaryA endix;Suppl mentaryDatarvail bl onlineatwww.liebcrtonline.com<h!tp://www.lieberto line .com/dia>)wasusedtolinkestim tefhprecisionpa¬ rameter(712withthcovariatcs,hroughfunction log{E(ff,2)}=/>o+Vn*CEN,-xA\v,TYPE, I/\,lirxDUR,•w.IxRET1/>„.,22 +l>n.,3xRET3,-/WAWAR +I'hmiXBMI,/'qvpxCPEP, +xHBA,-/v,.xACE, (wheret eGENrepr s ntsg nder,DURrepresentsdu atio , RET1representsnoretin pathy,T2represen sbackground retinopathy,RET3represen sp ol ferativetinopathy,AWR representsawa n ssofhypoglycemia,BMIrepresentb dy
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FIG.1.(a)Ex mpleof/ Kmatrixindicatorv ri bles/—nusymptoms;K-nu berofepisod )f s bject 6010withsymptoms1-26listedver icallyanhypoglycemicepisodesli thorizontally.Eachreportsymptim rke withasquare,(b)Rearr ngementofthmatrixowsdc lumnsor snappecor i gthfrequ ncywith whichsymptomsareexpe ien edndcolumnsccordingthnu b rofsymptomsp repisod(b tfoll i gdes¬ cendingorderfr mthop-l ftcorner).
DIA-2010-0207-Zammitt_3P.3d03/16/117: 6Page4 4 massindex,CPEPrepr sents-p ptidc,HBAreprhe¬ moglobinAle,andCErepresentsngiotensiconv rting enzyme),andtheffectofachcovarialcw sssessedu ng 95%equal-tailedBayesi nint rv lsofthec rresponding/> coefficients. Results Atotalf3,474episodeshypoglycemiafr m59patients wereexamin d,ofhich91%confirmedbycapillary glucosereadings.Afterexclusionofhypo yc micepisode occurringwithin24hfapreviousevent,.699episodesre¬ mainedforan lysis.T bl2summar zesthbjectc arac¬ teristicsandhypoglycemicp o ewithina hgroup.Th mostcommonlyrec rdedsymptomswereeakness,de¬ creasedoncentration,sw ing,a dhunger(28.7%,28.2%. 21.8%,and.1ofepisodesrespectively). Thedistributionoftestimatedprecis nara rr,2 isskewed,withmostsubjectshavingloconsist ncy (Fig.2a)Estimatesoftheconvert dnsistencyparam t r ?,=100/(1+rr2)havemeanof5 .3ndSD16.7(Fig. 2b).Themainsamplequarl lesof?,ar(/ ,-18.0<j(1 2s-37,6 - ._50.2,(jo.??—62 7andi/i96. . Somesubjectsinthistudymeriindivid alconsi eration, Subject1028(typedia et sfor>15ear )w sas mptom¬ aticdur ngllofhis45recordedepiso s.Her orted hypoglycemiaawar nessscore18 f7,denotingt t llo sf warningsymptoms,andh dthehighestestimatedcons s-
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lowervariabilityintheisymptomsnt osei hhigh awareness. However,itsubjects1028and4 03(asymptomaticon0% and74%ofepisodes,respectively)rxclu dfr mth analysis,onlygenderh ssig ificanteffect,withfemal beinglessconsistentthamales(/>gc„=-0.43with95% Baycsianinterv l0.82,03)(Fig.3b) Discussion Thepres ntstudyhademonstratendquantifi cpisode-to-cpisode,intra-in ividualvariabilitysymptoms ofhypoglycemiareportedbyadultswithdiabet s.Ilso foundsomedeterminantsofinter-individualdiffere ce thissymptom(in)consistcncy.Iacceptedatea hd ¬ vidual'shypoglycemiasymptomco plexiharacteristic. However,thidrangea dsk w ddist ibutionf precisionarametera~~demonstratethwithin-subject symptomprofilesvaryubstantiallybetweenepisodean thatpeoplesh wmarkedindividualdifferenceswithr sp ct totheircons stencyfsymptomreporting.Conver ne precisionarametertohn maliz dc ns stency c,facilitatesbetween-a dwithin-patientcomparisonsf consistencyestimates,althoughthereinpredefinedutoff todifferentiateconsistenta dinc nsistdividu ls. —bac, bnb3 bep9p bbmi b3w3f b/mt3— blt bdu, -b<fpo b„.
-1.00 50.51 Coeftbientsfpatient—specificcovariate
HYPOGLYCEMIAS MPTOMVARIABILITYINDIABETES is' JUL QO051.0.52 a"3 406SO103 FIG.2.Histogramsf(a)estim tedprecisionarametern,2 and(b)estimatedco sistencyparameter?,=100(1+,). —bac. ......bhba —bbmi bavtai -b,tK
•b„M
-0,50.5 Coefficientsfpatient-specificcovar ate
FIG.3.(a)Posteriorm anscircle )nd95%equa -tailedBayes nint rvba sf stand rd zeco ffic ntsfp tient- specificcovariates.f'.lc ,umangioten inonv rtinge zymeacti ty;;hypoglycemiaw n sr ;bhm, bodymassindex;/'Cpcp»stimulatedC-peptide;f»jor,durationfdiabe e ;gen rhem globiAlnr ti¬ nopathy;t>rvi2,backgroundretinopathy;l'rcl]p p lifcr ivcretin/ iyfH„ty edi b tes,( )A alysise taf r exclusionofsubjects1028and4 03.
DIA-2010-0207-Zammitt_3P.3d03/16/117: 6 mPage6 6 Themostcommonlyrep rtedsymptomswereeakn s, decreasedconcentration,sw ating,ahung r.Thesev previouslybe ndemonstratedtheearliestperc ved symptomsofhypoglycemia2''andthosethatrcmostc m¬ monly13andccurately12ssociatedwithhyp glycemia. However,themainaimft isstudyasnotpop¬ ulationsimilaritiesbr thertoex mi ein ra-individual consistencyfsymptomreport ng. Thestatisticalanalysesitpre nttudyr issomm¬ portantintsforat e teduc tionandhypogly miare¬ search.First,whenpatientsa ct ugheirhypoglyc mic symptomsareidiosyncratic,th yhouldlsobeinformt a theirsymptomswillprobablyvarybet eenepisodes.R ¬ inforcingthispointmayavoidfailurerec gn zehypogly¬ cemiaasr sultofsymptomvariat on.Second,itpr bablv usefulforpati ntstohavenwar n ssowc nsist nth ir symptomsarcbecausepeoplwhoh vetl tonreliable symptomofhypoglycemianlydetectbl odg ucosel v l below3.9mmol/Lon50%fccasions,whereaindividual withfouromo ereliablesymptomsc gnizsimilarbl d glucoselevelon75%foccasi ns.13Fi a ly,pr vioustudies havereliedonv ryfewsnapshotsfthyp glyc micym ¬ tomprofile,eitherrec rdedduringxperime talhypoglv e- mia1""wordocumentedretrospectivelybypatientsinwha wasthoughtrepresenttheir"typical"symptomprofile."'"-*'" Thefindingsoftpres ntstudychallengev lidit latterapproachforthepurposefdvi ingindividualati nts, asthedegr eofbetwecn-episodcvariabilityimuchr ater thanhaspreviouslybeappreciated. Ofthefactorsexamined,onlyemalge d rincre sed symptomvariabilityinstematicway.Althoughmp ired awarenessassociat dithincre sedsymp omconsis¬ tencyinhenitialanalysis,iffectwolo g robs rved oncethewoindividualsithawarenessscorf7r excluded.Onofthlimitationssa alysisst cannotdistinguishbe weenompletelyonsiste tper o withfullsymp oma arenessndconsistentlys mptom¬ aticindividual.However,f rsithcombin tion ofsymptomaticandsymptomatiepis des,thpre encer absenceofsymptomscontributethnsist ncye r symptomprofile,anditwasthoughtimp rtantnexclude asymptomaticepisodescompletely. Itwassurprisingth tt ebj ctreat ditho alagen wasasymptomaticduring36%ofepis des,de itrec rding anormalhypoglycemiawar nessscore.1Allisepisod wereconfirm dithglucosereadings.ItheUnit dKi g¬ dom,patientstreatedw thralagrnoroutinelysk d tocheckapillaryglucoselev l ,sh dprobablyn tre¬ alizedthathiswarenessimp irrioroartic pation inthisstudy. Therelationshipbetweconsistencyfsympt mport¬ ingandge derh sotbe nr p rt dpr viously.Sympt ms ofhypoglycemiadev lopatsimilarbl odlucosethresh lds inmenandwomenithtyp1diabetes,33uthagnitude ofthecountcrrcgulatoryresponseilow rwomen,3 hich mayinfluencethetensitvofsymptomaticrespons . Femalecounterrcgulatoryresponsesarl affectedbyn¬ tecedenthypoglycemiaandexerciseharesponsesimen." Itcouldbehypoth sizedhategend rdiffer c snis studyrelatetounder-reportingbyfemal sassultoflow r symptomintensity,butnotposs blec nfirthisa subjectswerenoaskedtotsymp omintensity.
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Itispossiblehatotherfac ors,uchaactivitiesen¬ gagingtheindividualtimeofepisode,yhavn effectonsymptomconsis ency,buitwouldlogist - callydifficu ttost dyheseingreat ret i .Ea liework hasclassifiedypoglycemicsympto sinphy iol gical terms."'''Appropriategroupingfymptomsybeabl toaccountf rdditionalsourcesfbetween-groupvariation foranindividualpatientthmodel,usgivingscope forincludingrelevanteffectssymptomgroupnfut e analyses. Notallhypoglycemicepisodesinthisstudywerec n¬ firmedbiochemically.How ver,t presenceofy i al symptomsthatresolvewi hing ti nofcarbohydrate conventionallytaksevid cefhypoglyc mia.Insisten onbiochemicalcorroborationw uldhavefurth rrestric ed thenumberofepisod savailablel rn ysisnm sti¬ sodes(91%)wereconfirmed. Insubjectswithnormalawarene s,itouldbnter sting tostratifyepisodesaccordingbloglu selevelin¬ vestigatewhetherth shadneffectosymptomr por ing. However,thisanotpossibleit r entstudyf rsev¬ eralreasons.Althoughfallinb o dgluco eadult withoutdiabetestriggerhsecr tionofounler egulatory hormonesandtheons tfcog itivesymptomatic changesatreproducibleblo dglucosethresholds"with n definedhierarchy,37thesehreshol sb comealteredi ¬ betes,andthsameloogluco el vlmayff ctindividu ls withdiabetesnfferentay .Second,atafromFi ld studiescannev rbasontrolledd age er ti laboratory.Confi mationfhyp glycemiamayaveoc¬ curredseveralminutesbefooaft rr scuearb hydrate wasadministered.Thus,tbloodgl co emeasur mentay nothavecoincidedexactlywiththblglu osea irr peakofsymptomintensity.Finall ,bl odglucosem tersar lessaccurateinthehypoglyc micrange,dtwould havebeenpossibletconfirmh ereadingswithv nou samplesoutsidethc nfinftightlyregulatedlab r tory study.However,th ri epotentialexaminethisqu s¬ tioninafoll w-upstudy. Thestudyhasseveraltrengths,includingtsize(2,699 episodesofhypoglycemia),itprosp ctivedesign,anu¬ ration.Althoughs mepreviousstudieshacollect dymp¬ tomsprospectively,12'3""'"heyhavnotattemptedc pare symptomsbetweenepisodes.Furtherm re,pro ectivfi l datacouldberegardedsmorg n ralizableth nhypogly¬ cemiadataollectedund rlab ratorynditions. Thepres ntstudydemonstratest ain ra-i dividual between-episodesym tomvariabilityimuchgr aterh n hasbeenpreviouslyappreciatedndtharemark d individualdifferencesnthisconsistency.Caut onsho ldb exercisedwhenint rpretingpatients'retrosp ctivecallof whattheyregardobeir"typical"hypoglyc micsymp¬ toms.Femalegend rw shelyfactorou dhav systematicas ociationwithincreasedv riabilityofth symptomco lex.Giventhisobs rvedvariability,clinicia s shouldadvisepatientsgainstbe gtoodogmaticinheir perceptionofwhatc nstitutesth rard nalhypoglycemic symptoms,asthe emayvarconsid rablybetweenepisodes. Thisvariabilityshouldalsobecons deredwh ninterpreting hypoglycemicsymptomresponsesunderdiff re texperi¬ mentalconditionsrwhemp ringdifferenttherap utic interventions.
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DIA-2010-0207-Zammitt-Suppl_3P.3d03/16/117:09 mPage1 SupplementaryAp endix Modelf rintra-individualc sistency Wehaveassum dthatnindividual'ssymptomprofile dependsolat tfactorsexpre ingthint nsityfgiven symptomonagivenoccasi nndthindividual'sprop nsity toexperiencehatsymptom.Tmod lthatwdev lopim¬ pliesthatassessmentofintra-individualconsistencybase onapri ciplefhierarchi alsymptomeportingwhereord ismposedbyothpr p nsityandintensit . Toaccountforvari ssourcefun e taintyas ciated withtheproc ssofapplyingthierarchi alst uctured ¬ scribedabovetsymptompro ensityandepisoint n ity, logistic-typelatentvariablemodeliused.IfwletY„■*d note theindicatorrandomv ri bletakingthev lu1ifsubj c / experiencessymptomjaepisodAnd0otherwise,w assumeBerno lli(p;,*)for/—1l,j-a d k=1,...,K(inourdata/5926andvariesfromt 135),wherep,*giv sthcorrespondingreporti gpr bab lity andisderivesfollow .Wa sumethatindivid al/reports symptomjatepisodekwhen,,/?»exceedsthr s olz,*, withlatentvariablesx„>0and/I*>0representingthpro¬ pensityforsymptomjandthinte sityfe iso ek,r ¬ spectively,forindividual/.Thethresholdst„*arc n ider toberandomv riables,awessumth tfogi nin¬ dividual/theyfollowacommonlog-n r aldis ribution, thatis, r,,*~log-normalf/ij,cr])fo /=1,—I(1) where//,and<ijprovi ethmeanandtv ria ceoflog( „t). Therefore,theprobability,,*oindividualreporting symptomjaepisodekigivenb Piik-Pr(<»(2) fori=1/,/ 1,.,/,andk,—K,where<!'()de¬ notesthcumulativedis ributionfuncti nofasta dard normalvariable.Theme noftlogarithththresh lds, Ellogfr,,*))=// ,isnotfprimaryinte esheandwith ut anylossofgenerality,wcas t//,-0f rallsubject/. Underthismodeltvalu sY„*arconlycon itionallyin¬ dependent,withoccurrencefsymptomsa rossnwithin episodesdepen ingother l vantprop sity(a,/),andlso theunderlyingepisodeinte sity(/?,*),whichintroduas¬ sociationsam ngsymptomsthr ught eimposedhierarchi¬ calstructureofoc urrence.Al o,asepisodesof hypoglycemiaoccurringwithin24fapre ed ngepisod wereexcludedfromthisstudy,tmod ldocn ta su e anycorrelationstructurebetwe nintensitlev lofsucces¬ siveepisod s. Theunknownvariancep ram ter]ofthehresholddis¬ tributionprovidesameasureofthesymptom-r portingcon¬ sistencyofanindividualpatie t.Tosimp ifyn tation,wu Wj=(Tj2toden tetheprecisionaram terofthresh ld distributionthroughoutt isappendix.Undertassumed log-normalmodelwhavvar(r;,-*)—-1)li varft,,),-)=0s-».Equi lcntly,limvar(tijk=asw-»x. Here,tofacilitatinterpret tionandcomparisons,weus
functionof~1givenasthrcscaledcons tencyp ram ter, Ci=100/(1+nj)withrange(0,1 0).Forla gecthhresholds gethi hlyconcentratedaroundco stantval er".res lting
inconsistentreportingfsymptomsa s ciatedwithlate symptompro ensitya„ndepiso eint sityf .ksuchthat ctijlljk>r'i-Therefore,consistentsympt mr portingia soci¬ atedwithhighconcentrationfththresholddist bution, correspondingtincreasi gvalueofthconsistencypa¬ rameterCj. Sensitivitytohresholddist ibuti n Thelev loftconsistencyparameterfore chsubjectw estimatedunderaBaycsi npproach. ThethresholdsT;,tcanalt rnativelybssumetofoll w otherdistributions.Herwc ns d rthat,fopatienti,y aredr wnfromWcibullfamily,thatis, r,ji~Wcibull(t>/,/,)for/—1,— andtheprobabilityofindividu lreportingsympt mja episodekisexpre sethoughappropriatcumulat ve distributionfunction( dfas Pijk-Pr(r,,t<Xijp k)-1-cxp{-/.jfriiPjk)'' for/1,.,..,/,andA.C,swiththemean parameterinthlog-nor almod l,thesc lpar met roft thresholddistributi niass medknownndtt=1.T unknownparameterofthhresholddis ributi np ovid sa measureofthesymptom-reportingconsist ncyfanindi¬ vidualpatient,withvor(z„k)-T(1+2/ \)-|1/t',)|2. Thisgives limvnr(Tjjk)=0,ast';—-x implyingthathighv,aluescorrespondtconsi te tsymp¬ tomreporting,aswastheca eith,und rtlog-normal thresholddistribution.Aga ,rescaledv sionsoftpa¬ rametercanbeusedforconv nienc ,example, I/,-100/(1lv~').Thereisclosagreementbetw etcon¬ sistencyparametere timat sund rthetwomod ls,as wn inFigureS1,verifyingthatoanalysisisr btchoice ofthehresholddis ributi n. Posteriorestimatesfindividualsubj cts FollowingaBaycsianappr ch(e.g.,reference1)inthi Appendix),weconsiderinde e dentpriordistributi sfor thelatentvariablesa-,-,-Gannnafy ,8,)fo/=1,—/d j =1/,Pjk~Cniumn('iifSp),/' ,...,/,witha propriate valuesfor•/„8„yp,andtexpressrel tivprioignora ce (hereya-p1and8,-p0.1).Asint isworked t focusonbetween-individualvariabi ityfsymptom ,itn t relevanttoassumehiera chic ls tti gofcommondis ri¬ butionsforthelatentprop nsityvariablesEstim tif a,7ndft*isnformebythfrequencywithhichsymp om isreportedthroughoutallepisodesntnumbeof symptomsperparticulae isode.Foridentifiabili vandin¬ terpretationpurposes,wehavlsimposedco ner-type
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Generalizedlin rmodela alysisforssoci tion betweenconsistencya dp tient- pecificfa or Generalizedlin armodel(GLM)m thodologyw suse
toinvestigateheff ctftfoll wing10patient-sp cific covarialcsonnsistency:ge der,ag ,typdiab tes, durationofdiabetes,presenceretinopathy,hypoglyc mia awarenessscore,bodym ssindex,stimulatedC-pcptido, hemoglobinAle,andserumangiot nsinconvertingzyme activity.Gender,typofdiabetes,andpresencefretinop¬ athywereincludedthmo lsategoricalfactor(s maintext),whilealot erc variatesassum dnu erica vaIues. Theestimatedposteriormeanofthpr cisioaram ¬ ter,<7>,-E(rc,|i/)ismodeledasthresponsev iablein BaycsiangammaGLM.Thisismoreappr priatee sur tobemodeledasthGLMresponsevariabco par d withcforwh cadistribut onnthescal d(0,1 0) rangemaynotbeturallyfoundorjustifi d.Thus,w assume
SUPPLEMENTARYFIG.I.Estimatedposteriorme nof
C,- -100/(1ln])againstposteriormeanofi ,-10 /(1Iv')• constraintothelogarithmsfthe eparamet rs (lOg2,|=logft0./=1) Wealsossignr ativelyvaguein rg mmaprior distributiontohevarianceparam ter,ff'-lnvGamma(y„,/>„) for/—1,.Iwhe eagainy0-8n—0.1. Posteriorestimatesfr,w rderiv df eachsubjectinth analysisusingMarkovch inMonte-Carlom thodology(e.g.. seeTierneyinthmainarticl )ndd splay diTabl Si.Credibleint rva sforc,we eidf sompati nts,re¬ flectinglimitedinformationinthoc urreep sodes.Ah s¬ togramandtheempiricalcu ul tivedis ributionfun tionf Ci,theposteriormeansfc„arcgivinthmainarticl . Relationshipbetweenconsistencyme ur andnumberofe ptymbedd dcells Inthiswork,t econsi tencyofindividualpatientw n reportingsym t msthroughoutaseriesfhypoglycemic episodeshasbeenassociatedwithprinc plu derwh symptomsareexperiencedaccordingtohier r hicalo d r determinedbytheirlate tp opensityandtl ntin sity ofepisodes.Thmbe dede ptyc llsinFigur1thmain articleprovidevidencofdevi tiofromth sprincipleint e observedc mpl xfsymptomsfoeachindividua .Figur S2aillustratesth tconsis ency,ae tim t dinourm del, relatedtohenumb rofembeddedptyce ls,anther for theconsistencyparameter,inoura proachsagreement withtheprincipleofhiera chicasymptomeporting.F gur S2brevealsthatestimatedconsistencyialsonegatively relatedtoheot lnumb rfsymptomsrep r dthroughout allepisodes(XI,1/;./.*)foreachp tient.Thpointstow rd potentialpresenceofadditionalv riationinththreshold levelofindividuals,suggestingthatanxtend dm lay alsobeconsideredithfuturtallowforandomeffects associatedsymptoms.
whichgivesE(«',)—»/andvarffi',—nij/s.Thsu tab lityo
thegammaerrorsandlte nativeGLMassumptionsedis¬ cussedlaterinthiAppendix.Tmeancon i tencyrespon in,isl nkedtopatient-specificcategoricalfactorandconti ¬ uouscovariatethroughafun ti noft eormi,-exp(\Jb) for/-1,—/,whe eb-(b .I'i..biz)7is11vectorfr al valuedcoeffici ntsandxj-(l,A'i.„—.V12.,)isthcovariatc vectorcorrespondingtthord rinwhi htc arialcsa givenabove(withthunitvaluegi i gtin ercept,/»,»,ofth linearfunction).Notethatgendera dtypfdiab tesa ¬ countforonecoeffici nteach(withm lepati tsandtype1 diabetesgivingthbaselinc t gori s),wh lretin pathy accountsforthreecoefficie tsusi gs m-ln-/e oconstrain forcomparingeffectstameanlev l.Asbefore,wassu e relativepriorigno nceaboutthemodelp rame ers,us g theindepend ntpriors/»/—N(0,r g)—010an /~lnv-Gamma(-/;,8>)withny,=10V/>=8;0~\Therear eightpat entsw tunspecifiedrecordsicovariatesreti¬ nopathy,C-peptideanhemoglobinAl .UnderBaycsian perspective,thmissingvalu saincludedthan ly ib treatingthecovaria esasrandomv ri blesbestimat dy themodel.Firsteirpriodis r butionef n ,athen estimatescanbeobtainedfrthjointp s riordistribu io ofthemodelparam tersanissingv luesgiventhob¬ serveddata(sIbrahimetI.2).H rewas umv gprior distributionsforthehrecovaria cs.Po er oestimaf thel'icoeffici ntsarobtainedthr ughMarkovchaMonte- Carlosimulati n.Theeffectofe chcova i teiassess dus ng 95%equal-tailedcredibinte valsbas donthma gi al posteriordensities;»(''il<£)• Thegammafa ilywasconsideredappropriatintheGLM analysisfortworeason :irst,thevari nceff ',w sound be non-constant,a diparti ularv r(rl';)■*.E(w,)(FigS3)— atypicalfeatureoftheg mmdistribution;ndsecond,the gammadensityisnaturalchoicefomode ingr ,=2,th t isthereciprocaloftvarian eftheno maldis ributionof IOg(T,*).


































































































































































































































































































































































































































Hypos,hypoglycemiaepis des;T1ln <5t ediabetwi h<5years'u at on;T l >15,diabet si h>1years'ur t on;
T2Ins<,typediabet sreatedwi hinsulinfor2ear ;lns•5,td abreatedi hinsulinf -y r ;T2t b ,t pdiab treatedwithoralagents.
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wherem,isassociatedithpatient-specificcovar tos througheidentitylinki ,—xjb,a djbrsef r . Again,relativelyvaguepriorswerassumedfollparame¬ ters.Thimodeldin tpr videbetterf ta acom¬ paredwiththgammaformul tion(Eq.3).T sis demonstratedbythelow rvaluesfthpo riore n ofthedevianceanddevianceinformationcr terionft gammamodel(T blS2).Adiscussiononthefhe modelassessm ntcriteriaigivenSpic elhalt rl.'(w notethatbecauseewomod lshavs mnumberof parameters,bothcriteriag vequi alentresults). References nTheoryandB \
lAnalysi
1.BergerJO:StatisticalD c s Berlin:Springer,1985. 2.IbrahimJG.ChenM-H,LipsitzSR:B y generalizedlin rmodelswithcovari tesi CanJStat2002;30:55-78. 3.SpiegelhalterDJ,B stNGCarlinA,vad rL nde: Bayesianm asuresofodelcomplexityandfit(wi hdis¬ cussion).JRStatocerB2tX12;64583-640.
anmethodsfor ;singatrandom.
DelayedR coveryofCognitiveFunc onllowingHypoglycemiainAdultsWithType1Diab s EffectofImpairedAwaren ssHy ogly mia Nicola.Zammitt,1RoderickEWarren,1IanJDeary,2a dBri nM.F ier' OBJECTIVE—Recoverytimesofcognitivefunctionsw rex¬ aminedft rexposurethypoglyc miaipeoplewithdiab s withandwithoutimpairedhypoglycemiaawa ness. RESEARCHDESIGNANDMETHODS—Atotalf36subjects withtype1diabe srestudi d(20withnormalh poglycemia awareness[NHA]nd16ithimpairedhypoglyc miaawar ness [IHA]).Ahyperinsulinemicglucosec a pw sus dtlo r bloodglucoset2.5mmol/1(4g/dl)(hyp glycemia)f r1 tomaintainbl odglucoset4.5mmol/1(81g dl)(euglycemia onseparateccasions.Cog itivt twerappli ddu ngeach experimentalconditionandwerer p a d10-to5- i intervalsfor90minaftereuglycemiah db eestored. RESULTS—IntheNHAgroup,performa cewasim airedll cognitivetasksduringhypoglycemiaa dremai edimpa rf upto75minhechoicereactiontim(CRT)askP=0.03, -q2=0.237).IntheHAgroup,perf rmancedidt.det riorat significantlydur nghypo lycemia.Wh nallsubjectsw rea a¬ lyzedwithinthesamegen rallin armo l,perf rmancew s impairedduringhypoglycemialltasks.Sign f cantimpair¬ mentduri grecoverypersist dforupt40minthCRTa k (P=0.04,r\2125)withasignificant,glycemia-awareness interactionforCRTafternhoufyp glycemia(P=0.045, -q2=0.1 4).Performancetheail-makingBt swasim¬ pairedforupto10minaft reuglycemiawasrestored(P=0. 24, ■n2=0.158). CONCLUSIONS—Followinghypoglycemia,threcoverytim fordifferentcognitivetasksva iedconsid rably.IthHA group,perf rmancewasnotsignificantlyimpairedduringhy ¬ glycemia.Thestateofawaren sshypoglyc miam yinflu ce cognitivefunctiondur nga df erhyp lycemia.Diabet s57: 732-736,2008 Fromthe'Departm ntfDiab tes,R yalInfir aryfEdinburgh,Ed n r Scotland,U.K.;andthe-DepartmentfPsychology,Univ rsityEdi bur h Edinburgh,Scotland,U.K. Addresscorrespondenceandr ri trequ ststProf orB ianM,F , Departmentofi betes,R yalInfir aryEdinburgh,51L tlFrance Crescent,EdinburghHlfi4SA.,Scot a d,U.K.E-m il:hrian friortfduht. scot.nhs.uk. Receivedforpublication22M y007ancceptedi revisf rm18 November2007. Publishedaheaofprintthttp://diabeles.diabelesjournals.orgo26N ¬ vember2007.1) 1:10.2337/db07-0695. Additionalinformationf rthisart clecbef u dnonl neappe ixt http://dx.doi.org/10.2337/db07-0695. B.M.F.hasbeenmemberofadvisorypan lf rdhr ceived honoraria/consultingfeesfromEliLil y,sanofi-aventis,Olax SmithK i e,d Takeda. CRT,choicereactionlime;DSST,dig tsymbolubs itutionl st;IHA, impairedhypoglyc miaawar ness;NHA,no lhypoglycemiaawar ne s; RVIP,rapidvisualinformat onprocessing;TMB,t ik gB. 02008bytheAmericanDiabetesAssoc a ion. Thecostsfpnblicotiontarticlew rdef ayedip tbpthpa m tfope charges.T isart clemu tthe eforehe ebymark d"adv rtisement"i ccordance withISl.l. .C.Section1734solelytindicatethisfa
Therecoveryofcognitivefunctionfollowinghy¬ poglycemiahasnolreceivedi orousvaluation. Previousstudiesexam nednon iabeticolun¬ teers(1-3)insmallumbers3),didolinclude




Statisticalanalysis.Cogn tivescoreswercomp r du inggen ralli r modeling(repeated-measuresANOVA).Inthfullmod l,inclu inga lsub¬ jects,hypoglycemiaawar nessstatuathbetween-s bjectf c or.Th experimentallyinduc dstaleofhyp glyc miversusuglyc miawath within-subjectfactor.Age,sex,durationofiab tes,ndord rfexposure hypoglycemiahadnosignificantofl cintheresul s,a dt sef x d elfecls/covariableswe ether forexclud dfromthfin lmo .Indi ual testscoreswithinasinglelamps udyerr ctedfb s li eperfor¬ mancebysublr clingthe rbas linecorf omt irsteachlimp i t. Themodelcomparedt esadjustedscor sbetwe ntheuglyc micn hypoglycemicconditions(repealedm asure).Theffectsfhy oglycemiai NHAandIgroupsseparatelyrelsoreported.Stati ticalsignific ncewas accepted/'<0.05.P rtialfwasusetoindicateeff ctsize.Analys sre performedusingSPSSforWindowsversion12.0. RESULTS Cognitivetasks Table1showsmean±SDteslscoresc rr ctedf r baselineperformance.CRTandTMBscor sarc mple¬ tionlimes:alow rscorerepresentsbelt rpe formance. TheDSSTscoreiIhnumb rofite so pl tedi2 min;ahigherscorerepresentsbelt rperf rma ce.T effectsofglycemicconditionw refirstexa inedwithi NIIAandIILgroupsthenf rllsubjectscombined includinginteractionbetweegly emicconditionnd awarenessstatus.AconsiderablepracticelT lwap¬ parentonthDSSTt skbutnoleCRdTMB tasks.Therandomizedcounterbalancedtu ydesigcon¬ trolsf rpracticeeffects. NHAsubjects Performanceallcognitivetestsw ssi ificantlyim¬ pairedduringhy oglyc miainNIIAsubjects(Table1nd Figs.L4,2,and3, ).PerformanceDSSTandTMB deterioratedsignificantlydu nghypo lyc miabutre¬ vertedtobaselineassoonuglycemiawasr stored (Table1).CRTremainedimpairaft rrestorationof euglycemia,withsi n ficantdifferencesb tweethhypo¬ glycemicandeuglycemicco ditionst20,34and75 min(Table1ndFig.A) IHAsubjects InI1Asubjects,cognitivetes sdidnosh wsignificant impairmentduri ghypoglycemia,w ththexc ptionf theDSSTtaskfter60minofhyp glycemia(P=0. 41; Table1andFigs.IB,2 dS )Therewerosignifi¬ cantdifferencesuringthrecoveryphase.Comp r d withNIIAsubjects,trendsowardasm llerdet rioration inperformanceandmorrapidrecoveryfoll winghyp ¬ glycemiaw reobs rv d. Allsubjects Poorerperformancedu i ghy glycemiaversuseugly¬ cemiawasseenforallcognitivet sk .Thdiff r nce persistedforCRTat.20,3 n4minaft reuglycemia wasrestored(P=0.04,f.125)anforTMBt10 minaftereuglycemiawasrestored(P=0.024,rf- 0.158).Therewasnopersistenceofimpairm ntDSST performance. Comparisonofeffect,hyp glycemiainNHAnd IHAsubjects DSST.Theinteractionb tweegly micconditionnd hypoglycemiaawar ness(hereaft rt rm dhg cemia- awarenessinteraction)asignificanto lyht rtf hypoglycemia(Table2)P=0.009),suggestingthathypo¬ glycemiacausedsignific ntlygr aterimpairm nt,iNIIA subjectsthaninIIIAsubje . CRT.Performancew simpairedduringhypoglyc mia andt20,3a4minftereuglycemiawasrestored (P=0.04,Y]2.1 5).Theglycemia-awarenessinler c- DIABETES,VOL.57,MARCH2968
lionwassignificantlyalthee dfhypoglycemia(P= 0.045,t|2=1 4).Thisinfert att eN lAgroup,r lative tolheirbasel nep rformance,wasmoreaf ect ddu i ghypoglycemiathanIIIAgroup,butt rew reno significantbetwoen-groupdiff r cesuri grecov ry. TMB.heglycemia-awarenessinteractionw snotsignif¬ icanttytimepoin . DISCUSSION Resultsfromthepresenttudyuggestt r econc usions. First,inallsubjectscombined,gn tiveperformancewas significantlyimpaireddur nghypoglyc miaicomparison witheuglycemia,consistenthnumerousprevi usstud¬ ies(20).S cond,cognitiveperformancewassig ificantly impairednNIIAsubj ctsalone,whereaso lynonsignifi¬ canttrendswereseeniIIIAsubjects.Thidiffer nce appearstosugge tthatindividualswithIIIAarles affectedbyhypogly emiathant osewithNIIA.Af rmal NIIA-IIIAdifferencerequiresasignif antinteractionb ¬ tweenawar nessstatuandglyc miccondit on;thiwa seenforCRTalthndfhypoglycemiaaf rDSSTl thestartofhypoglycemia,withoutcorr ctionf multiple comparisons.Thstudythereforep ovidesefir t,b limited,evid nceforaormallytesteddiffere cenh cognitiveeffectfhyp glycemiad p ndingstalf awareness.Third,CRTremaineds g ificantlyp olo ged upto75minafterhypoglyc miainNIIAsubjects( ndp to40mininallsubjectscombined),andTMBco pletion timeremainedsignificantlyprolo ged10naft r hypoglycemiainallsubjectscombined.Thesdat suggestthatomeaspectsfc gnitivefunctionre ain impairedfoclinicallysig if antlimeft rcorr tion ofhyp glycemia. TheabsolutedifferencesnCRTb tw ntgr ps weresmall.Th satrendtow rdimprovementi CRTduringtheeuglycemicconditionitNIIAgroup withacorrespondingdeteriorationinheIIIAg oup.T is highlightst eimportancefeuglycemiccontrolar thateachgroup'sperformancedu i ghypoglycemiais comparedwithperformancedu i guglyc miaannolt thatofadifferentgroup,t uscontrollingfbelween- groupdiffe encesthatmayn lbappar nt. Thepresent,studyhasrongpowerf rwithin- ubject comparisonsbutislespowerfuladetectingb tween- subject.differences;highpowerforamedium-effects z differenceb tw eng oupsreq ir sov r50subjectsp group.Itismpossibletexcludesomverlapinhypo¬ glycemiaawarenessbetw nthogroupc e scoringmethodsr quiresomdegrefsubjectiveself- assessment.ThIIIAubjec sl ohadlong rdurati nof diabetesndmoremicr vasculardis e,althoughI1IA appearstobstronglyass ciatedwithdi b tesuration,
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